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Currently, cardiovascular diseases (CVDs) are still the main cause of 
mortality worldwide. Thus, there is a necessity to search for new 
strategies for the prevention and treatment of CVDs, and the flavonoid 
hesperidin could have cardioprotective effects. However, the literature 
is scarce, and some results are controversial. Moreover, the mechanisms 
of action by which hesperidin exerts its protective effects have not been 
fully defined, and omics science can study the impact of hesperidin 
consumption on metabolic pathways to determine how hesperidin 
exerts its health beneficial effects.  
 
OBJECTIVES 
The main objective is to evaluate the effects of the consumption of 
hesperidin in orange juice (OJ) and hesperidin-enriched orange juice 
(EOJ) on cardiovascular disease risk biomarkers, particularly on blood 
pressure (BP), and to elucidate the possible mechanisms of action 
through the application of different omics approaches in human 
samples: transcriptomics and metabolomics, and proteomics approach 
in experimental rat models to know its effects on key cardiovascular 
organs such as heart and kidney. 
 
METHODS AND RESULTS 
To achieve it, five projects were carried out: 1) a systematic review to 
known the scientific evidence available on the subject in humans and 
experimental rat models with cardiovascular disease risk factors 
(CVDRFs) following the PRISMA 2015 guidelines and PICOS criteria; 
2) a randomized, parallel, double-blind, placebo-controlled clinical trial 




500 mL/day for 12 weeks of OJ (392 mg/day of hesperidin), EOJ (670 
mg/day of hesperidin) or control drink, performing also two single dose 
studies of 6 hours, to evaluated its effects on BP (CITRUS study); 3) a 
transcriptomic analysis realised on peripheral blood mononuclear cells 
(PBMCs) by the Agilent’ Microarray Platform in a subsample of 37 
subjects from the CITRUS study after 12 weeks and also after the single 
dose studies; 4) metabolomics analysis that included targeted approach 
performed by high-performance liquid chromatography in plasma and 
urine samples in a subsample of 129 subjects of the CITRUS study, and 
nontargeted metabolomic approach performed by nuclear magnetic 
resonance spectroscopy in serum samples in a subsample of 52 subjects 
and in urine samples in a subsample of 129 subjects of the CITRUS 
study; 5) an experimental study with metabolic syndrome rats that 
consume 100 mg/kg body weight/day of hesperidin supplementation or 
not hesperidin supplementation was performed to realize a proteomics 
approach of heart and kidney tissues. 
The results from the systematic review showed that hesperidin improve 
lipid profile and blood glucose levels in animal models with CVDRFs. 
However, no definitive conclusion can be drawn in humans. From 
CITRUS study, the results indicated that the consumption of hesperidin 
in OJ and EOJ has beneficial effects by reducing the levels of systolic 
BP and pulse pressures (PP) in a dose-dependent way in humans. 
Moreover, transcriptomic approach showed the ability of hesperidin to 
downregulate pro-inflammatory human genes; metabolomics approach 
showed the ability of hesperidin to decreases human metabolites related 
with BP, oxidative stress and inflammation; and finally, proteomics 




related with an improvement of cardiovascular system in rat heart and 
kidney tissues. 
CONCLUSIONS  
Hesperidin reduces human BP in a dose-dependent way. Thus, the 
hesperidin enrichment achieved with EOJ, can be a useful co-adjuvant 
tool for BP and PP management in pre- and stage 1 hypertensive 
subjects. The mechanisms of action by which hesperidin exerts its 
beneficial effects can be explained through transcriptomics and 
metabolomics approaches in humans which demonstrated 
cardioprotective actions through decreases in pro-inflammatory genes 
and decreases in serum endogenous metabolites related to BP, oxidative 
stress and inflammation. Moreover, the proteomic approach realized in 
kidney and heart tissues of metabolic syndrome rats, showed that 
hesperidin changes proteomic profiles exerting positive effects on two 
main organs involved on BP regulation and cardiovascular system, 
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Currently, cardiovascular diseases (CVD) are the main cause of 
mortality worldwide.(1) Triggering these diseases is tobacco smoking, 
physical inactivity, and unhealthy diet. Thus, the main risk factors 
implicated in CVD development are modifiable, meaning that we can 
act on them and reduce the risk of developing it.(2) However, every 
year more than 17 million people die worldwide from CVD.(3) 
There is an ongoing development of new drugs to treat CVD and their 
intermediate biological factors such as hypertension, 
hypercholesterolemia, diabetes and obesity, but the partial efficacy, 
partial intolerance and several adverse effects create the necessity to 
search for new strategies or coadjutant strategies for the prevention and 
treatment of CVD.(4) Therefore, the scientific world focuses their 
research on finding new bioactive compounds from food and beverages 
with beneficial effects on cardiovascular health. Moreover, the study of 
their impact on metabolic pathways through the omics science approach 
to determine their mechanisms of action and to identify new biomarkers 
of diseases or treatment response is also considered. Omics science 
refers to a field of study in biological sciences that includes 
transcriptomics, proteomics, metabolomics or genomics, with the 
objective of collecting a large number of biological molecules involved 
in the function of an organism at a defined moment and under certain 
conditions.(5) 
 
It is well recognized that healthy dietary patterns have significant 
benefits for CVD treatment and CVD prevention.(6) In this sense, there 
is the Mediterranean diet, traditionally characterized by a high intake of 
seasonable vegetables, legumes, fruits, grains, fish and seafood, poultry 
protein, olive oil, and nuts and low intake of dairy products, red meat, 
processed meat and sugary drinks. The Mediterranean diet was linked 
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with the improvement in lipid profile, insulin sensitivity and endothelial 
function in subjects with cardiovascular disease risk factors (CVDRFs), 
acting on inflammation and antithrombotic and oxidative stress 
markers.(7) Another example is the DASH diet (Dietary Approaches to 
Stop Hypertension) characterized by a low consumption of salt and high 
intake of fruits, vegetables, whole grains, low-fat dairy and lean protein, 
which has demonstrated significant blood pressure (BP) reductions in 
subjects with hypertension,(8) which is one of the most important 
CVDRFs.  
 
In this sense, most of these observed effects on cardiovascular health 
are attributable to bioactive compounds, and one of the most important 
are phenolic compounds, founded in plants products and mainly present 
in species, fruits, vegetables, olive oil, nuts and beverages.(9) Phenolic 
compounds are classified into two large families: flavonoids and 
nonflavonoids.  
Phenolic compounds have gained much interest in this field because of 
their demonstrated capacity to exert beneficial effects on various 
diseases, including CVDs,(10) and they have been reported in several 
randomized controlled trials (RCT), the gold standard studies for 
efficacy evaluation in clinical research.(11) One of the most studied 
phenolic compounds related to the Mediterranean diet is phenolic 
compounds from olive oil. In this sense, it is reported that the 
consumption of a functional virgin olive oil enriched with olive oil and 
thyme phenolic compounds enhanced the expression of cholesterol 
efflux regulators, promoting major high-density lipoprotein function 
and having a beneficial effect on hypercholesterolaemic subjects.(12) 
Thus, another randomized controlled clinical trial also demonstrated the 
cardioprotective effect of virgin olive oil and virgin olive oil enriched 
33 
 
with phenolic compounds on oxidation, blood coagulation, lipid 
transport and immune response.(13) On the other hand, there are some 
promising phenolic compounds not largely studied until today, and one 
of them is the flavonoid hesperidin.  
Hesperidin, naturally present in citrus fruits and the main flavonoid of 
orange and orange juice (OJ), has been shown in preclinical and clinical 
studies to have a therapeutic effect in several diseases, including CVDs, 
due to its anti-inflammatory and antioxidant effects, and its capacity to 
decrease lipids and improve insulin sensitivity.(14) Moreover, 
hesperidin could exert promising hypotensive activities.(15,16) 
However, the literature about hesperidin effects is scarce, and some 
results are unclear and controversial. 
Besides, OJ is one of the most consumed beverages throughout the 
world(17) and is totally integrated into our dietary pattern. However, 
currently the health impact of fruit juices consumption is 
controversial.(18) Thus, assessing the beneficial effects of OJ on health 
can be interesting and relevant.  
In addition, to the best of our knowledge, the mechanism of action by 
which hesperidin exerts its possible beneficial effects has not been 
clearly and fully defined. Finally, no omics approach has been 
performed to study the effects of hesperidin on the transcriptome, 
metabolome, or proteome profile, since omics science can shed light on 
the mechanisms of action.  
 
Therefore, looking at the possible potential of the flavonoid hesperidin 
on cardiovascular health, the possibility of using hesperidin or 
hesperidin-rich foods and beverages as a coadjutant treatment or 
prevention strategy for CVDs, and particularly on BP, and due to the 
scarcity of the available literature, further research is needed. 
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Accordingly, a randomized controlled trial will be developed to know 
hesperidin effects on BP and the most efficient dose of hesperidin in 
humans. Moreover, to know the mechanisms of action and the 
biological effects of hesperidin, an omics science approach will be 




















Figure 1. Graphical representation of the justification section of the 
present doctoral thesis. Abbreviations: BP, blood pressure; CVDRFs, 


























CHAPTER 1. A worldwide health problem: 
cardiovascular disease. 
 The life expectancy of the world population has been increasing 
over the decades and currently, the average number of years of life in 
the world is 72(19), and in Spain it is 83.(20) The increase is due to the 
eradication of several diseases, the mortality reduction of usual 
pathologies and changes in daily life such as better food control and 
hygiene measures. 
 
In this sense, CVDs are one of the most advanced fields in research and 
contribute to an increase in life expectancy. A few decades ago, heart 
attack and stroke involved fatal outcomes, but today, the prognosis has 
changed, and patients can recover and live normally.(21) However, 
CVDs continue to be the main cause of mortality in the world according 
to the World Health Organization (WHO) (1) and the main cause of 
mortality in Spain according to the Instituto Nacional de 
Estadística.(22) Thus, more people die every year from CVDs than 
from any other cause. The statistics show that in 2030 more than 23 
million people will die from CVDs.(23) 
Several factors influence the development of CVDs, but the experts 
mainly highlight the progressive ageing of the population and the loss 
of healthy lifestyle habits. Age is a risk factor itself, and the possibility 
of developing CVDs increases with advancing age.(21) However, a 
change towards a healthier and more active life opens a window of 
possibilities to transform the course of CVDs.  
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1. 1 Definition of cardiovascular disease. 
CVD is a multifactorial disease consisting of a set of disorders of heart 
and blood vessels that include:(23) 
• Hypertension. 
• Coronary heart disease or heart attack. 
• Cerebrovascular disease or stroke. 
• Peripheral vascular disease. 
• Heart failure. 
• Rheumatic heart disease. 
• Congenital heart disease. 
• Cardiomyopathies. 
 
1. 2 Pathophysiology of atherosclerosis.  
Atherosclerosis, an inflammatory disease characterized by oxidative 
stress and systemic inflammation, is the main cause of the major 
incidence and mortality of CVD mentioned above.(24) It is known that 
the formation of atherosclerotic lesions occurs due to local 
inflammation in the vascular wall that is induced by dyslipidaemia, 
normally because of high low-density lipoprotein-cholesterol (LDL-c) 
levels,(25) and is produced because of lipid and leucocyte accumulation 
in blood vessels producing plaque formation.(26) Gradually, the plaque 
hardens and causes narrowing of the arteries, restricting blood flow. 
Later, the plaque can rupture and form a thrombus (blood clot) causing 
a further blockage of blood flow and therefore, the availability of 
oxygen to the body’s organs.(26) 
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Thus, atherosclerosis is characterized by endothelial dysfunction and 
the accumulation of low-density lipoprotein particles (LDLp), immune 
cells and necrotic debris in the endothelial space, and endothelial 
activation triggers the expression of leukocyte adhesion molecules such 
as E-selectin and P-selectin, glycoproteins such as intercellular 
adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 
(VCAM-1), chemokines such as monocyte chemoattractant protein-1 
(MCP-1), etc.(27) Then, the accumulation of LDLp promotes the 
release of macrophage colony stimulating factor (M-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), 
facilitating monocytes maturation.  
 
Additionally, LDLp turn into oxidized LDL (oxLDL) particles, and 
they can be recognized by macrophage receptors (CD36 or LOX-1). 
Consequently, the receptors activate nuclear factor kB (NF-kB) 
signaling, producing pro-inflammatory cytokines such as interleukin 1 
beta and tumour necrosis factor (TNFα), generating foam cells. Foam 
cells capture oxLDL and lysosomal acid lipase converts esters of 
cholesterol into free cholesterol and fatty acids. Therefore, M1 
macrophages, Th1 cells and some B cell subtypes produce pro-
inflammatory cytokines and chemokines promoting atherosclerosis. 
On the other hand, Bregs, Tregs and M2 macrophages suppress 
inflammation reducing the size of the plaque and stabilizing the 
atherosclerotic lesion.(27) The graphical representation of 

















Figure 2. Pathogenesis of atherosclerosis. Source: (Herrero-
Fernandez B et al. 2019).(27) 
 
1. 3 Cardiovascular disease risk factors. 
A risk factor is defined as the measurable characteristic that is causally 
associated with an increased rate of a disease; and that is an independent 
and significant predictor of the risk of presenting a disease.(28) Thus, 
CVDRFs are those that increase the possibility of developing CVDs.  
In this sense, it is known that CVDRFs can be divided into two 




Non-modifiable risk factors are those that we cannot influence. Factors 
included in this category are the following:(2)  
- Family history of CVDs. 
- Age. 
- Sex: the male sex has a higher risk of developing CVDs. 
- Ethnicity: CVD mortality rates are especially high among black 
men. 
- Socioeconomic status.  
 
On the other hand, modifiable risk factors are those related to habits or 
behavior performed by humans, which are susceptible to being 
modified. In this category, the following factors are included:(2)   
- Tobacco use. 
- Physical inactivity.  
- Physiological stress.  
- Diet.  
 
Smoking is one of the most preventable risk factors that contributes the 
most to the development of CVDs.(29) There are group therapies and 
medication approaches that can be used to stop smoking cigarettes, thus 
reducing the CVD risk. On the other hand, physical inactivity increases 
CVD risk by 1.5 times.(30) Regular physical activity protects against 
CVDs since it reduces body weight, lipid levels, blood glucose and BP 
levels. Moreover, reducing the progression of atherosclerosis decreases 
oxidative stress, increases sensitivity to insulin and decreases the 
incidence of coronary disease. Therefore, it reduces the total and CVD 
morbidity and mortality.(27) 
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Finally, the role of diet is crucial in the development and prevention of 
CVDs since the association between eating habits and CVDs is well 
known.(30) Unhealthy behavior increase the main risk factors that lead 
to CVDs such as BP, blood glucose, blood lipids, overweight, obesity 
and diabetes, resulting in hypertension, hypercholesterolaemia, 
hypertriglyceridaemia, or metabolic syndrome. Therefore, changes in 
diet are one of the keys to follow to impact CVDRFs.(31) 
 
In this sense, in Table 1 there is a general description of risk goals and 
target levels for the most important CVDRFs according to the European 
Cardiology Society (ESC). Thus, achieving these target levels can 
prevent the development of CVDs. 
 
 
Table 1. Risk goals and target levels for the most important 
cardiovascular diseases risk factors according to the ESC. 
Smoking  No exposure to tobacco.  
Diet  Healthy diet low in saturated fat with a focus on 
wholegrain products, fruits, vegetables, and fish.  
Physical activity  3.5-7 hours moderately vigorous physical activity every 
week or 30 – 60 min most days.  
Body weight  BMI 20-25 kg/m2. 
Waist circumference <94 cm in men and <80 cm in 
women.  
















-Very high-risk: <70 mg/dL, or a reduction of at least 
50% if the baseline is between 70 and 135 mg/dL. 
-High-risk:  <70 mg/dL, or a reduction of at least 50% 
if the baseline is between 100 and 200 mg/dL. 
-Moderate risk: <100 mg/dL. 
-Low risk: <116 mg/dL. 
 
 
-For very high risk: <85 mg/dL. 
-For high risk: 100 mg/dL. 
-Moderate risk: 130 mg/dL. 
 
<150 mg/dL. 
Diabetes  HbA1c <7%. (<53 mmol/mol). 
Abbreviations: BMI, body mass index; BP, blood pressure; LDL-c, low-
density lipoprotein-cholesterol; HDL-c, high density lipoprotein cholesterol; 




1. 4 Prevention of cardiovascular diseases. 
To prevent CVDs, a coordinated pool of activities at the individual or 
population level to eliminate or reduce CVD incidence to the lowest 
level is needed.(33) From 1994 to the present, the reference guidelines 
on CVD prevention are the guidelines of the ESC. The guidelines have 
been revised several times and the latest version was published in 2020.  
These guidelines showed the role of lifestyle including diet in the 
prevention and treatment of CVDs since the probability of developing 
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CVDs is associated with unhealthy dietary patterns such as excessive 
intake of sodium, processed food, added sugars or unhealthy fats, and 





CHAPTER 2. Diet, nutrition and cardiovascular disease. 
 
 In this section we will explain the general perspective of the 
influence of dietary patterns such as the Western diet and 
Mediterranean diet, nutrients such as sodium and fibre, bioactive 
compounds such as flavonoids, and functional food such as citrus fruits, 
on CVDs and their main risk factors. 
 
Dietary habits influence the risk of developing CVDs by influencing 
CVDRFs, such as blood cholesterol levels, body weight and blood 
glucose levels.(35) Vast scientific evidence has shown that nutrition 
might be the most significant preventive factor of CVD death and can 
reverse heart disease. Additionally, diet can be used to manage excess 
weight, hypertension, diabetes and dyslipidaemia.(36)  
 
Thus, Table 2 summarizes the characteristics of a healthy diet according 
to the last update of the European Cardiology Society (ESC) for CVD 
prevention in clinical practice. 
For that reason, as dietary-associated risk is the most important 
behavior factor influencing global health, there is increased 
experimentation with the use of “food is medicine” interventions to 
prevent, manage and treat chronic diseases such as CVDs. However, 
CVDs remain the leading cause of death and disability in developed 
countries, and the challenge through dietary interventions in CVDs is 
to create more effective strategies to motivate populations to change 




Table 2. Characteristics of healthy dietary habits.  
Saturated fatty acids to account for <10% of total energy intake, 
through replacement by polyunsaturated fatty acids. 
Trans unsaturated fatty acids: as little as possible preferably no 
intake from processed food, and <1% of total energy intake from 
natural origin. 
<5 g of salt per day. 
30–45 g of fiber per day, preferably from wholegrain products. 
≥200 g of fruit per day (2–3 servings). 
≥200 g of vegetables per day (2–3 servings). 
Fish 1–2 times per week, one of which to be oily fish. 
30 g unsalted nuts per day. 
Consumption of alcoholic beverages should be limited to 2 glasses 
per day (20 g/day of alcohol) for men and 1 glass per day (10 g/day 
of alcohol) for women. 
Sugar-sweetened soft drinks and alcoholic beverages consumption 
must be discouraged. 
 
Adapted from: (Piepoli MF, et al. 2016). (34) 
 
From the 1990s there has been a transition from a nutrient-based to a 
dietary-based approach for addressing nutritional interventions in 
CVDs because of the new evidence that emerged from randomized 
clinical trials and meta-analyses. There is evidence (with few 
exceptions such as sodium or trans-saturated fatty acids) that single 
nutrients have effects of limited magnitude on chronic diseases such as 
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CVDs compared with whole foods or with complex integrated dietary 
interventions expressed as dietary patterns.(31) 
It is known that a westernized diet, characterized by a high intake of 
proteins derived from processed and read meats, saturated fats, refined 
grains, sugar, salt and alcohol and a low intake of vegetables and fruits, 
is associated with an increased risk of metabolic and chronic diseases 
such as CVDs.(37) On the other hand, the most well-studied dietary 
patterns that have beneficial effects on health, especially on 
cardiovascular health and hypertension, are the Mediterranean and 
Dietary Approach to stop Hypertension (DASH) diets. The composition 
of the Mediterranean diet and DASH diet are detailed in Table 3.  
 
Both dietary patterns are associated with a lower risk of clinical 
cardiovascular events.(31,38) However, the first diet that demonstrated 
a reduced mortality risk for CVDs was the Mediterranean diet. It was 





Table 3. The composition of Mediterranean and DASH diets. 
Mediterranean diet DASH diet 
-High content in fresh fruits, 
vegetables, whole grains, and 
fatty fish (rich in ꞷ-3 PUFA). 
-Low content in red meat. 
-Substituted lower-fat or fat-free 
dairy products for higher-fat 
dairy foods. 
-Olive oil, nuts, or margarines. 
-High in vegetables, fruits, low-fat 
fermented dairy products, whole 
grains, poultry, fish, and nuts. 
-Low in sweets, sugar-sweetened 
beverages, and red meats. 
-Low in saturated fat, total fat, and 
cholesterol. 
-Rich in potassium, magnesium, 
and calcium. 
-Rich in protein and fiber. 
Abbreviations: DASH, Dietary for Approach to Stop Hypertension; 
PUFA, poly-unsaturated fatty acids. Adapted from: (Ravera A et al. 
2016).(40) 
 
The Mediterranean diet, characterized as rich in whole grains, fruit, and 
vegetables and low in meat, with a considerable amount of fat from 
olive oil and nuts,(40) was first described in 1979 by the American 
biologist Ancel Keys when he observed that the population of the shores 
of the Mediterranean Sea (in Greece, south of Italy and Yugoslavia) had 
a lower incidence of CVDs. Later, it would be reported that a 
Mediterranean diet protects against coronary heart diseases and reduces 
the risk of the development of diabetes mellitus type 2 and metabolic 
syndrome.(41,42) This type of diet can reduce CVD risk by 
mechanisms that reduce BP, lipids, glucose, endothelial function, waist 
circumference and body mass index (BMI).(43) Additionally, it has 
49 
 
been reported that a Mediterranean diet can increase nitric oxide (NO) 
bioavailability and can have antioxidant and anti-inflammatory 
properties. Moreover, the Mediterranean diet seems to have beneficial 
effects on the synergy among various cardioprotective nutrients and 
foods.(43) 
 
On the other hand, in the 1990s, a research group led by Lawrence 
Appel evaluated the effects of a diet rich in fruit, vegetables and low-
fat dairy foods on BP levels in a randomized study called the Dietary 
Approach to Stop Hypertension (DASH) trial. The DASH diet has 
demonstrated efficacy in treating hypertension without anti-
hypertensive medication. Moreover, the DASH diet decreases the risk 
of developing diabetes in randomized controlled clinical trials and 
reduces cardiovascular mortality in prospective cohort studies.(44)  
 
Both the Mediterranean and DASH diets demonstrated an improvement 
in large CVDRFs, including long-term weight gain, BP levels, glucose-
insulin homeostasis, lipid profile, inflammation and endothelial 
function.(43,44) 
 
Last, vegetarian diets also showed beneficial effects on cardiovascular 
health. It is known that vegetarian patterns reduce CVD mortality and 
the risk of coronary heart disease.(45) In addition, in 2014 a non-
controlled study showed that heart disease could be reversed by a low-
fat vegan diet.(46) Moreover, recently published review concluded that 
a vegetarian diet exerts beneficial effects on BP levels, lipid profiles, 
platelet aggregation, obesity, metabolic syndrome and type 2 diabetes 
mellitus.(45) All its benefits are the result of the lower exposure to 
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harmful substances contained in animal products such as saturated fats 
and cholesterol, and greater consumption of whole plants rich in fibre 
and bioactive compounds.(45) 
 
2. 1 Nutrition and cardiovascular health: nutrients. 
The evidence shows that some beneficial effects on several CVDRFs 
are the higher intake of specific nutrients present in foods and the lower 
intake of another nutrients.  
 
For example, the intake of long-chain ꞷ-3 polyunsaturated fatty acids 
and their consequent higher circulant levels are protective against 
CVDs.(47) This is due to the anti-inflammatory and anti-atherosclerotic 
effects achieved by altering the fatty acid composition of inflammatory 
cells.(48) On the other hand, the reduced consumption of saturated fats 
and trans-fats also shows positive effects on cardiovascular health 
decreasing LDL-c levels.(49) For that reason, the American Heart 
Association/American College of Cardiology (AHA/ACA) published 
in guidelines for the management of reducing CVD risk that included 
the recommendation of ensuring the intake of polyunsaturated fatty 
acids and reducing the intake of saturated and trans-fat fatty acids.(50) 
 
On the other hand, the AHA/ACA also reported that the consumption 
of salt and sodium present naturally in foods and added during cooking 
can affect the CVDs risk. In this sense, reduced sodium intake is related 
to lower BP levels in adults, which is useful in preventing or treating 
hypertension and decreasing the risk of developing CVDs.(50) It is 
known that a higher dietary sodium intake increases extracellular 
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volume and cardiac output, increasing BP levels. Moreover, combined 
with sodium intake, abnormal serum levels of potassium and 
magnesium may affect CVDs because of their influence on 
hypertension, arrhythmia, and myocardial infarction. This relation is 
one of the most studied, and in Figure 3, the metabolism of sodium, 
potassium and magnesium in the body and their relationship with BP 












Figure 3. The metabolism of sodium, potassium and magnesium in the 
body and their relationship with BP levels. Adapted from: 
(Mohammadifard N et al. 2018).(51) 
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Moreover, several case-controls and prospective observational studies 
showed inverse associations between micronutrients such as the levels 
of vitamin A and vitamin E and the risk of CVDs.(34) Additionally, a 
correct intake of dietary calcium has beneficial effect on the 
cardiovascular system through the improvement in lipid profile, BP, 
obesity, insulin secretion, inflammation and anti-thrombotic 
agents.(51) It is known that micronutrients can exert their protective 
effect in three forms: decreasing endothelial cell damage, increasing 
NO production and/or inhibiting the oxidation of LDL-p. (24) 
Additionally, prospective cohorts and meta-analyses observe that a 
higher intake of total fibre decrease the risk of coronary artery disease, 
stroke and diabetes mellitus type 2, decreasing blood cholesterol levels 
and BP, while a deficiency of fiber intake was associated with the 
development of CVDs.(24) 
There is much scientific evidence that relates the beneficial effects of 
certain nutrients to CVDs and their risk factors. Therefore, the 
recognition of appropriate nutrients and their adequate intake have an 
important role in preventing CVDs. It is important to focus on the 
possible beneficial effects of specific nutrient intake to avoid possible 
deficiencies in nutrients that can lead to the development of 





2. 2 Nutrition and cardiovascular health: bioactive 
compounds and functional foods. 
The term “functional food” was coined in Japan and the USA in 
1970.(52) Functional foods are foods fortified with different probiotics 
and microorganisms, or natural or processed foods that have 
biologically active compounds and specific health-promoting benefits 
that have been scientifically substantiated.(52)  
Table 4 summarizes some of the most studied functional foods, their 
respective bioactive compounds, and their potential mechanism of 
action. 
 
Table 4. Bioactive compounds, functional foods, and potential 
mechanisms.  
Bioactive compound: Functional food: Potential mechanism: 
Tocopherols,  
ꞷ-3 fatty acids 
Nuts Lowering blood 
cholesterol 
Fiber  Legumes Inhibition of LDL-p 
oxidation 
Genistein and daidzein Soy proteins Antioxidant action and 
platelet aggregation 
Flavonoids  Dark chocolate Lowering blood TG, 
decreasing BP and 
antioxidant action 
Lycopene  Tomato Antioxidant action  





Grapes Endothelial function, 
antioxidant action and 
platelet aggregation 
Phytochemicals  Whole grains Lowering blood TG and 
decreasing BP 
Abbreviations: LDL-p, low-density lipoprotein particles; TG, 
triglycerides; BP, blood pressure. Adapted from: (Asgary S et al. 
2018).(52) 
 
The presence of some bioactive compounds present naturally in food 
and beverages is also responsible for the prevention and treatment of 
CVDs because of their beneficial effects on atherosclerosis 
development, reducing LDL-c levels, inflammation, and oxidative 
stress.(9) 
 
In recent decades, the number of studies evaluating the physiological 
activities of bioactive compounds from food has markedly increased, 
and phenolic compounds are one of the most studied. However, due to 
the large types of phenolic compounds and controversial results 
reported, more research is needed in this area since the identification of 
beneficial effects on cardiovascular health through phenolic compound 
intake could be part of the new nutritional treatment tools.  
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CHAPTER 3. Phenolic compounds. 
 
 In this section, the definition and summary of the characteristics 
and effects of phenolic compounds will be reported, focusing on 
flavonoids since they are studied in the present doctoral thesis.  
Phenolic compounds are secondary metabolites of plants present in high 
concentrations in several species, food, and beverages. In contrast to 
minerals, vitamins and other nutrients, the deficiency of phenolic 
compounds intake does not produce specific deficiency diseases, 
although adequate phenolic compounds intake has beneficial effects on 
health status, especially on chronic diseases.(53) 
 
Currently, phenolic compounds are one of the most studied bioactive 
compounds because they are the most consumed antioxidant.(54) Total 
phenolic compounds ingestion, according to our previous results, 
ranged from 1196.7 to 1967.9 mg/day in an adult healthy Mediterranean 
population.(55) It is known that cocoa, tea, fruits, and vegetables are 
the main foods rich in phenolic compounds (56), and a high intake of 
specific phenolic compounds has been linked to reduced mortality from 
specific vascular diseases and cancers.(57) 
 
3. 1 Classification of phenolic compounds. 
There are more than 8000 different types of phenolic compounds that 
differ between them depending on the number of phenolic rings they 
have, and the substituent attached to the rings.(9) Phenolic compounds 





Flavonoids are the most common type in plants and consist of 15 
carbons with 2 aromatic rings connected by a 3-carbon bridge (Figure 
4).  
The main subclasses of flavonoids are flavonols, flavones, flavan-3-ols, 
isoflavones, flavanones and anthocyanidins. Yellow and red onions are 
especially rich sources of flavonols containing high concentrations of 
quercetin; rooibos tea and caffeine-free beverages have high 
concentrations of flavones such as apigenin and luteolin; leguminous 
plants are especially rich sources of isoflavones containing high 
concentrations of daidzein and genistein; citrus fruits have high 
concentrations of flavanones such as naringenin and hesperetin; and 




The main non-flavonoids present in food are phenolic acids, and gallic 
acid is the most common. Non-flavonoids also include stilbenes and 
lignans (Figure 5).  
The main stilbenes are resveratrol, present in red wine and blueberries, 
while secoisolariciresinol is the most common lignan, present in 

















Figure 4. Structure of flavonoid and their subclasses. Source: (Del 





Figure 5. Structure of the main non-flavonoids: gallic acid 
(phenolic acid), resveratrol (stilbene) and enterodiol (lignan). 
Adapted from: (Del Rio D et al. 2013).(9) 
58 
 
3. 2 Absorption and metabolism of flavonoids. 
Flavonoids present in the diet are mainly present in their glycoside 
form, and deglycosylation takes place in the small and large intestines, 
depending on the type of sugar moiety. Two enzymes have been 
reported to act as β-glucosidases in the small intestine against flavonoid 
monoglucosides: lactase-phlorizin hydrolase (LPH) and cytosolic β-
glucosidase.(9) 
An example of the absorption and metabolism of flavonoids, 
















Figure 6. Absorption and metabolism of flavonoids. Quercetin 
glycosides represent the absorption and metabolism of flavonoid 
glycosides. Epicatechin represents the absorption and metabolism of 
the flavonoid subclass, the flavan-3-ols. Abbreviations: SGLT, sodium-
dependent glucose transporter; LPH, lactase-phlohizin-hydrolase; 
CBG, cytosolic β-glucosidase; MRP, multidrug resistance protein; P-
gp, P-glycoprotein. Source: (Bondonno CP et al. 2015).(58)  
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3. 3 Health effects of flavonoids. 
At the end of the 19th century the chemical structure of flavonoids was 
identified and in the early years of the 20th century, flavonoids and their 
related substances were synthesized in the laboratory. Finally, in the 
1930s Albert Szent-Györgyi focused his attention on the effects of 
specific flavonoids on human health.(59)  
Since the effects of flavonoid consumption have been studied for 
decades, in vivo and in vitro studies were performed to determine their 
mechanisms of action and their implications on biological pathways. 
Additionally, epidemiological studies and clinical trials in humans were 
performed to evaluate the effects of flavonoid consumption.  
 
Epidemiological evidence has demonstrated a reduction in the risk of 
fatal CVDs in subjects with a high flavonoid intake. Moreover, 
prospective studies observed an association between high flavonoid 
intake and a lower risk of CVD mortality and future cardiovascular 
events.(60)  
On the other hand, human randomized clinical trials showed protective 
effects of flavonoid consumption against CVDs. For example, 
flavonoids of phenol-enriched olive oils modulate oxidative balance 
producing cardioprotective effects,(61) and flavonoids of flavonoid-
rich apple improve endothelial function decreasing the risk for 
CVDs.(62) 
In this sense, several studies have shown benefits of flavonoid 
consumption on the prevention and treatment of several lifestyle-related 
diseases,(56) including atherosclerosis,(63) coronary heart diseases(64) 
and metabolic syndrome.(65)  
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Meta-analyses reported that the consumption of flavonoid-rich foods is 
associated with a reduced risk of cause-specific mortalities such as 
those attributable to cancer, diabetes, and CVDs.(57) Additionally, 
observational studies showed a lower risk of cardiometabolic events 
with a high dietary intake of flavonoids.(66,67) In human clinical trials, 
flavonoid consumption also shows beneficial effects on several 
parameters related to chronic diseases. For example, RCT performed on 
subjects with CVDRFs such as hypertension, overweight or obesity, 
diabetes and dyslipidaemia, reported that the daily consumption of 
chocolate containing 70% cocoa, rich in gallic acid, for 6 weeks 
improved biochemical parameters (such as total cholesterol (TC), LDL-
c and triglycerides (TG)) and waist circumference.(68) In another 
randomized clinical trial, both the single dose and chronic consumption 
of flavonoid-rich apple improved the endothelial function, an 
independent risk factor for CVDs.(62) Moreover, after daily 
consumption for 8 weeks of blueberry, rich in anthocyanins, the  
systolic BP levels were reduced in postmenopausal women with pre and 
stage 1 hypertension, due to the increase in NO production.(69) A 
recently published review shows that flavonoid-enriched foods 
decrease BP levels and improve endothelial function by promoting 
vascular dilation in geriatric patients, who are characterized by multiple 
chronic diseases.(70) Furthermore, consumption of OJ, which is 
naturally rich in hesperidin, for 4 weeks, increases endothelium-
dependent microvascular reactivity and decreases  diastolic BP.(71) 
Thus, several clinical trials were performed in humans with one or more 
CVDRFs to evaluate the effects of different flavonoids. However, there 
are differences among different flavonoid and therefore, their effect on 
health cannot be generalized, and each type of flavonoid needs to be 
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studied. Thus, the effects of some of them are currently controversial, 
and some flavonoid classes have not been sufficiently studied to date. 
Thus, investigating how the consumption of specific flavonoids 
influences different conditions is useful to find new ways to prevent and 
treat diseases such as CVDs.  
 












Figure 7. Potential health benefits of dietary flavonoids. Source: 
(Del Rio D et al. 2013).(9) 
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3. 4 Mechanisms of action. 
The first mechanism of action described for flavonoids was focused on 
their direct antioxidant effects.(56) However, the concentrations of 
these compounds in most tissues do not reach the minimum needed to 
have a significant effect in terms of scavenging free radicals.(56) 
Additionally, other molecular mechanisms of action have been 
identified such as the implication on cellular signalling pathways, 
regulating nuclear transcription factors and lipid metabolism, and 
modulating inflammatory mediators synthesis such as interleukins and 
TNFα.(72) In this sense, in vitro and in vivo as well as epidemiological 
and experimental studies highlighted the anti-inflammatory activity of 
flavonoids.(73)  
 
While the molecular mechanisms continue to be clarified, the identified 
signalling pathways include AMP-activated protein kinase (AMPK), 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α), peroxisome proliferator-activated receptor gamma (PPAR-
γ) and nuclear factor-κB (NF-κB). Nevertheless, the mechanism of 
action by which several flavonoids exert beneficial effects remains 
unclear. On the other hand, there are many identified flavonoids to date, 
and the observed effects on molecular pathways for some of them are 
unlikely to be generalizable to others because of their differential 





CHAPTER 4. The flavonoid hesperidin. 
  
 In this section, the definition, characteristics, metabolism, 
bioavailability, and health effects of the flavonoid hesperidin will be 
presented. Moreover, we introduce the actual evidence of the effects of 
hesperidin on cardiovascular health since it is the focus of the present 
thesis.  
The flavonoid hesperidin (hesperetin 7-O-rutinoside) is founded in 
glycosylated form in food, and when it is absorbed in the organism is 
transformed into aglycated form called hesperetin. In bloodstream, 
hesperetin can be conjugated into sulfate and glucuronides forms.(14) 
The chemical structures of hesperidin and hesperetin are represented in 
Figure 8. 
Hesperidin is found in the peel of citrus fruits representing 90% of citrus 
flavonoids but a considerable amounts are found in their juices.(75) 
Moreover, hesperidin is the main citrus flavonoid of orange fruit and its 
juice, and orange and OJ are the most common citrus fruit products 
consumed in Europe.(17) Furthermore, the consumption of hesperidin 
















Figure 8. Chemical structures of hesperidin form (A) founded in 
food, and hesperetin form (B) founded when hesperidin is 
absorbed. Source: (Xiong H et al. 2019).(77) 
 
 
4. 1 Health effects of the flavonoid hesperidin. 
In recent years, the flavonoid hesperidin has gained much attention in 
the phenolic compounds research due to its reported beneficial effects 
on health. Observational studies have reported that citrus fruit 
consumption is associated with a lower risk of acute coronary 
events.(78) Moreover, preclinical and clinical studies have 
demonstrated the possible therapeutic action of the flavonoid hesperidin 
on several diseases, such as psychiatric disorders, neurological 
disorders, carcinoma and CVDs, because of its anti-inflammatory, 
antioxidant, and other interesting properties.(79) 
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There is evidence of the beneficial effect of hesperidin on the 
cardiovascular system.(80) Figure 9 shows the possible beneficial 











Figure 9. Effects of hesperidin consumption on cardiovascular 
disease risk factors in humans. Abbreviations: TG, triglycerides; 






Lipid profile and adiposity: 
First, in animal models, hesperidin administration improves the lipid 
profile in rats with type 2 diabetes and hypercholesterolaemia. In this 
sense, it is known that dyslipidaemia is an important and significant risk 
factor for the development of atherosclerosis. Additionally, hesperidin 
administration increases high-density lipoprotein-cholesterol (HDL-c) 
levels and decreases TG, TC and LDL-c levels in metabolic syndrome 
rats.(81) Moreover, in type 2 diabetic rats, hesperidin decreased the 
plasma free fatty acids and plasma and hepatic TG levels after 5 weeks 
of daily consumption.(82) The improvement is produced because of the 
downregulation of the synthesis of very low density lipoprotein 
(VLDL) in hepatocytes, the inhibition of lipogenesis and the promotion 
of beta oxidation of fatty acids.(83) Moreover, hesperidin can suppress 
hepatic fatty acid synthase and glucose-6-phosphate dehydrogenase and 
decrease fatty acid oxidation and carnitine palmitoyl transferase 
activity.(84) 
Second, similar results were obtained in human studies. In 
hypercholesterolaemic subjects, hesperidin consumption through OJ 
improved lipid profiles increasing HDL-c concentrations and 
decreasing the LDL-c/HDL-c ratio.(85,86) Thus, hesperidin might 
benefit atherosclerosis by reducing lipid levels because of its anti-lipid 
peroxidation and antioxidant properties.(87)  
However, unlike the studies in animals, in humans, there is controversy; 
some studies see similar results as those in animal studies, while other 
studies did not observe its effects.(88,89)   
On the other hand, the alteration of adipose tissue and its dysfunction 
promotes the development of obesity, an independent risk factor for 
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CVDs, and hesperidin seems to be a possible therapeutic agent for 
obesity. It is known that the chemical structure of the flavonoid 
hesperidin is one of the most effective inhibitors of adipocyte formation 
since hesperidin can induce a decrease in TG concentration in 
preadipocytes.(90)  
In animal models of obesity or metabolic syndrome, hesperidin reduces 
body weight and adipose tissue weight.(91,92) In contrast, in human 
studies the actual evidence is controversial. In some studies, daily 
hesperidin consumption reduces body weight in subjects with obesity 
or overweight and in hypercholesterolaemic subjects(93,94) and can 
increase adiponectin levels in patients with myocardial infarction.(86) 
However, other studies in humans did not show positive results for 
weight loss or obesity-related biomarkers.(95,96) 
 
Blood pressure and endothelial function: 
As we previously detailed, high BP levels are one of the most important 
CVDRFs, and endothelial dysfunction is also an important contributor 
to the pathobiology of atherosclerotic CVD.(97)  
It has been demonstrated that hesperidin has an anti-hypertensive effect 
in renovascular hypertensive rats that involves the suppression of the 
renin-angiotensin system(98). Additionally, the anti-hypertensive 
effect of hesperidin was suggested to be mediated by the vascular NO 
synthase pathway and the reduction of oxidative stress by 
overexpression of NADPH oxidase, improving endothelial function in 
rats.(98) 
In vitro studies have demonstrated an increased production of NO in 
endothelial cells after hesperidin administration. Additionally, in vivo 
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studies in rats showed that hesperidin can prevent NO deficiency and 
hypertension, and the possible mechanism involved its anti-
inflammatory and antioxidant effects.(99) Animal studies also showed 
the capacity of hesperidin to exert antioxidant activity. In this sense, 
NO is an important vasodilator produced by the vascular endothelium 
with the objective of regulating the vascular tone.(99) Thus, decreased 
NO production results in higher vascular resistance and increased BP 
levels. Therefore, hesperidin seems to improve this aspect. 
In animal models and in vitro studies, the effects of hesperidin 
consumption on BP and endothelial function are clear; however, in 
human studies, the effects are controversial. In subjects with at least one 
CVDRF, the sustained hesperidin consumption decreases systolic and 
diastolic BP levels and improves the endothelial 
function.(71,93,100,101) Nevertheless, there are studies that did not 
show beneficial effects on BP and endothelial function.(102,103) 
 
Glucose metabolism: 
The main complication of diabetes is CVDs, and there are several 
studies both in vitro and in vivo that have shown positive effects of 
hesperidin consumption on glucose homeostasis. 
Recently, in an in vitro study, both hesperidin and hesperetin inhibited 
the non-enzymatic glycation of proteins, the main reaction involved in 
the formation of advanced glycation end-products which has an 
important role in the pathogenesis of diabetes.(104) On the other hand, 
hesperidin can affect the gene expression of glucose-regulating 
enzymes, such as phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase, influencing glucose metabolism and glucose 
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regulation.(105) Additionally, hesperidin can decrease the blood 
glucose concentration by upregulating hepatic glucokinase and PPAR-
γ and adipocyte GLUT4.(106)  
In human clinical trials, similar to the evidence for BP and endothelial 
function, there is no clear effect of hesperidin on glucose metabolism. 
To the best of our knowledge, to date no study has found a positive 
effect of hesperidin consumption on plasma glucose levels or insulin in 
humans.(101,103,107) 
 
4. 3 Metabolism and bioavailability of the flavonoid 
hesperidin. 
The absorption of flavonoid glycosides normally occurs in epithelial 
cells of the small intestine by the enzymes lactase phlorizin hydrolase 
and B-glycosidase, and the metabolites obtained are transported into the 
bloodstream.(9) However, bioavailability studies have shown that the 
flavonoid hesperidin is resistant to enzymes of the stomach and small 
intestine; therefore, hesperidin can arrive intact at the colon.(9) It is 
known that only 30% of hesperetin metabolites are absorbed in the 
small intestine and the other 70% are absorbed in the colon.(108) 
At the colon, hesperidin is converted to glucuronides form by alpha-
ramnosidase and microbiota.(109) Then, the hesperidin molecule 
realizes the aglycone form called hesperetin.  
Hesperetin is released into the bloodstream in glucuronide form and 
sulfate conjugates.(110) Three of the most relevant metabolites of 
hesperidin founded in the organism are: hesperetin 7-O-B-D 





A schematic representation of hesperidin metabolization in the colon is 
represented in Figure 10.  
 
The bioavailability of the flavanone hesperidin depends on the type of 
food matrix form in which it is ingested (juice, extract, capsules, etc.), 
the processing techniques, and the characteristics of the host, such as 
health status, age, sex, genetics and/or gut microbiota 
composition.(112) In this sense, it is known that the bioavailability of 
hesperidin is not different between orange fruit and OJ with higher 
doses of hesperidin. The similar bioavailability is likely due to the 
metabolism of flavanones being saturated when the intake exceeds a 
certain limit.(113) On the other hand, when hesperidin is consumed by 
capsules or supplements, the bioavailability is similar to hesperidin 
consumed by food or beverages.  
 
Finally, it is known that subjects can be stratified into three categories 
depending on their capacity to absorb and excrete hesperidin 
metabolites: high, medium and low.(110) Therefore, as we previously 
mentioned, the bioavailability of the flavanone hesperidin depends on 

















Figure 10. Graphical representation of hesperidin metabolization 




CHAPTER 5. Omics science: the future of research. 
 The word omics refers to an area of study in biological sciences 
that includes various disciplines including genomics, transcriptomics, 
proteomics, and metabolomics (Figure 11), as well as other emergent 
omics such as metagenomics, lipidomics, glycomics or foodomics. The 
ending -ome is used to describe the object of study of each field, such 
as the genome, transcriptome, proteome, or metabolome.(5) 
 
The omics sciences involve the analysis of a large volume of data using 
bioinformatics tools to bring great advances in the basic knowledge of 
biological issues and the study of organisms and their functions, all 
through genetic tracing.(114) The omics approach provides a good 
option for hypothesis-generating experiments, as holistic approaches 
analyse all available data to describe a hypothesis in situations when no 
hypothesis is known or prescribed due to a lack of data.(5) In addition, 
as the omics sciences allow for study at the molecular level of the 
different elements that include biological systems (cells, tissues, etc.) in 
all their complexity, omics also allows for the study of the interactions 
and relationships that occur between the internal components of the 
individual and the external elements.  
 
In this sense, omics applications can be used to prove the connections 
and interrelationships among the many scenarios in a complex 












Figure 11. Graphical representation of the main omics sciences 
(own source).  
 
In addition, there are two types of analyses: nontargeted and targeted. 
Nontargeted approaches have the objective of detecting, identifying, 
and quantifying as many genes, proteins or metabolites in a biological 
sample as possible. In contrast, a targeted approach identifies a group 
of genes, proteins or metabolites previously selected.(115) Thus, the 
wide coverage of nontargeted approaches has the potential to identify 
new metabolic pathways and new disease biomarkers. 
 
In this section of the present doctoral thesis, we focus on 
transcriptomics, metabolomics, and proteomic approaches.  
 
5. 1 Transcriptomics approach.  
The starting point of molecular biology represents the flow of genetic 
information from genes to the respective functions in cells and 
organisms. This process begins with the transcription of 
deoxyribonucleic acid (DNA), the genetic information repository. DNA 
is transcribed by the ribonucleic acid (RNA) polymerase enzymes into 
RNA and after that, a subset of RNA is translated into protein. 
75 
 
However, not all RNAs are translated into proteins. Some of them will 
have a structural function (such as rRNAs), develop a regulatory 
function (such as siRNAs) or be long non-coding RNAs (lncRNAs), 
that they do not be translated into proteins but demonstrate their 
capacity to play important roles in human diseases such as 
cardiovascular and cancer disorders. Therefore, the transcriptome is a 
set of RNA molecules present in a cell, a set of cells or in an organism. 
However, transcriptomics also provides important data regarding the 
content of cell non-coding RNAs, such as lncRNAs.(116) 
 
Transcriptomics analysis is the study of the transcriptome, the complete 
set of RNA transcripts, that is produced by the genome under specific 
conditions in a specific cell, using high-throughput methods, such as 
microarray analysis. A microarray is a tool used to detect the expression 
of thousands of genes at the same time. DNA microarrays are 
microscope slides that are printed with thousands of tiny spots in 
defined positions, with each spot containing a known sequence or gene. 
Then, the unknown DNA molecules are cut into fragments by 
restriction endonucleases and fluorescent markers are attached to these 
DNA fragments, allowing the reaction with probes of the DNA 
microarray.(5) 
 
Transcriptomic analysis is used in research and biomedicine for disease 
diagnosis, biomarker discovery, risk assessment of new drugs, etc. 
Moreover, transcriptomics analysis also allows the identification of 
pathways and metabolic changes produced because of environmental 
stresses such as diet. In this sense, transcriptome analysis is commonly 
used to compare samples that received different external conditions to 
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identify genes that are differentially expressed in distinct cell 
populations, or in response to different treatments. Additionally, it is 
commonly used to compare healthy and disease states to determine, for 
example, the mechanisms of pathogenesis.(116) 
 
5. 2 Proteomics approach. 
Proteomics, first used in 1996 by Marc Wilkins, is the study and 
characterization of the proteome. The proteome is defined as all the 
protein content of a cell, tissue or biological fluid in specific conditions, 
characterized by their localization, interactions, expression, structure 
and functions.(117) The proteome changes from time to time, from cell 
to cell and in response to external factors.  
 
Proteomics analysis is one of the most important methods to determine 
gene function, although it is more complex than genomics. Proteins are 
effectors of biological function, and their levels not only depend on 
mRNA levels but also depend on the control and regulation of 
translation.(117) Therefore, proteomics is considered the most 
important set of data to characterize a biological system. In this sense, 
proteomics offers complementary information to genomics and 
transcriptomics needed to understand complex biochemical 
processes.(118) Furthermore, the understanding of protein expression, 
and thereby what and how biological processes are regulated at the 
protein level allows the understanding of the molecular basis for 
diseases and the option to shed light on disease prevention, diagnosis, 




There is diverse proteomics approaches and one of the most relevant 
tools to identify, characterize and quantify proteins on a large scale, is 
mass spectrometry (M-S), which allows the analysis of complex protein 
mixtures with high sensitivity.(119) M-S is a technique that ionizes all 
chemical compounds in a sample, resulting in charged molecules that 
are analysed depending on their mass-to-charge ratios. For the simple 
pre-separation of complex protein mixtures before M-S analysis, one- 
or two-dimensional polyacrylamide gel electrophoresis was often used 
in the past.(5) Currently, off gel-nanoLC-(Orbitap) MS/MS is used 
because it is more efficient in identifying novel proteins in various 
biological systems. 
 
The identification of differentially expressed proteins in healthy and 
diseased subjects allow the discovery of new biomarkers in biomedical 
research. For example, recent work demonstrated the implication of 
several proteins in heart failure in subjects through proteomic analysis, 
allowing new plasma biomarker discovery for heart failure.(120) 
Moreover, as the application that will be realized in the present doctoral 
thesis, proteomics can provide insight into the effects of specific 
compounds, such as the flavonoid hesperidin, on the proteome to 
explore the molecular mechanisms involved in the cardioprotective 
effects of hesperidin.(121) 
 
5. 3 Metabolomics approach. 
Metabolomics emerged in the third millennium with the intention of 
measuring all the small molecule metabolites in a biological system, or 
at least most of them. For that reason, the improvement in instrument 
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technologies has improved the metabolomics analysis, most notably in 
the sensitivity and mass range of mass spectrometers.(122) 
 
The metabolome is the global profile of metabolites in a biological 
sample. Metabolites are the natural intermediate products of metabolic 
reactions catalysed by enzymes that occur in cells, including an 
immense variety of endogenous small molecules such as amino acids, 
lipids, nucleic acids, sugars, fatty acids, etc., as well as exogenous 
chemicals such as pharmacological agents, toxins or xenobiotics. Thus, 
metabolomics is the study of metabolites in response to environmental 
stimuli and genetic alterations, giving a full-scale analysis of cellular 
and tissue metabolism and providing a more comprehensive 
understanding of biology.(122) 
Typically, metabolomics uses high-resolution analysis together with 
statistical analysis such as principal component analysis, to obtain an 
integrated picture of the metabolome. The most commonly used 
methods by which the metabolome is assessed are nuclear magnetic 
resonance spectroscopy and M-S.  
 
The metabolic profiles obtained permit the development of diagnostic 
and/or prognostic tools that have the potential to significantly alter the 
management of CVDs.(123) For example, several works identified both 
urinary and plasma metabolites correlated with BP levels and 
hypertension, such as alanine or hippuric acid.(124) On the other hand, 
branched-chain amino acids (BCAA) levels have been linked with 




For that reason, knowing the metabolome profile of individuals can 
offer translation from research to clinical practice to substantially affect 
the diagnosis, prognosis, and treatment of cardiovascular medicine. In 
nutritional interventions, a metabolomics approach can offer the 
possibility of identifying new biomarkers to determine the intake of 
specific compounds such as hesperidin and to relate it to the biological 
effects observed. Biomarkers are constituents present in biofluids such 
as blood and urine that can be used to indicate dietary exposure to 
compare it to the recommended or estimated intake. Moreover, in 
human intervention studies, biomarkers can indicate dietary changes 
and can be exposure biomarkers. Furthermore, metabolomics offers 
away to evaluate the contribution of dietary factors by associating 
circulating metabolites with global CVDs but also with specific 
CVDRFs such as BP.(126) 
 
5. 4 Omics approach for the prevention and treatment of diseases. 
The molecular measurements from large-scale omics data could be 
integrated into models of disease risk prediction adding valuable 
information to traditional clinical tests to better stratify patients into 
high- or low-risk groups for the potential of developing a disease such 
as CVD. However, currently, the cost of performing an omics analysis 
is high. 
 
Nevertheless, the integration of different omics techniques is expected 
to become increasingly powerful for disease treatment and prognosis 
and has even been suggested to be useful in disease regression.(127)  
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The simultaneous integration of science omics was called systems 
biology in the past, and foodomics when it was applied to the food,(128) 
but nowadays it is called multi-omics (Figure 12).  
Multi-omics approach could be powerful in better understanding the 
mechanisms and pathways implicated to identify key drivers that have 













Figure 12. Workflow with integrated omics showing input datasets 


















 Our hypothesis is that the intake of hesperidin, the main 
flavonoid of citrus fruits presents mainly in orange and OJ, might exert 
beneficial effects on CVDRFs, particularly reducing BP, in humans. 
Moreover, the mechanisms of action of hesperidin by which it could 
improve CVD can be elucidated through different omics approaches, 
such as transcriptomics, metabolomics, and proteomics, both in humans 
and in experimental animal models. 
 
OBJECTIVES 
The main objective is to evaluate the effects of the consumption of 
hesperidin in OJ on different CVDRFs on humans, particularly on BP, 
and to elucidate the possible mechanisms of action and the biological 
effects involved though the application of different omics approaches 
such as transcriptomics, metabolomics and proteomics, both in humans 
and animal models. 
The following specific objectives have been set:  
 
Objective 1: 
To summarize and evaluate the current scientific evidence from animal 
studies and human RCTs to determine the effects of hesperidin on 
cardiovascular risk biomarkers. 
 
Objective 2:  
To assess the sustained and acute effects, and the sustained 
consumption influence on acute effects, of real-life doses of OJ and a 
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hesperidin-enriched dose on BP, PP, and cardiovascular risk 
biomarkers in pre- and stage-1 hypertensive individuals. 
 
Objective 3:  
To determine whether the sustained and single dose consumption of 
hesperidin in OJ and EOJ can change the transcriptomic profile of 
PBMCs of subjects with pre- and stage 1 hypertension to elucidate 
possible mechanisms of action of the hesperidin and their role in CVD. 
 
Objective 4: 
To determine new biomarkers of the biological effects of hesperidin in 
OJ applying nontargeted metabolomics approach in plasma/serum and 
urine samples after both single dose (6 hours) and sustained (12 weeks) 
consumption, validated through targeted metabolomics analyses of 
compliance biomarkers in subjects with pre- and stage 1 hypertension. 
 
Objective 5:  
To determine the changes in proteomic profiles of kidney and heart 
tissues, as key organs involved in BP regulation and cardiovascular 
system, in healthy and metabolic syndrome rats after hesperidin 
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Effects of hesperidin consumption on cardiovascular risk
biomarkers: a systematic review of animal studies and
human randomized clinical trials
L. Pla-Paga, J. Companys, L. Calderon-Perez, E. Llaurado, R. Sola, R. M. Valls, and A. Pedret
Context: The cardioprotective effects of the flavonoid hesperidin, which is present in
citrus products, are controversial and unclear. This systematic review was conducted
in accordance with the PRISMA 2015 guidelines. Objective: To evaluate the current
evidence from animal and human clinical studies and thus determine whether the
consumption of hesperidin exerts beneficial effects on cardiovascular risk factors.
Data sources: PICOS (Population, Intervention, Comparison, Outcome, and Study
Design) criteria defined the research question. Searches of the PubMed and
Cochrane Plus databases were conducted and studies that met the inclusion criteria
and were published in English in the last 15 years were included. Data extraction:
The first author, year of publication, study design, characteristics of animals and
humans, intervention groups, dose of hesperidin, route of administration, duration of
the intervention, cardiovascular risk biomarkers assessed, and results observed were
extracted from the included articles. Results: A total of 12 animal studies and 11
randomized clinical trials met the inclusion criteria. In the animal studies, the glu-
cose, total and LDL cholesterol, and triglyceride levels decreased with chronic flavo-
noid consumption. In the human studies, endothelial function improved with flavo-
noid consumption, whereas no conclusive results were observed for the other
biomarkers. Conclusions: Animal studies have revealed that hesperidin and hes-
peretin consumption reduces glucose levels and various lipid profile parameters.
However, a definitive conclusion cannot be drawn from the existing human clinical
trials. Further research is needed to confirm whether the findings observed in ani-
mal models can also be observed in humans. Systematic Review Registration:
Prospero registration number CRD42018088942.
INTRODUCTION
Cardiovascular diseases (CVDs) constitute the main
cause of mortality throughout the world.1 The latest sta-
tistical data from the World Health Organization
showed that ischemic heart disease and stroke caused
15 million deaths in 2015 worldwide.1
Currently, there is a growing interest in identifying
new bioactive compounds with healthy effects on
CVDs, which can then be used to develop functional
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foods, and phenolic compounds have gained much in-
terest in this field of research. Polyphenols are second-
ary metabolites of plants, and more than 8 000 different
types exist, which can be classified into different groups
depending on the number of phenolic rings they con-
tain and the type of substituent attached to the rings.2
Polyphenols are divided into two large families: flavo-
noids and non-flavonoids. Flavonoids are the most
abundant type in plants, and the main subclasses in-
clude flavonols, flavones, isoflavones, flavanones, antho-
cyanidins, flavan-3-ols, and dihydrochalcones.2
Flavonoids can be found in many commonly consumed
fruits and vegetables, and numerous studies have shown
their benefits for the prevention and treatment of differ-
ent pathologies.3–5 In recent years, citrus flavonoids,
which are present in different citrus fruits, particularly
in orange juice, have gained the attention of the food
industry because they may exert beneficial effects on
different cardiovascular risk factors (CVRFs)6 and be-
cause orange juice is one of the most consumed bever-
ages throughout the world.7 In European adults, the
mean flavonoid intake is 428 mg/day.8
The main citrus flavonoid of orange fruit and or-
ange juice is hesperidin, which is found in greater quan-
tities in the peel and represents 90% of citrus
flavonoids.9 Hesperidin (hesperetin-7-O-rutinoside) is a
flavanone glycoside and the dietary form of the agly-
cone hesperitin.6 Normally, the absorption of flavonoid
glycosides such as hesperidin occurs in epithelial cells
in the small intestine and is facilitated by the enzymes
lactase phlorizin hydrolase or cytosolic b-glucosidase,
resulting in the separation of the aglycone and its trans-
portation into the bloodstream.2 Then, the metabolites
are transported to the liver for phase II metabolism, and
they can be recycled by the enterohepatic recirculation
in the small intestine. However, bioavailability studies
show that only 30% of hesperetin metabolites are
absorbed in the small intestine and the other 70% are
absorbed in the colon,2 via microbiota and alpha-
rhamnosidase activity,10 where the hesperidin is con-
verted to glucuronides. In-vitro studies have revealed
that hesperidin stimulates the production of nitric oxide
(NO) in endothelial cells,11,12 inhibits the secretion of
endothelin-112 and inhibits platelet activity by inhibit-
ing the activities of specific phospholipases and cycloox-
ygenase-1.13 Animal studies have shown that hesperidin
exhibits antioxidant capacity and endothelial protection
against reactive oxygen species in spontaneously hyper-
tensive rats, and improves hyperlipidemia and hyper-
glycemia in diabetic rats.14 Conversely, other animal
studies have not found that hesperidin exerts beneficial
effects on glucose or insulin levels, lipid profile, or
blood pressure.15,16 In contrast, several observational
studies have shown that citrus fruit consumption is
associated with a lower risk of acute coronary
events.17,18 However, the findings from human ran-
domized clinical trials (RCTs) are not consistent: some
studies have found that daily consumption of orange
juice decreases systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP),19 and increases the total
plasma antioxidant capacity or decreases lipid peroxida-
tion,20 but others have not reported any beneficial
effects on blood pressure or the lipid profile after hes-
peridin consumption.21,22 To the best of our knowledge,
the current scientific evidence on the effects of hesperi-
din on cardiovascular risk biomarkers obtained from
animal studies and human RCTs has not been systemat-
ically reviewed, and thus, no conclusive remarks can be
drawn.
Therefore, the present systematic review aimed to
determine whether hesperidin consumption might exert
beneficial effects on cardiovascular risk biomarkers.
The objective was to summarize and evaluate the cur-
rent scientific evidence from animal studies and human
RCTs to determine the effects of hesperidin on cardio-
vascular risk biomarkers.
METHODS
This systematic review was conducted according to
the PRISMA 201523 (Preferred Reporting Items for
Systematic reviews and Meta-Analysis) guidelines
and was registered with PROSPERO on February 20,
2018, under the ID number CRD42018088942. The




Animal studies and RCTs were eligible for the system-
atic review in accordance with the review’s PICOS crite-
ria. The complete PICOS criteria for inclusion and
exclusion of studies are described in Table 1.
Information sources, search strategy, and study
selection
A literature search of the PubMed (https://www.ncbi.
nlm.nih.gov/pubmed/) and Cochrane Plus (www.biblio-
tecaco-gov/pubmed) databases was performed using
medical subject headings (MeSH). The complete search
strategy is shown in Table 2. The literature search was
restricted to English-language articles published be-
tween January 2003 and January 2018.
To ensure the accurate identification of eligible
studies, a two-step selection process was used. To con-
firm the eligibility of the included articles, the titles and
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abstracts of the studies identified using the search strat-
egy were screened independently by two authors (LP-P
and JC). The full text of the potentially eligible studies
was then retrieved and independently assessed for eligi-
bility by the same two authors. Any disagreement be-
tween the authors over the eligibility of a study was
resolved through discussion with a third author (LC-P).
Data collection and extraction
From the total number of articles identified by assign-
ing appropriate MeSH terms, any duplicate articles
within and between the databases were removed. The
remaining articles were assessed primarily according to
their title and abstract, and then according to their full
text, and those studies that did not meet the eligibility
criteria were removed.
The following data were extracted from the in-
cluded animal studies: first author, year of publication,
study design, characteristics of the animals, intervention
groups, dose of hesperidin, route of administration, du-
ration of the intervention, cardiovascular risk (CVR)
biomarkers assessed, and results observed.
The following data were extracted from the RCTs:
first author, year of publication, study population, pop-
ulation age and health status, characteristics of the nu-
tritional intervention, dose of hesperidin, consumption
matrix, duration of the intervention, method used to
confirm compliance with the intervention, CVR bio-
markers assessed, and results observed.
Study quality and risk of bias in the individual studies
Assessments of the quality and possible risks of bias in
each RCT included in the present systematic review
were performed using Review Manager software
(RevMan; version 5.3), a tool provided by the Cochrane
Collaboration. The following items were included in the
assessments: random sequence generation, allocation
concealment, blinding of participants and personnel,
Table 1 PICOS criteria for inclusion and exclusion of studies
Parameter Inclusion criteria Exclusion criteria
For the animal studies
Participants Rats or mice with at least one CVRF (obesity, dyslipidemia,
hypertension, diabetes, or metabolic syndrome)
Studies performed on animal models that were not
rats or mice
Intervention Some type of intervention based on hesperidin Combination of different classes of phenolic com-
pounds (other than citrus flavonoids) and combina-
tion with other nutrients, components, or drugs
(vitamin C, caffeine, or hypertension drugs)
Comparisons Different doses of hesperidin and/or hesperidin consump-
tion and non-consumption
Outcomes Studies that assessed the effects of hesperidin on bio-
markers or risk factors related to CVDs: anthropometric
parameters, vascular parameters, glucose and insulin
levels, lipid profile and coagulation, inflammation and
oxidation biomarkers
Study design Randomized and non-randomized, acute and chronic fol-
low-up, published in English
Studies published before January 2003 and in any
language other than English
For the RCTs
Participants Humans of all races, ages, and genders with at least one
CVRF (obesity, dyslipidemia, hypertension, diabetes, or
metabolic syndrome)
Humans with no CVRF
Intervention Some type of nutritional intervention based on the con-
sumption of hesperidin from food, drink, or supplement
Combination of different classes of phenolic com-
pounds (other than citrus flavonoids) and combina-
tion with other nutrients, components, or drugs
(vitamin C, caffeine, or hypertension drugs)
Comparisons Different doses of hesperidin and/or hesperidin consump-
tion and non-consumption
Outcomes Studies that assessed the effects of hesperidin consump-
tion on biomarkers or risk factors related to CVD: anthro-
pometric parameters, vascular parameters, glucose and
insulin levels, lipid profile and coagulation, inflammation
and oxidation biomarkers
Study design Randomized controlled clinical trials, parallel and crossover
design, acute and chronic follow-up, published in
English
Reviews, expert opinion, comments, letter to editor,
case reports, conference reports, observational
studies, animal studies, and studies published be-
fore January 2003 and in any language other than
English
Abbreviations: CVDs, cardiovascular diseases; CVRF, cardiovascular risk factor; RCTs, randomized clinical trials.
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blinding of outcome assessments, incomplete outcome
data, selective reporting, and other biases. The risk of
bias in each study was classified as “low,” “unclear,” or
“high.” Two authors (LP-P and JC) evaluated the risk of
bias in the RCTs, and any disagreement between them
over the risk of bias of a study was resolved through dis-
cussion with a third author (LC-P).
RESULTS
Animal studies
Study selection. A total of 698 articles were identified
from the two databases (643 in PubMed and 55 in
Cochrane Plus). Of these, 367 duplicate articles were
Table 2 Search strategy and MeSH terms used
For the animal studies For the RCTs
Search strategy:
-Electronic databases: PubMed and Cochrane Plus
-Publication dates: January 2003 – January 2018
-Species: Other animals
Search strategy:
-Electronic databases: PubMed and Cochrane Plus
-Publication dates: January 2003 – January 2018
-Species: Humans
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removed and 292 of the remaining 331 articles were ex-
cluded because they did not meet the inclusion criteria,
7 were excluded because they were review articles, and
6 were excluded because no full text was available. As a
result, 12 articles were included in the systematic re-
view. Figure 1 shows the study selection process for the
animal studies included in the review.
Study characteristics. Table 3 shows the general charac-
teristics of the 12 animal studies included in the system-
atic review. Further details of each study are presented
in Table S1 in the Supporting Information online. The
12 studies included in the systematic review were con-
trolled animal studies involving an intervention group
that was administered flavanone and a control group
that was not administered flavanone. In 9 of the studies,
hesperidin was orally administered,15,21,22,24–29 while in
2 of the remaining 3 studies hesperidin was adminis-
tered by gavage,30,31 and in the other study hesperidin
was administered intravenously.32 The doses of hesperi-
din ranged from 5 mg/kg of body weight/day to 200
mg/kg of body weight/day in 10 studies and from 0.08%
to 4.60% of the total calorie intake in the other 2 studies.
The duration of the intervention ranged from 7 days to
24 weeks. All the animals had at least one CVRF, such
as hypertension, myocardial ischemia, systemic inflam-
mation, hypercholesterolemia, and type 2 diabetes. The
sample size ranged from 4 to 16 animals in each group,
and of the 12 studies, 8 were performed on rats and 4
on mice.
Figure 1 Flow diagram of the literature search process for animal studies.
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Results for anthropometric parameters. The effect of hes-
peridin consumption on body weight was evaluated in 6
studies.15,21,24,25,27,30 Of these, 4 studies reported no sig-
nificant changes,15,16,24,25 1 study reported a significant
decrease,27 and 1 study did not specify the outcome.30
Akiyama et al27 reported that the administration of a
daily oral dose of hesperetin of 4.60% of total calorie in-
take to type 2 diabetic rats for 4 weeks prevented the
weight gain, of 13.56 g, observed in the control group.
In another study that examined the effect of hesperidin
consumption on visceral fat,15 no significant changes
were observed.
Results for vascular parameters. The effect of hesperidin
on SBP was evaluated in 3 studies21,25,32: 2 of these stud-
ies reported no significant changes21,25 and 1 study
reported a significant decrease in SBP.32 Yamamoto et
al32 reported that intravenous administration of an
acute dose of 5 mg/kg of body weight of hesperetin to
hypertensive rats significantly decreased SBP by 9.90 6
1.70 mmHg, compared with the control group. The
same study32 also reported that an acute dose of 5 mg/
kg of body weight of hesperetin-7-O-b-D-glucuronide
significantly decreased SBP by 8.70 6 0.80 mmHg,
compared with the control group. The effect of hesperi-
din on DBP was evaluated in 2 studies,21,32 but no sig-
nificant changes were observed.
Results for glucose and insulin levels. The effect of hes-
peridin on blood glucose was evaluated in 7 stud-
ies.15,24,26–28,30,31 Six of these studies reported decreases
in blood glucose24,26–28,30,31 and 1 study found no sig-
nificant changes.15 Iskender et al24 reported that the
oral consumption of 100 mg/kg of body weight/day of
hesperidin for 15 days significantly lowered blood glu-
cose levels in type 2 diabetic rats by 9.25 mmol/L, com-
pared with the control group. Jia et al31 observed that
the consumption of 50 mg/kg of body weight/day of
neohesperidin (derived from hesperidin) by gavage for
6 weeks significantly lowered blood glucose levels in
type 2 diabetic mice by 7.73 mmol/L, compared with
the control group. Kumar et al30 found that the con-
sumption of 200 mg/kg of body weight/day of hespere-
tin by gavage for 24 weeks significantly lowered blood
glucose levels in type 2 diabetic rats by 5.99 mmol/L,
compared with the control group. Mahmoud et al26
detected significant reductions – of 9.49 mmol/L – in
the blood glucose levels of type 2 diabetic rats after oral
consumption of 50 mg/kg of body weight/day of hes-
peridin for 30 days, compared with the control group.
Akiyama et al27 found that daily consumption of hes-
peretin at a dose of 4.60% of total calorie intake for 4
weeks significantly lowered blood glucose levels in type
2 diabetic rats by 1.61 mmol/L, compared with the con-
trol group. In addition, Jung et al28 reported that the
oral consumption of 200 mg/kg of body weight/day of
hesperidin for 5 weeks significantly lowered blood glu-
cose levels in type 2 diabetic mice by 7.84 mmol/L,
compared with the control group.
The effect of hesperidin on serum insulin levels was
evaluated in 3 studies,26,27,29 of which 2 reported signifi-
cant increases in insulin levels26,29 and 1 reported a
significant decrease.27 Mahmoud et al26 reported that
the oral consumption of 50 mg/kg of body weight/day
of hesperidin for 30 days significantly raised insulin lev-
els in type 2 diabetic rats by 6.05 mU/mL, compared
with the control group. Jung et al29 found a significant
increase of 18.13 mU/mL in the insulin levels of type 2
diabetic mice after 5 weeks of oral consumption of 200
mg/kg of body weight/day of hesperidin, compared
with the control group. Moreover, Akiyama et al27
reported that oral daily consumption of hesperidin at a
dose of 4.60% of total calorie intake for 5 weeks of inter-
vention significantly lowered insulin levels in type 2 di-
abetic rats by 90.64 mU/mL, compared with the control
group.
Results for lipid profile. The effect of hesperidin con-
sumption on total cholesterol (TC) levels was evaluated
in 4 studies.15,22,27,28 Of these, 3 reported significant
decreases in TC levels22,27,28 and 1 study found no sig-
nificant changes.15 Selvaraj and Pugalendi22 observed
that the oral consumption of 200 mg/kg of body
weight/day of hesperidin for 7 days significantly low-
ered TC levels in rats with myocardial ischemia by 0.40
mmol/L, compared with the control group. Akiyama et
al27 noted that daily consumption of hesperetin at a
dose of 1% and 4.60% of total calorie intake for 4 weeks
significantly lowered TC levels in type 2 diabetic rats by
1.71 mmol/L and 2.51 mmol/L, respectively, compared
with the control group. Moreover, Jung et al28 reported
that the oral consumption of 200 mg/kg of body
weight/day of hesperidin for 5 weeks significantly low-
ered TC levels in type 2 diabetic mice by 0.81 mmol/L,
compared with the control group.
The effect of hesperidin consumption on high-den-
sity lipoprotein cholesterol (HDL-c) levels was evalu-
ated in 3 studies.15,22,28 Two of these studies reported
no significant changes in HDL-c15,28 and the other
study reported a significant increase.22 Selvaraj and
Pugalendi22 reported that the oral consumption of 200
mg/kg of body weight/day of hesperidin for 7 days sig-
nificantly increased HDL-c levels in rats with myocar-
dial ischemia by 0.34 mmol/L, compared with the
control group.
The effect of hesperidin consumption on low-den-
sity lipoprotein cholesterol (LDL-c) levels was assessed
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in 2 studies,15,22 and significant decreases were observed
in both studies. Ferreira et al15 observed that the oral
consumption of 100 mg/kg of body weight/day of hes-
peridin for 15 days significantly lowered LDL-c levels in
mice with systemic inflammation by 0.29 mmol/L, com-
pared with the control group. In addition, Selvaraj and
Pugalendi22 observed that the oral consumption of 200
mg/kg of body weight/day of hesperidin for 7 days sig-
nificantly decreased LDL-c by 0.67 mmol/L, compared
with the control group.
The effect of hesperidin consumption on triglycer-
ide (TG) levels was evaluated in 5 studies.15,22,27,28,31
Four of these studies reported significant
decreases22,27,28,31 and the other study reported no sig-
nificant changes.15 Jia et al31 noted that the consump-
tion of 50 mg/kg of body weight/day of neohesperidin
by gavage for 6 weeks significantly lowered TG levels in
type 2 diabetic mice by 2.05 mmol/L, compared with
the control group. In rats with myocardial ischemia,
Selvaraj and Pugalendi22 observed that the oral con-
sumption of 200 mg/kg of body weight/day of hesperi-
din for 7 days significantly lowered TG levels by 0.18
mmol/L, compared with the control group. Akiyama et
al27 noted that daily consumption of hesperetin at a
dose of 1% and 4.60% of total calorie intake for 4 weeks
lowered TG levels in type 2 diabetic rats by 0.66 mol/L
and 0.91 mmol/L, respectively, compared with the con-
trol group. Lastly, Jung et al28 stated that the oral con-
sumption of 200 mg/kg of body weight/day of
hesperidin for 5 weeks of intervention lowered TG lev-
els in type 2 diabetic mice by 1.74 mmol/L, compared
with the control group.
Results for inflammation biomarkers. The effect of hes-
peridin on interleukin-6 (IL-6) levels was evaluated in a
study by Ferreira et al.15 Using a mouse model of sys-
temic inflammation, this study reported a significant
decrease of 58.64 pg/mL after the oral consumption of
100 mg/kg of body weight/day of hesperidin for 4
weeks, compared with the control group.
Results for oxidation biomarkers. The effect of hesperi-
din on nitric oxide levels was evaluated in a study by
Mahmoud et al.26 The study reported a significant de-
crease of 5.08 mg/dL after the oral consumption of 50
mg/of body weight/day of hesperidin for 30 days in type
2 diabetic rats, compared with the control group.
Human randomized controlled trials
Study selection. A total of 1917 articles were identified
from the searches of the two databases (1 495 in
PubMed and 422 in Cochrane Plus). Of these, 1 486 du-
plicate articles were removed and 393 were excluded
because they did not meet the inclusion criteria. Thus,
11 articles were included in the systematic review.
Figure 2 shows the study selection process for the RCTs
included in the review.
Study characteristics. Tables 4 to 6 show the characteris-
tics of the RCT studies included in this systematic re-
view. Further details of each study are presented in
Table S2 in the Supporting Information online. The 11
studies included in this review were RCTs involving
some type of nutritional intervention. In fact, the inter-
ventions in 3 of the 11 included RCTs consisted of sup-
plementation with a placebo capsule or a hesperidin
capsule,11,33,34 whereas those in the 3 other studies con-
sisted of the administration of a control drink (CD) or
orange juice (OJ).35–37 In addition, the interventions in
2 other studies involved the consumption of different
drinks with different hesperidin concentrations,38,39
whereas those in 2 and 1 of the remaining RCTs con-
sisted of no product intervention vs OJ administra-
tion40,41 and supplementation with a placebo or
hesperidin capsule or consumption of OJ,
respectively.42
Four of the studies comprised a parallel de-
sign,33,34,40,41 and the other seven comprised crossover
designs.11,35–39,42 Ten of the included RCTs involved a
long-term follow-up, and one of these also involved a
short-term follow-up. The other RCT involved only a
short-term follow-up. The duration of the intervention
in the long-term studies ranged from 1.5 to 13 weeks,
and the duration in the short-term studies ranged from
4 to 5 hours. Nine of the studies were conducted with
European populations, and the other 2 investigated
South American populations. The sample sizes ranged
from 22 to 194 subjects, and the ages of the subjects
ranged from 18 to 69 years. All the subjects had at least
one CVRF, such as dyslipidemia, overweight, obesity,
and/or metabolic syndrome. The methods used to con-
firm intervention compliance involved keeping 3- or 5-
day food records, maintaining 24-hour dietary records,
returning all used and unused capsule boxes, and self-
reporting.
Assessment of the quality and risk of bias. The risk of
bias in each individual RCT is detailed in Figure 3. Six
of the 11 RCTs used an adequate random sequence gen-
erator; 3 studies incorporated adequate allocation con-
cealment; 5 studies performed adequate blinding of the
participants, personnel, and outcome assessment; 9
studies presented completed data; and 6 studies pre-
sented their study protocol with all the reported out-
comes. Regarding other types of bias, potential conflicts
of interest were considered, and 8 studies reported a
lack of conflicts of interest.
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Effects of chronic hesperidin consumption on
cardiovascular risk biomarkers.
Results for anthropometric parameters. The characteris-
tics of the long-term RCTs included in this review in re-
lation to anthropometric parameters are detailed in
Table 4.
The effect of hesperidin consumption on body
weight was evaluated in 3 studies.34,39,40 Of these, 2
studies reported significant decreases,39,40 and 1 study
found no significant changes.34 Rangel-Huerta et al39
observed that the consumption of 237 mg/day or 582.50
mg/day of hesperidin in 500 mL/day of OJ for 12 weeks
reduced the body weight of overweight or obese sub-
jects by 1.30 kg and 1.80 kg, respectively, compared
with basal levels. No differences between the different
hesperidin concentrations were observed. Aptekmann
and Cesar40 noted that the consumption of 54.60 mg/
day of hesperetin in 500 mL/day of OJ for 13 weeks of
intervention significantly reduced the body weight of
hypercholesterolemic subjects by 1 kg, compared with
basal levels. No significant differences were observed
between the intervention and control groups.
The effect of hesperidin consumption on the body
mass index (BMI) was evaluated in 5 studies11,34,39–41: 3
of these studies reported no significant changes11,34,41
and 2 studies found significant decreases.39,40 Rangel-
Huerta et al39 observed that the consumption of 237
mg/day and 582.50 mg/day of hesperidin in 500 mL/day
Figure 2 Flow diagram of the literature search process for randomized clinical trials.
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of OJ for 12 weeks reduced the BMI of overweight or
obese subjects by 0.50 kg/m2 and 0.70 kg/m2, respectively,
compared with basal levels. No differences between the
different hesperidin concentrations were observed.
Aptekmann and Cesar40 reported that the consumption of
54.60 mg/day of hesperetin in 500 mL/day of OJ signifi-
cantly reduced the BMI of hypercholesterolemic subjects
by 0.30 kg/m2 after 13 weeks of intervention, compared
with basal levels. No significant differences were observed
between the intervention and control groups.
The effect of hesperidin consumption on body fat
was evaluated in 1 study and a significant decrease was
observed.40 Specifically, Aptekmann and Cesar40 reported
that 54.60 mg/day of hesperetin in 500 mL/day of OJ sig-
nificantly reduced the body fat of hypercholesterolemic
subjects by 4.30% after 13 weeks of intervention, com-
pared with basal levels. No significant differences were ob-
served between the intervention and control groups.
Results for vascular parameters. The characteristics of
the long-term RCTs included in this review in relation
to vascular parameters are detailed in Table 4.
The effect of hesperidin consumption on SBP and
DBP was evaluated in 5 studies.11,33,38,39,42 Of these,
Figure 3 Risk of bias graph (A) and summary (B) of the randomized clinical trials included. 1 indicates a low risk of bias, - indicates a
high risk of bias, and ? indicates an unclear risk.
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3 reported no significant changes11,33,38 and significant
decreases were detected in the other 2 studies.39,42
Rangel Huerta et al39 observed that the consumption of
237 mg/day of hesperidin for 12 weeks reduced the SBP
and DBP of overweight or obese subjects by 4 mmHg
and 3 mmHg, respectively, compared with basal levels.
No significant differences were observed in a compari-
son with the group administered a lower concentration
of hesperidin. Morand et al42 reported that the con-
sumption of 292 mg/day of hesperidin – in the form of
pure hesperidin capsules or provided naturally with 500
mL/day of OJ for 4 weeks – reduced the DBP of over-
weight subjects by 5.30 mmHg and 4.50 mmHg, respec-
tively, compared with basal levels. Significant
differences were observed in a comparison with the
control group.
The effect of hesperidin consumption on endothe-
lial function was evaluated in 3 studies11,33,36: 2 of these
studies reported significant increases11,36 and the other
study found no significant changes.33 In subjects with
metabolic syndrome, Buscemi et al36 observed a signifi-
cant increase in flow-mediated dilation (FMD) of 2.20%
after 1.5 weeks of the consumption of 159.50 mg/day of
hesperidin in 500 mL/day of OJ. Significant differences
between the intervention group and the control group
were observed. Similarly, in subjects with metabolic
syndrome, Rizza et al11 reported a significant increase
in FMD of 2.48% after 3 weeks of the consumption of
500 mg/day of hesperidin in capsule form, and the dif-
ferences between the intervention and control groups
were significant.
Results for glucose and insulin levels. The characteristics
of the long-term RCTs included in this review in
relation to glucose and insulin levels are detailed in
Table 4.
The effect of hesperidin consumption on plasma
glucose levels was evaluated in 5 studies.11,33,35,39,42 Of
these, 4 reported no significant changes,11,33,35,42 and a
significant increase was observed in the other study.39
Specifically, Rangel-Huerta et al39 observed significant
increases of 0.30 mmol/L and 0.20 mmol/L in the glu-
cose levels of overweight and obese subjects after the
consumption of 237 mg/day and 582.50 mg/day of hes-
peridin in OJ, respectively, for 12 weeks, compared with
basal levels. Significant differences were observed be-
tween both intervention groups.
Four studies evaluated the effect of hesperidin con-
sumption on plasma insulin levels11,33,39,42: 3 of these
studies reported no significant changes,11,33,42 whereas a
significant decrease was detected in the other study.39
Rangel-Huerta et al39 noted a significant decrease of
1.20 mU/mL in the insulin levels of overweight or obese
subjects after the consumption of 237 mg/day of hesper-
idin in OJ for 12 weeks, compared with basal levels.
Significant differences were found between both inter-
vention groups.
The effect of hesperidin consumption on the
QUICKI index was evaluated in 2 studies; neither of
these studies reported any significant changes.11,33
Results for lipid profile parameters. The characteristics
of the long-term RCTs included in this review in rela-
tion to lipid profiles are detailed in Table 5.
The effect of hesperidin consumption on TC levels
was evaluated in 8 studies.11,33–35,39–42 Of these, 6
reported no significant changes11,33,34,39,42 and 2 studies
reported significant decreases.35,36 Aptekmann and
Cesar40 found that the TC levels of overweight subjects
were significantly decreased by 0.22 mmol/L, compared
with basal levels after 13 weeks of consumption of 54.60
mg/day of hesperetin in OJ. No significant differences
were observed between the intervention group and the
control group. Cesar et al41 reported a significant de-
crease of 0.46 mmol/L in the TC levels of hypercholes-
terolemic subjects who consumed 42 mg/day of
hesperetin in 750 mL/day of OJ for 8 weeks, compared
with the control subjects. No significant differences
were observed between the intervention and control
groups.
Eight studies evaluated the effect of hesperidin
consumption on LDL-c levels.11,33–35,39–42 Of these, 6
reported no significant changes,11,33–35,39,42 while sig-
nificant decreases were found in the other 2 stud-
ies.40,41 Specifically, compared with the basal level,
Aptekmann and Cesar40 observed a significant de-
crease of 0.44 mmol/L in the LDL-c levels of over-
weight subjects after 13 weeks of the consumption of
54.60 mg/day of hesperetin in OJ. No significant dif-
ferences were observed between the intervention and
control groups. Cesar et al41 observed a significant
decrease of 0.49 mmol/L in the LDL-c levels of hyper-
cholesterolemic subjects who consumed 42 mg/day of
hesperetin in OJ 8.5 weeks. No significant differences
were observed between the intervention and control
groups.
The effect of hesperidin consumption on HDL-c
levels was evaluated in 8 studies.11,33–35,39–42 No
significant changes were detected in 7 of these stud-
ies,11,33–35,39,41,42 and the other study reported a sig-
nificant increase.40 In overweight subjects,
Aptekmann and Cesar40 found that the consumption
of 54.60 mg/day of hesperetin in OJ for 13 weeks in-
creased HDL-c levels by 0.23 mmol/L, compared with
basal levels. No significant differences were observed
between the intervention and control groups.
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Eight studies evaluated the effect of hesperidin con-
sumption on TG levels.11,33–35,39–42 Of these, 7 reported
no significant changes11,33–35,39,40,42 and the other study
reported a significant decrease.39 Compared with basal
levels, Rangel-Huerta et al39 observed a significant de-
crease of 0.09 mg/dL in the TG levels of overweight and
obese subjects who consumed 237 mg/day of hesperidin
in OJ for 12 weeks. No significant differences were ob-
served between the intervention and control groups.
The effects of hesperidin consumption on apolipo-
protein A-1 (Apo A-1) and apolipoprotein B (Apo B)
were evaluated in 3 studies,11,35,39 and different results
were obtained. Specifically, compared with basal levels,
Constans et al35 reported a significant increase in Apo
A-1 and Apo B levels of 5 mg/dL and 8 mg/dL, respec-
tively, in hypercholesterolemic subjects after the con-
sumption of 213 mg/day of hesperidin in OJ for 4
weeks. No significant differences between the interven-
tion and control groups were observed. Rangel-Huerta
et al39 noted a significant decrease of 4 mg/dL in the
Apo A-1 levels and also in the Apo B levels of over-
weight or obese subjects who consumed 237 mg/day
and 582.50 mg/day of hesperidin in OJ for 12 weeks,
compared with basal levels. No significant differences
were observed between the intervention and control
groups. In addition, Rizza et al3311 found no significant
changes between these two groups.
Results for coagulation, inflammation, and oxidative
biomarkers. The characteristics of the long-term RCTs
included this review in relation to the biomarkers of co-
agulation, inflammation, and oxidation are detailed in
Table 6.
The effect of hesperidin consumption on coagula-
tion biomarkers, assessed based on the plasma levels of
fibrinogen and homocysteine, was explored in 2 stud-
ies,11,35 but neither of these RCTs reported any signifi-
cant changes.
In one study, the effect of hesperidin consumption
on inflammation biomarkers was assessed according to
plasma protein serum amyloid A (SAA) levels,11 but no
significant changes were observed. Inflammation was
also assessed according to plasma IL-6 levels in 2 stud-
ies.36,42 Of these, 1 study observed a significant de-
crease,36 but no significant changes were detected in the
other study.42 Buscemi et al36 found a significant de-
crease of 3.30 pg/mL in the IL-6 levels of subjects with
metabolic syndrome after the consumption of 159.50
mg/day of hesperidin in OJ for 1.5 weeks, compared
with basal levels. Significant differences were observed
between the intervention and control groups. Four
studies evaluated the effects of hesperidin consumption
on the plasma levels of soluble vascular cell adhesion
molecule-1 (sVCAM-1) and soluble intercellular adhe-
sion molecule-1 (s-ICAM-1),11,33,35,42 and the plasma
levels of sE-selectin (soluble E-selectin) and sP-selectin
(soluble P-slectin) were evaluated in 3 studies11,33,35 and
1 study,33 respectively. None of these studies detected
any significant changes.
The effect of hesperidin consumption on oxidative
biomarkers was assessed according to plasma NOx lev-
els in 2 studies,36,42 but no significant changes were ob-
served. Additionally, plasma oxidized low-density
lipoprotein levels were assessed in 1 study, but no sig-
nificant changes were detected.39
Effects of acute hesperidin consumption on
cardiovascular risk biomarkers. The effects of acute con-
sumption of hesperidin were evaluated according to
vascular parameters (SBP, DBP, and endothelial func-
tion) and inflammation biomarkers (sVCAM-1,
s-ICAM-1, sE-selectin, and sP-selectin) in 2 studies, but
no significant changes in any of the investigated param-
eters were detected.
DISCUSSION
The current systematic review presents a summary of
the available scientific evidence regarding the effects of
hesperidin consumption on cardiovascular risk bio-
markers obtained from animal studies and human
RCTs.
The results from the animal studies included in the
present systematic review showed that daily consump-
tion of 50–200 mg/kg of body weight of hesperidin or
hesperetin for a period ranging from 15 days to 24
weeks significantly lowered blood glucose levels in type
2 diabetic rats and mice. As possible mechanisms of ac-
tion, other experimental studies with rats have sug-
gested that hesperidin consumption may increase
hepatic glycolysis and hepatic glucokinase activity and
decrease hepatic gluconeogenesis and hepatic glucose-
6-phospatase activity,43 which would inhibit the gluco-
neogenic pathway in liver cells44 and thus prevent the
progression of hyperglycemia.43,45 These beneficial
effects on glucose and insulin levels were not observed
in the human RCTs included in this systematic review.
However, it is interesting to note that only 5 of the 11
RCTs included in the review assessed the effects of hes-
peridin consumption on blood glucose levels, and the
population investigated in these RCTs were overweight,
obese, or hypercholesterolemic, whereas the animal
studies were performed on type 2 diabetic rats. Because
the types of population investigated in the RCTs that
evaluated glucose levels yielded no significant results
and because only a few RCTs evaluated the possible ef-
fect of hesperidin on glucose, more RCTs should be
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conducted with type 2 diabetic subjects to assess the
effects of hesperidin consumption on glucose and insu-
lin levels in order to confirm the results observed in ani-
mals. With respect to insulin levels, no relevant changes
were observed in either the animal studies or the hu-
man RCTs.
The animal studies included in the present system-
atic review demonstrated that daily consumption of
hesperidin or hesperetin at a dose of 50–200 mg/kg of
body weight and 1% or 4.60% of total calorie intake
improves the lipid profile by significantly reducing
blood levels of TC, LDL-c, and TG in rats and mice
with type 2 diabetes and myocardial ischemia. An in-vi-
tro study showed that the possible mechanism through
which hesperidin improves the lipid profile may involve
the modulation of hepatic lipid metabolism and the in-
hibition of Apo B in HepG2.46 In contrast, the results of
the RCTs included in this review did not show the same
conclusive results. In fact, only 240,41 of the 8 articles
that assessed lipid profiles observed a decrease in TC
and LDL-c levels. Interestingly, only one study41
assessed the effect of hesperidin on lipid profile in hy-
percholesterolemic subjects. This RCT observed marked
decreases of 0.47 mmol/L and 0.49 mmol/L in TC and
LDL-c levels, respectively,47 after the consumption of 42
mg/day of hesperidin in OJ for 8.5 weeks, and this find-
ing was clinically relevant.47 Thus, hypercholesterolemic
subjects constitute an appropriate population for fur-
ther evaluation of the specific effects of hesperidin on
lipid profile. The differences between the doses of hes-
peridin administered in the animal and human studies
(higher doses were used in the animal studies than in
the human RCTs) may also have contributed to the dif-
ference in the results obtained from these two types of
studies. Thus, more human RCTs are needed to better
understand the effects of hesperidin consumption on
lipid profile in humans.
The present systematic review showed that, in ani-
mal models, the consumption of hesperidin does not
improve anthropometric parameters, such as body
weight and visceral fat. However, it is important to note
that the animal studies included in this review were
conducted with rats or mice with normal body weight
and anthropometric parameters for their age; future
studies should investigate overweight or obese rats or
mice to allow more relevant conclusions to be drawn.
Similarly, in the human RCTs, there were no effects of
hesperidin on body weight, BMI, and body fat, and only
a limited number of studies have assessed these parame-
ters. Two39,40 of the 3 RCTs that evaluated the effect of
hesperidin consumption on body weight and BMI
observed reductions of 1.30–1.80 kg/m2 and 0.30–0.70
kg/m2, respectively, in overweight subjects after daily
consumption of 54.60–582.50 mg/day of hesperidin in
OJ for 12–13 weeks, compared with the basal values.
However, both of these studies had some limitations:
one was not a placebo-controlled clinical trial,39 and the
other study observed decreases in both the intervention
and control groups,40 probably owing to the fact that
volunteers tend to pay more attention to their health
when participating in a study.48
Hesperidin has aroused interest on account of its
possible effect on blood pressure because it has been
suggested that this compound exerts effects similar to
those found with other flavonoids, such as quercetin.49
In-vitro studies have shown that the improvements in
blood pressure and endothelial dysfunction observed af-
ter hesperidin consumption may be mediated by a de-
crease in NADPH oxidase 2, increase in plasma NO
metabolites, and an inhibitory effect on angiotensin-
converting enzyme.50,51 These data suggest that hesperi-
din may increase the secretion of NO by human endo-
thelial cells, inhibit cyclic nucleotide phosphodiesterase,
and increase cyclic AMP (adenosine monophosphate)
and GMP (guanosine monophosphate), thereby exert-
ing a vasorelaxant effect.14,52,53 Nevertheless, according
to the findings of the present review of animal studies
and RCTs, the consumption of hesperidin has no clear
effect on DBP and SBP levels. However, it is interesting
to note that the subjects assessed in the included RCTs
were overweight or obese, with no hypertension or ele-
vated blood pressure levels. Therefore, studies that eval-
uate the effect of hesperidin on blood pressure in
subjects with high blood pressure levels are needed for
us to draw a definitive conclusion about this CVRF.
Interestingly, 3 RCTs 11,33,36 included in the present re-
view assessed the effects of hesperidin on endothelial
function, and 2 of these11,36 observed improvements in
these parameters in subjects with metabolic syndrome
and increased CVRFs after 1.5–3 weeks of intervention
with 300–500 mg/day of hesperidin in OJ or capsule
form. Although the available evidence is scarce, it
appears that hesperidin consumption seems likely to in-
crease endothelial function. Thus, more human RCTs
are needed to determine whether hesperidin decreases
blood pressure and improves endothelial function in
hypertensive or type 2 diabetic populations.
The results obtained in the present review of RCTs
showed that hesperidin has no significant effects on bio-
markers of coagulation, inflammation, and oxidation.
However, few studies have assessed the effect of hesperi-
din on these biomarkers in relation to CVDs because al-
most all studies have focused on cancer and other
chronic diseases.26,54,55
One factor to consider is the interindividual vari-
ability in hesperidin bioavailability, which may, for ex-
ample, depend on the microbiota composition of each
subject.56,57 Thus, it is possible that different individuals
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administered the same dose of hesperidin can absorb
this compound to different degrees, and therefore, these
individuals would show different effects for the various
cardiovascular biomarkers. This could also explain the
differing results between the studies included in this re-
view because none of the studies considered the bio-
availability of hesperidin.
The RCTs included in the present review that ob-
served more significant changes39–41 presented many
potential risks of bias, which were classified as unclear
risk owing to insufficient information about allocation
concealment and blinding of participants, personnel,
and outcomes, or in terms of including a conflict of in-
terest based on the Cochrane risk of bias criteria. These
unclear risks of bias indicate potential problems related
to the methodological quality of the studies and hence
lead us to question the reliability of the results of the
RCTs. Therefore, further RCTs are needed with a lower
risk of bias and consequent improvement in quality.
One strength of this review concerns the standard-
ized methodology that was used. In addition, the in-
cluded studies were published recently and thus
presented strong scientific evidence, such as RCTs,
along with analyses of their individual risks of bias.
Moreover, the novelty of this review lies in the fact that
it was the first to evaluate the effects of hesperidin con-
sumption on different CVRFs based on both animal
models and human studies. However, the present re-
view has several limitations that warrant discussion.
The first is the scarce scientific evidence available from
human and animal studies that assessed the effects of
hesperidin on CVRFs. In most studies, the populations
used to evaluate the effects of hesperidin on different
CVRFs have not been the most appropriate for reaching
definitive conclusions. Thus, if the objective of a study
is to improve a specific cardiovascular risk factor – for
example, to reduce high serum cholesterol concentrations
in humans – the recommendation is to include subjects
that present with symptoms associated with this specific
CVRF, such as hypercholesterolemic patients.58 In addi-
tion, the studies included in this review utilized different
intervention durations, monitoring approaches, and meth-
ods of supplementation. However, the sample size in
some of the animal studies was perhaps insufficient for a
robust evaluation of the objectives, and in 2 studies, the
doses of hesperidin or hesperetin were not estimated in
milligrams, and therefore their dose-dependent effects
could not be compared with those of other studies. In ad-
dition, dose- and time-dependent effects, as well as the
physiological relevance of the dose used, were not evalu-
ated in the animal studies. Also, the possibility of residual
confounding related to hesperidin bioavailability cannot
be excluded. Moreover, even though compliance with the
nutritional intervention is necessary, dietary factors may
not have been considered to a sufficient degree because
only 3 RCTs controlled the participants’ diet through vali-
dated dietary records, and no biomarkers for consump-
tion were used in any of the included studies. Therefore,
other polyphenol compounds present in the diet may
have been responsible, either partially or entirely, for the
observed health effects. In addition, with inadequate mon-
itoring of the participants’ diet, it is possible that some
subjects had greater hesperidin intake than others because
they consumed food or beverages with significant
amounts of hesperidin, potentially affecting the study
results of the study. Thus, in nutritional RCTs, monitoring
of the participants’ diet is necessary to avoid confounding
between other dietary compounds and the dietary inter-
vention. Limiting hesperidin intake as a dietary recom-
mendation for all participants, monitoring their dietary
intake, and the use of biomarkers for consumption are
necessary to obtain robust results in this type of study.
Lastly, most of the articles included in this review lacked
statistical data, such as mean differences and their stan-
dard deviation and the standard error or confidence inter-
vals for each intervention, as well as their p-values.
Consequently, a meta-analysis, which would have pro-
vided more conclusive results, as well as a forest plot,
which would have provided a clearer presentation of the
results, could not be performed.
CONCLUSION
In conclusion, hesperidin consumption was found to
improve glucose levels and various lipid profile parame-
ters, such as TC, LDL-c, and TG, in animal models, but
no definitive conclusion regarding the effects of hesper-
idin on different CVRFs in humans can be currently
drawn. Further RCTs of greater quality are needed to
confirm that the results observed in animal models can
be translated to the human population and thus to eval-
uate whether the administration of hesperidin through
the consumption of citrus food or as a supplement
would serve as a new tool for the prevention and treat-
ment of CVDs.
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Iskender H et 
al. (2017) S1  
Controlled  4-6-week old male 
Wistar albino rats 
treated with STZ 
(type 2 diabetes) 
Control group (n=10) vs 
intervention group (n=10) 
0 mg vs 100 mg/kg 
body weight/day of 
hesperidin in aqueous 
suspension orally 
 
15 days Body weight, 
glucose 
-Body weight (g): 
Control group = B: 235.80 ± 14.35; F: 190.51 ± 10.16. NDA 
Intervention group = B: 242.50 ± 8.36; F: 205.54 ± 11.18. NDA 
No significant differences between intervention group and control group at the end of the study. 
 
-Glucose (mmol/L): 
Control group = B: NDA; F: 33.45 ± 1.12. NDA 
Intervention group = B: NDA; F: 24.20 ± 0.79. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
Dobias L et al. 









Control group (n=13) vs 
intervention group (n=13) 
0 mg (corresponding 
volume of distilled 
water) vs 50 mg/kg 
body weight/day of 
hesperidin orally 
suspended in distilled 
water 
4 weeks Body weight, SBP -Body weight (g): 
Control group = B: 282.00 ± 2.50; F: 301.00 ± 2.40. NDA 
Intervention group = B: 290.00 ± 2.70; F: 313.00 ± 2.60. NDA 
No significant differences between intervention group and control group at the end of the study. 
 
-SBP (mm Hg): 
Control group = B: 169.00 ± 2.20; F: 168.00 ± 2.62. NDA 
Intervention group = B: 161.00 ± 1.70; F: 166.00 ± 2.12. NDA 
No significant differences between intervention group and control group at the end of the study. 
 
Ferreira PS et 
al. (2016) S3  
Randomized, 
controlled 
9-week old male 
C57BL/6J mice with 
systemic 
inflammation caused 
by high fat diet 
 
Control group (n=10) vs 
intervention group (n=10)  
 
0 mg vs 100 mg/kg 
body weight/day of 
hesperidin orally added 
to the regular diet 





-Weight gain (g): 
Control group = B: NDA; F: 7.20 ± 3.60. NDA 
Intervention group = B: NDA; F: 5.60 ± 0.90. NDA 
No significant differences between intervention group and control group at the end of the study.  
 
-Visceral fat (%): 
Control group = B: NDA; F: 4.50 ± 1.90. NDA 
Intervention group = B: NDA; F: 3.80 ± 1.40. NDA 
No significant differences between intervention group and control group at the end of the study.  
 
-Glucose (mmol/L): 
Control group = B: NDA; F: 20.81 ± 3.27. NDA 
Intervention group = B: NDA; F: 18.70 ± 4.72. NDA 
No significant differences between intervention group and control group at the end of the study.  
 
-TC (mmol/L): 
Control group = B: NDA; F: 3.59 ± 0.05. NDA 
Intervention group = B: NDA; F: 3.17 ± 0.52. NDA 
No significant differences between intervention group and control group at the end of the study.  
 
-HDL-c (mmol/L): 
Control group = B: NDA; F: 2.16 ± 0.03. NDA 
Intervention group = B: NDA; F: 2.00 ± 0.39. NDA 
No significant differences between intervention group and control group at the end of the study.  
 
-LDL-c (mmol/L): 
Control group = B: NDA; F: 1.04 ± 0.31. NDA 
Intervention group = B: NDA; F: 0.75 ± 0.23. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-TG (mmol/L): 
Control group = B: NDA; F: 1.85 ± 0.16. NDA 
Intervention group = B: NDA; F: 2.18 ± 0.23. NDA 





Control group = B: NDA; F: 64.40 ± 44.30. NDA 
Intervention group = B: NDA; F: 5.76 ± 4.32. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
Jia S et al. 
(2015) S4  
Randomized, 
controlled 
8-weeks old male 
KK-Ay mice (type 2 
diabetic) 
 
Control group (n=10) vs 
Intervention group (n=10) 
0 mg (water) vs 50 
mg/kg body weight/day 
of neohesperidin 
(derived from 
hesperidin) by gavage 
6 weeks Body weight, 
glucose, TC, TG 
-Body weight (g): 
Control group = B: 38.39 ± 1.12; F: 43.18 ± 0.80. NDA 
Intervention group = B: 38.52 ± 1.17; F: 42.16 ± 1.73. NDA 
No significant differences between intervention group and control group at the end of the study. 
 
-Glucose (mmol/L): 
Control group = B: 10.16 ± 0.44; F: 20.91 ± 1.86. NDA 
Interventional group = B: 10.28 ± 0.35; F: 13.18 ± 2.72. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-TC (mmol/L): 
Control group = B: NDA; F: 6.10 ± 0.26. NDA 
Intervention group = B: NDA; F: 4.60 ± 0.36. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.01 
 
-TG (mmol/L): 
Control group = B: NDA; F: 3.73 ± 0.21. NDA 
Intervention group = B: NDA; F: 1.68 ± 0.22. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.001 
 
Yamamoto M. 
(2013) S5  









supplement) (n=4) vs 
Hesperetin-3’-O-β-D-
glucuronide supplement 
(H3 supplement) (n=4) 
0 mg vs 5 mg/kg body 




3 minutes (acute 
study) 
SBP, DBP -SBP (mm Hg): 
Control group = B: 193.40 ± 4.20; F: -3.50 ± 0.40. NDA 
Hesperetin supplement = B: 194.10 ± 4.70; F: -9.90 ± 1.70. NDA 
H7 supplement = B: 197.00 ± 3.40; F: -8.70 ± 0.80. NDA 
H3 supplement = B: 201.30 ± 4.20; F: -4.10 ± 0.80. NDA 
Significant differences between hesperetin supplement and control group at the end of the study. p<0.01 
Significant differences between H7 supplement and control group at the end of the study. p<0.05 
 
-DBP (mm Hg): 
Control group = B: 174.90 ± 3.80; F: data not shown. NDA 
Hesperetin supplement = B: 173.80 ± 3.90; F: data not shown. NDA 
H7 supplement = B: 179.80 ± 2.80; F: data not shown. NDA 
H3 supplement = B: 186.90 ± 6.00; F: data not shown. NDA 
No significant differences between the 4 groups at the end of the study. 
 
Kumar B et al. 
(2012) S6  
Controlled STZ treated Wistar 
albino rats (type 2 
diabetes) 
Control group (n=16) vs 
intervention group (n=16) 
0 mg vs 200 mg/kg 
body weight/day of 
hesperetin by gavage 
24 weeks Weight gain, 
glucose 
-Weight gain (%): 
Control group = F: 22.34%. NDA 
Intervention group = F: 45.35%. NDA 
NDA about differences between interventional group and control group. 
 
-Glucose (mmol/L): 
Control group = B: NDA; F: 27.67 ± 1.03. NDA 
Intervention group = B: NDA; F: 21.68 ± 2.06. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.001 
 
Mahmoud AM 
et al. (2012) S7  
Controlled  STZ treated while 
male albino rats 
(type 2 diabetes) 
Control group (n=6) vs 
intervention group (n=6) 
0 mg vs 50 mg/kg body 
weight/day of 
hesperidin in aqueous 
suspension orally 
30 days Glucose, insulin, 
NO 
-Glucose (mmol/L): 
Control group = B: NDA; F: 16.37 ± 0.23. NDA 
Intervention group = B: NDA; F: 6088 ± 0.22. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.01 
 
-Insulin (µU/mL): 
Control group = B: NDA; F: 15.50 ± 0.76. NDA 
Intervention group = B: NDA; F: 21.55 ± 1.13. NDA 





Control group = B: NDA; 13.60 ± 0.53. NDA 
Intervention group = B: NDA; F: 8.52 ± 0.48. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.01 
 
Selvaraj P et al. 









Control group (n=6) vs 
intervention group (n=6) 
0 mg vs 200 mg/kg 
body weight/day of 
hesperidin dissolved in 
carboxyl methyl-
cellulose post-orally 
7 days TC, HDL-c, LDL-
c, TG 
-TC (mmol/L): 
Control group = B: NDA; F: 2.72 ± 0.26. NDA 
Intervention group = B: NDA; F: 2.32 ± 0.18. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-HDL-c (mmol/L): 
Control group = B: NDA; F: 0.79 ± 0.06. NDA 
Intervention group = B: NDA; F: 1.13 ± 0.11. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-LDL-c (mmol/L): 
Control group = B: NDA; F: 1.54 ± 0.13. NDA 
Intervention group = B: NDA; F: 0.87 ± 0.05. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-TG (mmol/L): 
Control group = B: NDA; F: 0.87 ± 0.07. NDA 
Intervention group = B: NDA; F: 0.69 ± 0.04. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
Wang X et al. 
(2011) S9 
Controlled  8-weeks old male 
Wistar rats treated 
with   high-
cholesterol diet (2% 
TCD/day) 
Control group (n=15) vs 
intervention group (n=15) 
0 mg vs 0.08 % 
TCD/day of hesperidin 
12 weeks Body weight, 
SBP, DBP 
-Body weight (g): 
Control group = B: NDA; F: 544.50 ± 4.90. NDA 
Intervention group = B: NDA; F: 542.00 ± 9.00. NDA 
No significant differences between interventional group and control group at the end of the study. 
 
-SBP (mm Hg): 
Control group = NDA. 
Intervention group = NDA. 
No significant differences between interventional group and control group at the end of the study. 
 
-DBP (mm Hg): 
Control group = NDA. 
Intervention group = NDA. 
No significant differences between interventional group and control group at the end of the study. 
 
Akiyama S et 
al. (2009) S10 
Randomized  3-week old male GK 
rats (type 2 diabetes) 
Control group (n=6) vs 
intervention group 1 
(n=6) vs intervention 
group 2 (n=6) 
0% TCD/day vs 1% 
TCD/day of hesperidin 
vs 4.6% TCD/day of 
hesperidin 
4 weeks Body weight, 
glucose, insulin, 
TC, TG 
-Body weight (g): 
Control group = B: 53.67 ± 1.48; F: 179.97 ± 1.82. NDA 
Intervention group 1 = B: 52.98 ± 1.45; F: 172.30 ± 5.83. NDA 
Intervention group 2 = B: 52.81 ± 1.57; F: 166.41 ± 2.36. NDA 
Significant differences between intervention group 2 and control group + intervention group 1 at the end of 
the study. p<0.05 
 
-Glucose (mmol/L): 
Control group = B: 6.09 ± 0.19; F: 7.25 ± 0.35. NDA 
Intervention group 1 = B: 6.19 ± 0.18; F: 5.78 ± 0.22. NDA 
Intervention group 2 = B: 6.01 ± 0.14; F: 5.64 ± 0.17. NDA 
Significant differences between intervention group 2 and control group at the end of the study. p<0.05 
 
-Insulin (µU/mL):  
Control group = B: NDA; F: 116.17 ± 55.53. NDA 
Intervention group 1 = B: NDA; F: 14.04 ± 9.36. NDA 
Intervention group 2 = B: NDA; F: 25.53 ± 21.91. NDA 





Control group = B: NDA; F: 4.76 ± 0.14. NDA 
Intervention group 1 = B: NDA; F: 3.05 ± 0.11. NDA 
Intervention group 2 = B: NDA; F: 2.25 ± 0.10. NDA 
Significant differences between intervention groups and control group at the end of the study. p<0.05 
 
-TG (mmol/L): 
Control group = B: NDA; F: 1.30 ± 0.16. NDA 
Intervention group 1 = B: NDA; F: 0.64 ± 0.06. NDA 
Intervention group 2 = B: NDA; F: 0.39 ± 0.03. NDA 
Significant differences between intervention groups and control group at the end of the study. p<0.05 
 
Jung UJ et al. 
(2006) S11  
Controlled 5-weeks old male 
C57BL/KsJ-db/db 
mice (type 2 
diabetes) 
Control group (n=10) vs 
intervention group (n=10) 
0 mg vs 0.20 g/kg body 
weight/day of 
hesperidin added to the 
regular diet 
5 weeks Glucose, TC, 
HDL-c 
-Glucose (mmol/L): 
Control group = B: 21.06 ± 1.05; F: 39.66 ± 1.83. NDA 
Intervention group = B: 20.66 ± 1.07; F: 31.82 ± 1.11. NDA 
Significant differences between intervention group and control group at the end of the study. p<0,05 
 
-TC (mmol/L): 
Control group = B: NDA; F: 5.62 ± 0.12. NDA 
Intervention group = B: NDA; F: 4.81 ± 0.19. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
-HDL-c (mmol/L): 
Control group = B: NDA; F: 1.06 ± 0.07. NDA 
Intervention group = B: NDA; F: 1.17 ± 0.07. NDA  
No significant differences between intervention group and control group at the end of the study.  
 
-TG (mmol/L): 
Control group = B: NDA; F: 3.32 ± 0.19. NDA 
Intervention group = B: NDA; F: 1.58 ± 0.22. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
Jung UJ et al. 
(2004) S12  
Controlled 5-weeks old male 
C57BL/KsJ-db/db 
mice (type 2 
diabetes) 
Control group (n=10) vs 
intervention group (n=10) 
0 mg vs 0.20 g/kg body 
weight/day of 
hesperidin added to the 
regular diet 
5 weeks Insulin  -Insulin (µU/mL): 
Control group = B: NDA, F: 29.10 ± 1.81. NDA 
Intervention group = B: NDA; F: 47.18 ± 0.59. NDA 
Significant differences between intervention group and control group at the end of the study. p<0.05 
 
STZ, streptozotocin; NDA, no data available about p-valor between basal and final values within each group; SBP, systolic blood pressure; TC, total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; TG, triglycerides; IL-6, 
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500 mg/day of 
placebo capsule 
(n=32) vs 500 
mg/day of hesperidin 
capsule (n=33) 
0 mg/day in 
placebo capsule vs 
450 mg/day in 
hesperidin capsule 










-SBP (mm Hg): 
Placebo capsule = B: 131.00 ± 3.00; F: 129.00 ± 2.00. NS 
Hesperidin capsule = B: 135.00 ± 2.00; F: 130.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-DBP (mm Hg): 
Placebo capsule = B: 80.00 ± 2.00; F: 81.00 ± 2.00. NS 
Hesperidin capsule = B: 83.00 ± 1.00; F: 81.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-FMD (%): 
Placebo capsule = B: 5.57 ± 0.51; F: 5.43 ± 0.47. NS 
Hesperidin capsule = B: 4.50 ± 0.51; F: 4.29 ± 0.47. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 5.00 ± 0.10; F: 5.00 ± 0.10. NS 
Hesperidin capsule = B: 4.90 ± 0.10; F: 5.00 ± 0.10. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-Insulin (µU/mL):  
Placebo capsule = B: 8.35 ± 3.02; F: 7.63 ± 2.88. NS   
Hesperidin capsule = B: 10.66 ± 3.02; F: 11.66 ± 3.02. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-QUICKI: 
Placebo capsule = B: 0.42 ± 0.01; F: 0.23 ± 0.01. NS 
Hesperidin capsule = B: 0.34 ± 0.01; F: 0.42 ± 0.01. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 5.70 ± 0.20; F: 5.60 ± 0.20. NS 
Hesperidin capsule = B: 5.50 ± 0.20; F: 5.40 ± 0.20. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 3.60 ± 0.20; F: 3.60 ± 2.00. NS 
Hesperidin supplement = B: 3.50 ± 0.20; F: 3.40 ± 0.20. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-HDL-c (mmol/L): 
Placebo capsule = B: 1.50 ± 0.50; F: 1.50 ± 0.10. NS 
Hesperidin capsule = B: 1.50 ± 0.10; F: 1.50 ± 0.10. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-TG (mmol/L): 
Placebo capsule = B: 1.30 ± 0.10; F: 1.30 ± 0.10. NS 
Hesperidin capsule = B: 1.30 ± 0.10; F: 1.30 ± 0.10. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 214.00 ± 10.00; F: 215.00 ± 10.00. NS 
Hesperidin capsule = B: 210.00 ± 10.00; F: 190.00 ± 10.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sICAM-1 (ng/mL): 
Placebo capsule = B: 107.00 ± 5.00; F: 107.00 ± 5.00. NS 
Hesperidin capsule = B: 110.00 ± 5.00; F: 100.00 ± 5.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sE-selectin (ng/mL): 
Placebo capsule = B: 12.00 ± 1.00; F: 11.00 ± 2.00. NS 
Hesperidin capsule = B: 11.00 ± 1.00; F: 12.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sP-selectin (ng/mL): 
Placebo capsule = B: 78.00 ± 5.00; F: 83.00 ± 5.00. NS 
Hesperidin capsule = B: 94.00 ± 5.00; F: 83.00 ± 5.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




-FMD (%) at baseline: 
Placebo capsule = B: 5.57 ± 0.51; T2h: 5.08 ± 0.53. NS 
Hesperidin capsule = B: 4.50 ± 0.51; T2h: 4.23 ± 0.51. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-FMD (%) after 6 weeks of supplementation: 
Placebo capsule = B: 5.57 ± 0.51; T2h: 5.08 ± 0.53. NS 
Hesperidin capsule = B: 4.21 ± 0.48; T2h: 4.38 ± 0.51. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
INFLAMMATION BIOMARKERS: 
-Acute sVCAM-1 (ng/mL) at baseline: 
Placebo capsule = B: 214.10 ± 10.00; T2h: 213.00 ± 9.00; T4h: 206.00 ± 10.00. NS 
Hesperidin capsule = B: 210.00 ± 10.00; T2h: 207.00 ± 9.00; T4h: 209.00 ± 10.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sVCAM-1 (ng/mL) after 6 weeks of supplementation: 
Placebo capsule = B: 215.00 ± 10.00; T2h: 208.00 ± 9.00; T4h: 200.00 ± 10.00. NS 
Hesperidin capsule = B: 190.00 ± 10.00; T2h: 185.00 ± 9.00; T4h: 180.00 ± 10.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sICAM-1 (ng/mL) at baseline: 
Placebo capsule = B: 107.00 ± 5.00; T2h: 105.00 ± 4.00; T4h: 109.00 ± 5.00. NS 
Hesperidin capsule = B: 110.00 ± 5.00; T2h: 100.00 ± 4.00; T4h: 104.00 ± 5.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sICAM-1 (ng/mL) after 6 weeks of supplementation: 
Placebo capsule = B: 107.00 ± 5.00; T2h: 105.00 ± 5.00; T4h: 102.00 ± 5.00. NS 
Hesperidin capsule = B: 100.00 ± 5.00; T2h: 98.00 ± 5.00; T4h: 96.00 ± 5.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sE-selectin (ng/mL) at baseline: 
Placebo capsule = B: 12.00 ± 1.00; T2h: 12.00 ± 2.00; T4h: 12.00 ± 2.00. NS 
Hesperidin capsule = B: 11.00 ± 1.00; T2h: 10.00 ± 2.00; T4h: 11.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sE-selectin (ng/mL) after 6 weeks of supplementation: 
Placebo capsule = B: 11.00 ± 2.00; T2h: 9.00 ± 2.00; T4h: 10.00 ± 2.00. NS 
Hesperidin capsule = B: 12.00 ± 2.00; T2h: 11.00 ± 2.00; T4h: 11.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sP-selectin (ng/mL) at baseline: 
Placebo capsule = B: 78.00 ± 5.00; T2h: NDA; T4h: 83.00 ± 4.00. NS 
Hesperidin capsule = B: 94.00 ± 5.00; T2h: NDA; T4h: 90.00 ± 4.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sP-selectin (ng/mL) after 6 weeks of supplementation: 
Placebo capsule = B: 83.00 ± 5.00; T2h: NDA; T4h: 94.00 ± 5.00. NS 
Hesperidin capsule = B: 83.00 ± 5.00; T2h: NDA; T4h: 89.00 ± 5.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 












500 mL/day of low 
flavanone drink vs 
500 mL/day of high 
flavanone drink 
64 mg/day of 
hesperidin vs 549 
mg/day of 
hesperidin  
8 weeks  
 
 
SBP, DBP VASCULAR PARAMETERS: 
-SBP (mm Hg): 
Low flavanone drink on women = B: 126.00 ± 2.70; F: 125.00 ± 4.00. NS 
High flavanone drink on women = B: 123.00 ± 3.20; F: ± 124.00 ± 2.40. NS 
Low flavanone drink on men = B: 132.00 ± 4.30; F: 136.00 ± 4.00. NS 
High flavanone drink on men = B: 135.00 ± 5.60; F: 133.00 ± 3.40. NS 
Significant differences between sexes at the end of the study.  p<0.05 
 
-DBP (mm Hg): 
Low flavanone drink on women = B: 75.00 ± 1.60; F: 76.00 ± 1.60. NS 
High flavanone drink on women = B: 73.00 ± 1.70; F: 73.00 ± 1.60. NS 
Low flavanone drink on men = B: 81.00 ± 2.60; F: 82.00 ± 2.60. NS 
High flavanone drink on men = B: 79.00 ± 2.40; F: 79.00 ± 2.40. NS 
Significant differences between sexes at the end of the study.  p<0.05 
 












600 mL/day of 
control drink (CD) 
vs 600 mL/day of 
orange juice (OJ) 
0 mg/day in 600 
mL/day of CD vs 
213 mg/day of 
hesperidin in 600 
mL/day of OJ 
4 weeks for one 
drink test + 5 weeks 
for wash-out + 4 
weeks for the other 
drink test + 5 weeks 
for wash-out 
5 days-food record Glucose, TC, 
LDL-c, HDL-c,  
TG, Apo A-1, 





Differences compared to baseline: 
GLUCOSE METABOLISM: 
-Glucose (mmol/L): 
CD = F: -0.27. NS 
OJ = F: +0.06. NS 




CD = F: -0.35. p<0.05 
OJ = F: +0.20. NS 
No significant differences between CD and OJ at the end of the study.  
 
-LDL-c (mmol/L): 
CD = F: -0.32. p<0.05 
OJ = F: +0.11. NS 
No significant differences between CD and OJ at the end of the study.  
 
-HDL-c (mmol/L): 
CD = F: -0.07. NS 
OJ = F: +0.00. NS 
No significant differences between CD and OJ at the end of the study.  
 
-TG (mmol/L): 
CD = F: +0.10. NS 
OJ = F: +0.24. NS 
No significant differences between CD and OJ at the end of the study.  
 
-Apo A-1 (mg/dL): 
CD = F: -3.00. NS 
OJ = F: +5.00. p<0.05 
No significant differences between CD and OJ at the end of the study.  
 
-Apo B (mg/dL): 
CD = F: -1.00. NS 
OJ = F: +8.00. p<0.05 




CD = F: +11.00. NS 
OJ = F: +0.1. NS 
No significant differences between CD and OJ at the end of the study.  
 
-Homocysteine (μmol/L): 
CD = F: +0.64. p<0.05 
OJ = F: +0.33. NS 




CD = F: 579.79 ± 50.23. NS 
OJ = F: 558.62 ± 47.36. NS 
No significant differences between CD and OJ at the end of the study.  
 
-sICAM-1 (ng/mL): 
CD = F: 168.34 ± 11.03. NS 
OJ = F: 172.10 ± 11.70. NS 
No significant differences between CD and OJ at the end of the study.  
 
-sE-selectin (ng/mL): 
CD= F: 121.90 ± 12.30. NS 
OJ = F: 110.12 ± 9.98. NS 
No significant differences between CD and OJ at the end of the study.  
 
Rangel-Huerta 











500 mL/day of OJ vs 
500 mL/day of OJ 
with a high 
hesperidin 
concentration 
237 mg/day in 500 
mL/day of OJ vs 
582.50 mg/day of 
hesperidin in 500 
mL/day of OJ  
12 weeks for one 
intervention + 7 
weeks for wash-out  





BW, BMI, SBP, 
DBP,  glucose, 
insulin, TC, LDL-
c, HDL-c, TG, 




OJ = B: 90.40 ± 1.50; F: 89.10 ± 1.50. p<0.05 
OJ with high hesperidin concentration = B: 90.60 ± 1.50; F: 88.80 ± 1.50. p<0.05 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-BMI (kg/m2): 
OJ = B: 32.50 ± 0.40; F: 32.00 ± 0.40. p<0.05 
OJ with high hesperidin concentration = B: 32.60 ± 0.40; F: 31.90 ± 0.40. p<0.05 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
VASCULAR PARAMETERS: 
-SBP (mm Hg): 
OJ = B: 128.00 ± 1.00; F: 124.00 ± 2.00. p<0.05 
OJ with high hesperidin concentration = B: 127.00 ± 1.00; F: 124.00 ± 1.00. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-DBP (mm Hg): 
OJ = B: 79.00 ± 1.00; F: 76.00 ± 1.00. p<0.05 
OJ with high hesperidin concentration = B: 78. 00 ± 1.00; F: 77.00 ± 1.00. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 





OJ = B: 4.90 ± 0.10; F: 5.20 ± 0.10. p<0.05 
OJ with high hesperidin concentration = 5.00 ± 1.00; F: 5.20 ± 0.01. p<0.05 
Significant differences between OJ and OJ with high hesperidin concentration at the 
end of the study. p<0.05 
 
-Insulin (µU/mL): 
OJ = B: 12.70 ±0.70; F: 11.50 ± 0.60. p<0.05 
OJ with high hesperidin concentration = B: 13.80 ± 0.90; F: 12.70 ± 0.70. NS 
Significant differences between OJ and OJ with high hesperidin concentration at the 




OJ = B: 5.60 ± 0.10; F: 5.60 ± 0.10. NS 
OJ with high hesperidin concentration = B: 5.60 ± 0.10; F: 5.60 ± 0.10. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-LDL-c (mmol/L): 
OJ = B: 3.39 ± 0.08; F: 3.47 ± 0.08. NS 
OJ with high hesperidin concentration = B: 3.41 ± 0.08. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-HDL-c (mmol/L): 
OJ = B: 1.29 ± 0.03; F: 1.32 ± 0.03. NS 
OJ with high hesperidin concentration = B: 1.32 ± 0.03; F: 1.29 ± 0.03. NSD 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-TG (mmol/L): 
OJ = B: 1.49 ± 0.07; F: 1.40 ± 0.07. p<0.05 
OJ with high hesperidin concentration = B: 1.54 ± 0.07; F: 1.47 ± 0.06. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-Apo A-1 (mg/dL): 
OJ = B: 147.00 ± 2.00; F: 147.00 ± 2.00. NS 
OJ with high hesperidin concentration = B: 149.00 ± 2.00; F: 145.00 ± 2.00. p<0.05 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 
-Apo B (mg/dL): 
OJ = B: 95.00 ± 2.00; F: 91.00 ± 2.00. p<0.05 
OJ with high hesperidin concentration = B: 96.00 ± 2.00; F: 93.00 ± 2.00. NS 
No significant differences between OJ and OJ with high hesperidin  concentration at 






OJ = B: 335.00 ± 40.00; F: 343.00 ± 38.00. NS 
OJ with high hesperidin concentration = B: 322.00 ± 39.00; F: 326.00 ± 40.00. NS 
No significant differences between OJ and OJ with high hesperidin concentration at 
the end of the study.  
 










CVRF: 10-20% of 
cardiovascular 
risk the next 10 




767 mL/day of CD 
(n=15) vs 767 mL of 
OJ (n=13) 
0 mg/day in CD vs 
320 mg/day of 
hesperidin in OJ  





-SBP (mm Hg): 
CD = B: 128.20 ± 2.20; T5h: 123.60 ± 1.80. NS 
OJ = B: 126.30 ± 1.80; T5h: 123.60 ± 2.90. NS 
No significant differences between control drink and OJ at the end of the study. 
 
-DBP (mm Hg): 
CD = B: 80.20 ± 1.60; T5h: 75.10 ± 1.80. NS 
OJ = B: 77.90 ± 1.80; T5h: 73.60 ± 1.90. NS 
No significant differences between CD and OJ at the end of the study. 
 
-RH-PAT index: 
CD = B: 2.78 ± 0.18; T5h: 2.66 ± 0.17. NS 
OJ= B: 2.77 ± 0.13; T5h: 2.68 ± 0.19. NS 
No significant differences between CD and OJ at the end of the study. 
 













500 mL/day of CD 
(n=12) vs 500 
mL/day of OJ (n=19) 
0 mg/day in 
placebo drink vs 
159.50 mg/day of 
hesperidin in 500 
mL/day of OJ 
1.5 weeks Food diary 24 hours 
the day before the 
visit 




CD = B: 5.70 ± 2.40; F: 5.00 ± 1.80. NS 
OJ = B: 5.70 ± 2.40; F: 7.90 ± 2.70. p<0.05 
Significant differences between CD and OJ at the end of the study. p<0.05 
 
-GTN (%): 
CD = B: 17.90 ± 4.90; F: 17.90 ± 4.80. NS 
OJ = B: 17.90 ± 4.90; F: 18.80 ± 4.60. NS 




CD = B: 33.90 ± 2.60; F: 32.90 ± 3.20. NS 
OJ = B: 33.90 ± 2.60; F: 30.60 ± 2.60. p<0.05 




CD = B: 19.80 ± 4.60; F: 20.80 ± 6.20. NS 
OJ = B: 19.80 ± 4.60; F: 20.70 ± 7.20. NS 
No significant differences between CD and OJ at the end of the study. 
 













capsule/day vs 1 
hesperidin 
capsule/day 
0 mg/day in 
placebo capsule vs 
500 mg/day in 1 
hesperidin capsule 
3 weeks  BMI, SBP, DBP, 










Placebo capsule = B: 34.70 ± 1.50; F: 34.70 ± 1.50. NS 
Hesperidin capsule = B: 34.70 ± 70.00; F: 34.70 ± 1.50. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
VASCULAR PARAMETERS: 
-SBP (mm Hg): 
VCAM, ICAM, 
sE-selectin 
Placebo capsule = B: 138.00 ± 3.00; F: 132.00 ± 2.00. NS 
Hesperidin capsule = B: 138.30 ± 3.00; F: 134.00 ± 3.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-DBP (mm Hg): 
Placebo capsule = B: 89.00 ± 2.00; F: 90.00 ± 2.00. NS 
Hesperidin capsule = B: 89.00 ± 2.00; F: 90.00 ± 2.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-FMD (%): 
Placebo capsule = B: 8.24 ± 0.88; F: 7.78 ± 0.76. NS 
Hesperidin capsule = B: 8.24 ± 0.88; F: 10.26 ± 1.19. p=0.05 
Significant differences between placebo capsule and hesperidin capsule at the end of 
the study. p=0.02 
 
-GTN (%) 
Placebo capsule = B: 13.98 ± 1.32; F: 14.40 ± 1.02. NS 
Hesperidin capsule = B: 13.98 ± 1.32; F: 14.04 ± 1.08. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 7.33 ± 0.67; F: 7.16 ± 0.39. NS 
Hesperidin capsule = B: 7.33 ± 0.67; F: 6.99 ± 0.33. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-Insulin (μU/mL): 
Placebo capsule = B: 21.30 ± 2.10; F: 21.10 ± 1.90. NS 
Hesperidin capsule = B: 21.30 ± 2.10; F: 20.20 ± 2.10. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-QUICKI: 
Placebo capsule = B: 0.298 ± 0.004; F: 0.297 ± 0.003. NS 
Hesperidin capsule = B: 0.298 ± 0.004; F: 0.300 ± 0.004. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 4.65 ± 0.21; F: 4.81 ± 0.21. NS 
Hesperidin capsule = B: 4.65 ± 0.21; F: 4.52 ± 0.21. NS 
Significant differences between placebo capsule and hesperidin capsule at the end of 
the study. p<0.05 
 
-LDL-c (mmol/L): 
Placebo capsule = B: 3.09 ± 0.21; F: 3.17 ± 0.16. NS 
Hesperidin capsule = B: 3.09 ± 0.21; F: 2.99 ± 0.16. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
-HDL-c (mmol/L): 
Placebo capsule = B: 0.96 ± 0.05; F: 0.88 ± 0.05. NS 
Hesperidin capsule = B: 0.96 ± 0.05; F: 0.91 ± 0.05. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-TG (mmol/L): 
Placebo capsule = B: 1.80 ± 0.13; F: 2.04 ± 0.19. NS 
Hesperidin capsule = B: 1.80 ± 0.13; F: 1.87 ± 0.11. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-Apo A1 (mg/dL): 
Placebo capsule = B: 134.00 ± 5.00; F: 136.00 ± 7.00. NS 
Hesperidin capsule = B: 134.00 ± 5.00; F: 137.00 ± 6.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-Apo B (mg/dL): 
Placebo capsule = B: 90.00 ± 4.00; F: 93.00 ± 4.00. NS 
Hesperidin capsule = B: 90.00 ± 4.00; F: 88.00 ± 4.00. NS 
Significant differences between placebo capsule and hesperidin capsule at the end of 




Placebo capsule = B: 320.00 ± 14.00; F: 330.00 ± 16.00. NS 
Hesperidin capsule = B: 320.00 ± 14.00; F: 331.00 ± 15.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-Homocysteine (μM/L): 
Placebo capsule = B: 11.90 (10.30 – 14.90); F: 13.60 (10.60 – 16.70). NS 
Hesperidin capsule = B: 11.90 (10.30 – 14.90); F: 13.00 (10.20 – 15.50). NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
INFLAMMATION BIOMARKERS: 
-SAA protein (mg/L): 
Placebo capsule = B: 7.30 (5.60 – 6.10); F: 8.00 (5.60 – 11.20). NS 
Hesperidin capsule = B: 7.30 (5.60 – 6.10); F: 5.60 (3.20 – 7.80). NS 
Significant differences between placebo capsule and hesperidin capsule at the end of 
the study. p<0.05 
 
-VCAM (ng/mL): 
Placebo capsule = B: 956.00 ± 29.00; F: 976.00 ± 30.00. NS 
Hesperidin capsule = B: 956.00 ± 29.00; F: 950.00 ± 27.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
-ICAM (ng/mL): 
Placebo capsule = B: 291.00 ± 6.00; F: 299.00 ± 7.00. NS 
Hesperidin capsule = B: 291.60 ± 6.00; F: 294.00 ± 7.00. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-sE-selectin (ng/mL): 
Placebo capsule = B: 31.00 ± 2.00; F: 31.00 ± 2.00. NS 
Hesperidin capsule = B: 31.00 ± 2.00; F: 27.00 ± 2.00. NS 
Significant differences between placebo capsule and hesperidin capsule at the end of 
the study. p<0.05 












500 mL/day  of CD 
and placebo 
supplement vs 500 
mL/day of CD and 
hesperidin 
supplement vs 500 
mL/day of OJ 
0 mg/day in 500 
mL/day of CD and 
1 placebo 
supplement vs 0 
mg/day in 500 
mL/day of CD and 
292 mg/day of 
pure hesperidin 
capsule vs 292 
mg/day of 
hesperidin in 500 
mL/day of OJ 









-SBP (mm Hg): 
CD and placebo supplement = F: 133.70 ± 2.10. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +2.00 ± 2.90. NS 
CD and placebo supplement vs OJ = F: -2.00 ± 2.80. NS 
No significant differences between the three interventions at the end of the study. 
 
-DBP (mm Hg): 
CD and placebo supplement = F: 84.90 ± 2.10. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: -5.30 ± 2.00. 
p<0.05 
CD and placebo supplement vs OJ = F: -4.50 ± 2.00. p<0.05 




CD and placebo supplement = F: 6.10 ± 0.20. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +0.20 ± 0.20. NS 
CD and placebo supplement vs OJ = F: +0.00 ± 0.20. NS 
No significant differences between the three interventions at the end of the study. 
 
-Insulin (µU/mL):  
CD and placebo supplement = F: 16.90 ± 1.20. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: -1.30 ± 1.50. NS 
CD and placebo supplement vs OJ = F: -1.20 ± 1.50. NS 




CD and placebo supplement = F: 5.40 ± 0.20. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +0.40 ± 0.20. NS 
CD and placebo supplement vs OJ = F: +0.30 ± 0.20. NS 
No significant differences between the three interventions at the end of the study. 
 
-LDL-c (mmol/L): 
CD and placebo supplement = F: 3.50 ± 0.20. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +0.40 ± 0.20. NS 
CD and placebo supplement vs OJ = F: +0.30 ± 0.20. NS 
No significant differences between the three interventions at the end of the study. 
 
-HDL-c (mmol/L): 
CD and placebo supplement = F: 1.40 ± 0.10. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: 0.00 ± 0.10. NS 
CD and placebo supplement vs OJ = F: 0.00 ± 0.10. NS 




CD and placebo supplement = F: 1.30 ± 0.10. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +0.10 ± 0.10. NS 
CD and placebo supplement vs OJ = F: +0.10 ± 0.10. NS 




CD and placebo supplement = F: 1.98 ± 0.25. NSD 
CD and placebo supplement vs CD and hesperidin supplement = F: -0.19 ± 0.29. NS 
CD and placebo supplement vs OJ = F: +0.11 ± 0.29. NS 
No significant differences between the three interventions at the end of the study. 
 
-sVCAM-1 (ng/mL): 
CD and placebo supplement = F: 119.00 ± 119.00. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: -283.00 ± 157.00. 
NSD 
CD and placebo supplement vs OJ = F: -302.00 ± 154.00. NS 
No significant differences between the three interventions at the end of the study. 
 
-sICAM-1 (ng/mL): 
CD and placebo supplement = F: 360.00 ± 19.00. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: +16.00 ± 27.00. 
NSD 
CD and placebo supplement vs OJ = F: +28.00 ± 26.00. NS 




CD and placebo supplement = F: 37.90 ± 5.60. NS 
CD and placebo supplement vs CD and hesperidin supplement = F: -0.80 ± 7.00. NS 
CD and placebo supplement vs OJ = F: +13.50 ± 6.90. NS 
No significant differences between the three interventions at the end of the study. 
 
















capsules/day vs 4 
hesperidin 
capsules/day 
0 mg/day in 4 
placebo capsules 
vs 800 mg/day in 
4 hesperidin 
capsules 
4 weeks Participants returned 
all used an unused 
capsule boxes 





Placebo capsule = B: 74.00 ± 12.30; F: +0.09 ± 0.09. NS 
Hesperidin capsule = B: 74.00 ± 9.50; F: +0.19 ± 0.10. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-BMI (kg/m2): 
Placebo capsule = B:  25.10 ± 2.30; F: +0.02 ± 0.03. NS 
Hesperidin capsule = B:  25.10 ± 2.10; F: +0.07 ± 0.03. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 




Placebo capsule = B: 6.18 ± 0.85; F: 6.22 ± 0.05. NS 
Hesperidin capsule = B: 6.18 ± 0.83; F: 6.19 ± 0.05. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-LDL-c (mmol/L): 
Placebo capsule = B: 3.97 ± 0.71; F: 4.00 ± 0.04. NSD 
Hesperidin capsule = B: 3.99 ± 0.77; F: 3.99 ± 0.04. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-HDL-c (mmol/L): 
Placebo capsule = B: 1.51 ± 0.45; F: 1.54 ± 0.02. NS 
Hesperidin capsule = B: 1.52 ± 0.40; F: 1.53 ± 0.02. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
-TG (mmol/L):  
Placebo capsule = B: 1.44 ± 0.60; F: 1.26 ± 0.03. NS 
Hesperidin capsule = B: 1.31 ± 0.54; F: 1.24 ± 0.04. NS 
No significant differences between placebo capsule and hesperidin capsule at the end 
of the study. 
 
Aptekmann NP 












0 mL/day (n=13) vs 
500 mL/day of OJ 
(n=13) 
0 mg/day vs 54.60 
mg/day of 
hesperetin in 500 
mL/day of OJ 
13 weeks Self-report BW, BMI, body 
fat, CT, LDL-c, 
HDL-c, TG   
ANTHROPOMETRIC PARAMETERS: 
-BW (kg): 
Control group = B: 76.30 ± 15.30; F: 74.50 ± 15.90. p<0.05 
OJ group = B: 74.60 ± 13.00; F: ± 73.60 ± 12.40. p<0.05 
No significant differences between control group and OJ group at the end of the study. 
 
-BMI (kg/m2): 
Control group = B: 29.00 ± 5.33; F: 28.30 ± 5.81. p<0.05 
OJ group = B: 28.40 ± 4.46; F: 28.10 ± 4.47. p<0.05 
No significant differences between control group and OJ group at the end of the study. 
 
-Body fat (%): 
Control group = B: 39.30 ± 7.33; F: 33.80 ± 7.98. p<0.05 
OJ group = B: 37.70 ± 7.56; F: 33.40 ± 7.42. p<0.05 




Control group = B: 5.03 ± 0.70; F: 4.95 ± 0.76. NS 
OJ group = B: 4.82 ± 0.74; F: 4.60 ± 0.74. p<0.05 
No significant differences between control group and OJ group at the end of the study. 
 
-LDL-c (mmol/L): 
Control group = B: 3.50 ± 0.87; F: 3.33 ± 0.85. NS 
OJ group = B: 3.03 ± 0.64; F: 2.59 ± 0.79. p<0.05 
No significant differences between control group and OJ group at the end of the study. 
 
-HDL-c (mmol/L): 
Control group = B: 1.53 ± 0.29; F: 1.44 ± 0.32. NS 
OJ group = B: 1.27 ± 0.28; F: 1.50 ± 0.31. p<0.05 
No significant differences between control group and OJ group at the end of the study. 
 
-TG (mmol/L): 
Control group = B: 1.02 ± 0.30; F: 0.95 ± 0.27. NS 
OJ group = B: 1.14 ± 0.49; F: 1.12 ± 0.32. NS 
































0 mL/day (n=8) vs 
750 mL/day of OJ 
(n=14) 
0 mg/day vs 42 
mg/day of 
hesperetin  in 750 
mL/day of OJ 




Control group = B: 30.00 ± 6.00; F: 30.00 ± 5.00. NS 
OJ = B: 28.00 ± 5.00; F: 28.00 ± 5.00. NS 




Control group = B: 5.51 ± 0.73; F: 5.75 ± 1.04. NS 
OJ = B: 5.95 ± 0.55; F: 5.49 ± 0.78. p<0.05 
No significant differences between control group and OJ at the end of the study. 
 
-LDL-c (mmol/L): 
Control group = B: 3.69 ± 0.68; F: 3.82 ± 0.94. NS 
OJ = B: 4.16 ± 0.44; F: 3.67 ± 0.68. p<0.05 
No significant differences between control group and OJ at the end of the study. 
 
-HDL-c (mmol/L): 
Control group = B: 1.14 ± 0.34; F: 1.14 ± 0.31. NS 
OJ = B: 1.12 ± 0.18; F: 1.17 ± 0.18. NS 
No significant differences between control group and OJ at the end of the study 
 
-TG (mmol/L): 
Control group = B: 1.46 ± 0.60; F: 1.84 ± 0.73. p<0.05 
OJ = B: 1.48 ± 0.49; F: 1.66 ± 0.59. NS 
No significant differences between control group and OJ at the end of the study. 
 
CVRF, cardiovascular risk factors; SBP, systolic blood pressure;  DBP, diastolic blood pressure; FMD, flow-mediated dilatation; QUICKI, quantitative insulin-sensitivity check index; TC, total cholesterol; LDL-c, low density lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; 
TG, triglycerides; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intercellular adhesion molecule-1; sE-selectin, soluble E-selectin; sP-selectin, soluble P-selectin;  NS, no significant differences between basal and final values; CD, control drink; OJ, orange juice; Apo A-
1, apolipoprotein A-1; Apo B, apolipoprotein B; BW, body weight; BMI, body mass index; oxLDL, oxidized low density lipoprotein; RH-PAT index, reactive hyperemia-peripheral arterial tonometry index; NDA, no data available; GTN, glyceryl-nitrate dilation of the brachial artery; IL-6, 
interleukin 6; NOx, nitric oxide; SAA protein, serum amyloid A protein. 
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Projects 2, 3 and 4: Summarizing the 










The CITRUS study 
  
 This section explains the RCT called CITRUS, a competitive 
project, from which 3 projects were realized and reported in the present 
thesis. 
 
First, we will start with the evaluation of hesperidin consumption in OJ 
and hesperidin-enriched OJ (EOJ) in pre- and stage 1 hypertensive 
subjects on BP and PP (Project 2). Second, we evaluated the effects of 
hesperidin consumption in OJ and EOJ on the transcriptomic profile of 
PBMCs (Project 3). Finally, we evaluated the effects of hesperidin 
consumption in OJ and EOJ on plasma, serum, and urine metabolomic 
profiles (Project 4). 
 
Study design: 
A randomized, parallel, double-blinded, and placebo-controlled clinical 
trial was performed. All the participants were randomly assigned to one 
of the three intervention groups, namely control drink (CD), OJ and 
EOJ, and they consume 500 mL/day of the corresponding drink for 12 
weeks. Moreover, two single dose studies, one at the beginning of the 
study and the other one at the end of the study after 12 weeks, were 
performed. For single dose studies participants consumed 500 mL of 
the corresponding intervention drink in the postprandial state. 
 
After 1 week with control dietary habits following nutritionist 
recommendations to limit the total intake of flavonoid-rich foods and 
citrus-containing foods and maintain their normal dietary habits, the 
participants started the clinical trial. Moreover, 48 hours before the two 
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single dose studies, the participants realized a phenolic compounds-free 
diet.  
During the sustained study the subjects attended 7 visits (V), and the 
two single dose studies were performed at V1 and V7. The first single 
dose study (V1) was realized to determine the postprandial effects of 
hesperidin in OJ, and the second single dose study (V7) was realized to 
assess the postprandial effects of hesperidin in OJ after the sustained 
consumption. 
At V1, V3, V5 and V7 a 3-day food record was obtained to determine 
their dietary habits, and blood and urine samples in fasting conditions 
were collected. Moreover, at each visit, a physical examination, 
physical activity questionnaire class and anthropometric measurements 
were performed.    
 
Study population: 
From the subjects who attended to the preselection, 159 (53 women and 
106 men) were included. Participants has pre- or stage 1 hypertension.  
Inclusion criteria were: 
- Age from 18 to 65 years old. 
- SBP ≥120 mm Hg. 
- No family history of CVDs or chronic diseases. 
- Willingness to provide informed consent before starting the 
study. 
Exclusion criteria were: 
- BMI ≥ 35 kg/m2. 
- Fasting glucose > 125 mg/dL. 
- SBP ≥ 160 mm Hg  
- DBP ≥ 100 mm Hg 
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- Taking antihypertensive medications. 
- Hyperlipemia or antilipemic medication. 
- Smoking. 
- Pregnancy or intending to become. 
- Use of medications, antioxidants, vitamin supplements or 
adherence to a vegetarian diet. 
- Chronic alcoholism. 
- Physical activity > 5 hours/week 
- Intestinal disorders 
- Anemia (hemoglobin ≤13 mg/dL in men and ≤12 mg/dL in 
women). 
- Consumption of a research product in the 30 day prior to 
inclusion in the present study. 
- Failure to follow the study guidelines. 
 
The clinical trial was approved by the Clinical Research Ethical 
Committee of Hospital Sant Joan (14-12-18/12aclaassN1), Reus, Spain; 
was conducted in accordance to Helsinki Declaration and Good Clinical 
Practice Guidelines of the International Conference of Harmonization 
and were reported as CONSORT criteria. Finally, the clinical trial was 
registered at Clinical-Trials.gov: NCT02479568. 
 
Intervention drinks: 
The three intervention drinks were supplied by the Florida Department 
of Citrus of the United States of America. The intervention drinks were 
CD with no hesperidin content, OJ containing 392 mg/500 mL 
hesperidin, and EOJ containing 670 mg/500 mL hesperidin. 
Ferrer HealthTech of Murcia (Spain) provided the micronized 2S 
hesperidin used to enrich the EOJ intervention because it is the form 
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that is naturally present in OJ and the most bioavailable.(103) The 
detailed composition of the three drinks is reported in Supporting 
Information Table S1 of the published version of Project 2. 
 
Parameters measured:  
The following parameters were obtained and measured during the 
CITRUS study and reported in 3 different projects depending on the 
objective: 
-In the Project 2, the following were evaluated at V1, V3, V5 and V7:  
o SBP and DBP levels, and pulse pressure (PP). 
o Serum levels of homocysteine, F2α-isoprostanes, ICAM-1, 
VCAM-1 and uric acid.  
o For the single-dose study, SBP, DBP, PP and homocysteine 
were evaluated at baseline and after 2, 4 and 6 hours. 
-In the Project 3, the following were obtained to realize transcriptomic 
analysis at V1 and V7:  
o Blood samples to obtain PBMCs. 
-In the Project 4, the following were obtained to realize the 
metabolomics analysis:  
o Plasma samples at weeks 4, 8 and 12, and after 2, 4 and 6 hours 
of the single dose. 
o Serum and urine samples at V1 and V7. 
o Serum samples were obtained at baseline and after 2, 4 and 6 
hours of a single dose of hesperidin. 
 
Finally, Figure 13 presents a schema of the CITRUS study that includes 
the 3 projects realized in subjects with pre- or stage 1 hypertension to 

































Project 2: Effects of hesperidin in orange 
juice on blood and pulse pressures in mildly 
hypertensive individuals: a randomized 
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Abstract
Purpose To assess the sustained and acute effects, as well as the influence of sustained consumption on the acute effects, of 
orange juice (OJ) with a natural hesperidin content and hesperidin-enriched OJ (EOJ) on blood (BP) and pulse (PP) pressures 
in pre- and stage-1 hypertensive individuals.
Methods In a randomized, parallel, double-blind, placebo-controlled trial, participants (n = 159) received 500 mL/day of 
control drink, OJ, or EOJ for 12 weeks. Two dose–response studies were performed at baseline and after 12 weeks.
Results A single EOJ dose (500 mL) reduced systolic BP (SBP) and PP, with greater changes after sustained treatment where 
a decrease in diastolic BP (DBP) also occurred (P < 0.05). SBP and PP decreased in a dose-dependent manner relative to 
the hesperidin content of the beverages throughout the 12 weeks (P < 0.05). OJ and EOJ decreased homocysteine levels at 
12 weeks versus the control drink (P < 0.05). After 12 weeks of EOJ consumption, four genes related to hypertension (PTX3, 
NLRP3, NPSR1 and NAMPT) were differentially expressed in peripheral blood mononuclear cells (P < 0.05).
Conclusion Hesperidin in OJ reduces SBP and PP after sustained consumption, and after a single dose, the chronic consump-
tion of EOJ enhances its postprandial effect. Decreases in systemic and transcriptomic biomarkers were concomitant with 
BP and PP changes. EOJ could be a useful co-adjuvant tool for BP and PP management in pre- and stage-1 hypertensive 
individuals.
Keywords Orange juice · Hesperidin · Blood pressure · Pulse pressure · Pre-hypertension
Introduction
Flavonoid compounds are the most abundant phenolic 
compounds in plants, and citrus flavonoids, particularly 
present in orange juice (OJ), are attracting attention due to 
their beneficial effects on cardiovascular risk factors [1].
OJ is a main dietary source of flavanones, a subclass of 
flavonoids, and hesperetin-7-O-rutinoside (hesperidin) and 
naringenin-7-O-rutinoside (narirutin) are the main citrus 
flavanone components [2].
Data from cohort studies reported an inverse associa-
tion between citrus fruit/flavanone consumption and cer-
ebrovascular disease [3–5] and cardiovascular mortality 
[6–8]. Antihypertensive, antithrombotic, anti-inflamma-
tory, antilipemic, vasodilator, and antioxidant effects of 
hesperidin have been reported in animal models [9–11]. 
Similar outcomes have been observed for narirutin [12].
Recently, hesperidin has been shown to reduce the ath-
erosclerotic plaque area and macrophage foam cell forma-
tion in low density lipoprotein (LDL) receptor-deficient 
mice [11]. The aforementioned properties of hesperidin 
have been considered to be the mechanisms responsible 
for the beneficial effects of citrus flavanone consumption 
on cardiovascular disease in humans [13].
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Concerning the antihypertensive effects of citrus fla-
vanones, data from animal studies showed that hespere-
tin, a biological metabolite of hesperidin [10], exerts an 
antihypertensive effect in hypertensive rats but not in 
normotensive rats [9, 14]. The antihypertensive effect, 
as well as vasodilatory and anti-inflammatory activities, 
has been reported to be mediated by the hesperetin-7-O-
β-d-glucuronide conjugate [10]. In humans, a natural OJ, 
but not a hesperidin-enriched beverage, decreased blood 
pressure (BP) in overweight and obese individuals [15]. 
Similarly, chronic consumption of hesperidin reduced BP 
in type 2 diabetes patients [16], although no hypotensive 
effect was observed in healthy or overweight individuals 
[17, 18]. In individuals at moderate risk of cardiovascular 
disease (CVD), no changes in BP or other cardiovascular 
risk biomarkers were observed after a single dose of OJ 
or a hesperidin supplement at 5 h post intake [19]. Among 
flavonoids subclasses, flavone and flavan-3-ol compounds, 
but not flavanones, were related to the prevention of hyper-
tension in a cohort of 87,242 women from the Nurses’ 
Health Study [20].
Thus, data of the antihypertensive effect of hesperidin 
consumption in humans remain controversial. Therefore, 
we assessed both the sustained and acute effects, as well as 
the influence of sustained consumption on acute effects, of 
real-life doses of OJ and a hesperidin-enriched dose on BP, 
pulse pressure (PP), and cardiovascular risk biomarkers in 
pre- and stage-1 hypertensive individuals. Our hypothesis 
was that hesperidin in OJ would provide benefits on BP 
and PP not only after sustained consumption but also at 
postprandial level after a single dose.
Materials and methods
Study population
Participants from the general population were recruited by 
means of news in the newspapers, social networks, and tab-
leaux advertisements in the Hospital Universitari Sant Joan 
(HUSJ)-Eurecat, Reus, Spain, between January 2016 and 
June 2017. From 311 subjects assessed for eligibility, 159 
(53 women and 106 men) pre- or stage-1 hypertensive indi-
viduals, according to current guidelines [21], were recruited. 
Inclusion criteria were as follows: age from 18 to 65, systolic 
blood pressure (SBP) ≥ 120 mmHg, no family history of car-
diovascular disease or chronic disease, and willingness to 
provide informed consent before the initial screening visit. 
Exclusion criteria were: body mass index (BMI) ≥ 35 kg/
m2, fasting glucose > 125 mg/dL, SBP ≥ 160 mmHg and 
diastolic blood pressure (DBP) > 100  mmHg or taking 
antihypertensive medications, hyperlipemia or antilipemic 
medication; smoking, pregnancy or intending to become 
pregnant, use of medications, antioxidants, vitamin sup-
plements or adherence to a vegetarian diet, chronic alco-
holism, physical activity > 5 h/week, intestinal disorders, 
anemia (hemoglobin ≤ 13  mg/dL in men and ≤ 12  mg/
dL in women), consumption of a research product in the 
30 days prior to inclusion in the study, or failure to follow 
the study guidelines. Participants signed informed consent 
prior to their participation in the study, which was approved 
by the Clinical Research Ethical Committee of HUSJ 
(14-12-18/12aclaassN1), Reus, Spain. The protocol and trial 
were conducted in accordance with the Helsinki Declaration 
and Good Clinical Practice Guidelines of the International 
Conference of Harmonization (GCP ICH) and were reported 
as CONSORT criteria. The trial was registered at Clinical-
Trials.gov: NCT02479568.
Intervention products
Intervention beverages (supplied by the Florida Department 
of Citrus, USA) were control drink (CD), an OJ containing 
690 mg/L of hesperidin (the natural hesperidin content), 
and an enriched orange juice (EOJ) containing 1200 mg/L 
of hesperidin. Ferrer HealthTech (Murcia, Spain) provided 
the Micronized 2S Hesperidin used in EOJ enrichment. The 
2S form, the one present naturally in the OJ, is the most 
bioavailable [18]. Beverages were analyzed for hesperidin 
and narirutin content using chromatography–mass spectrom-
etry (LC–MS/MS) (Supporting Information Table S1). Daily 
doses of 500 mL of CD, OJ and EOJ, provided 0 mg/day, 
345 mg/day, and 600 mg/day of hesperidin, and 0 mg/day, 
64 mg/day, and 77.5 mg/day of narirutin, respectively. Inter-
vention drinks were similar in appearance and smell, and 
were differentiated only by a code assigned by an independ-
ent researcher not related to the study to guarantee blind-
ing. Flavanone contents of the OJ and the EOJ were stable 
throughout the study.
Study design
A randomized, parallel, double-blind, placebo-controlled 
clinical trial was performed (Supporting Information Fig. 
S1). Participants were randomly assigned to one of the 
three intervention groups—CD, OJ, or EOJ—to consume 
500 mL/day of the corresponding beverage for 12 weeks. 
Nested within the sustained consumption study were two 
dose–response studies, one at baseline and the other after 
12 weeks of sustained consumption, where the 500 mL/
dose was administered all at once and changes in the out-
comes were recorded in the postprandial state. Participants 
were randomly allocated to the three intervention groups 
by a computerized random-number generator made by an 
independent statistician. PROC PLAN (SAS 9.2, Cary, NC: 
European Journal of Nutrition 
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block sizes of 2, 4, and 6 was used. Participants, researchers 
and the statistician remained blinded to the type of product 
administered throughout the study.
After enrolment and following a 1-week run-in period 
with a control diet consisting of a maintained lifestyle and 
normal dietary habits based on nutritionist recommenda-
tions, the participants started the intervention trial. How-
ever, during the intervention period, the participants were 
instructed to also maintain their dietary habits, to completely 
refrain from consuming citrus-containing foods and to limit 
their total intake of flavonoid-rich foods (tea, coffee, cocoa, 
wine and other fruit juices) to reduce the possible masking 
effects that can exert these foods on BP [22, 23]. During 
the sustained study, participants attended seven visits (V) at 
the HUSJ-Eurecat. Dose–response postprandial studies, per-
formed at V1 and V7, lasted from 08:00 a.m. to 02:00 p.m., 
and participants received a light meal before leaving. In 
addition to the baseline (0 h), blood samples were collected 
at 2 h, 4 h, and 6 h after the single dose of 500 mL. The 
adherence of the volunteers to their dietary habits through-
out the study was assessed by a 3-day food record at V1, V3, 
V5, and V7. At each visit, subjects underwent a physical 
examination by a general practitioner and completed a Physi-
cal Activity Questionnaire Class AF [24], and anthropomet-
ric measurements were recorded. Samples were stored at 
-80ºC in the central laboratory’s Biobanc of HUSJ-Eurecat 
(biobanc.reus@iispv.cat) until required for batch analyses.
Compliance measures
The plasma levels of the following biomarkers of nutrient 
exposures were measured by LC–MS/MS in the plasma 
samples: hesperetin-7-O-β-d-glucuronide, hesperetin-3-O-
β-d-glucuronide, hesperetin-7-O-sulfate, naringin-4-O-β-d-
glucuronide, naringin-glucuronide and naringin sulfate. The 
extraction was carried out with a semi-automated process 
using Agilent Bravo Automated Liquid Handling Platform. 
Briefly, 20 μL of internal standard (Hesperetin d4) was 
mixed with 125 μL of plasma and 750 μL of methanol. The 
mixture was vortexed and centrifuged at 4700 rpm at 4 °C, 
and then 900 μL was evaporated in a Speed-Vac at room 
temperature. Residues were reconstituted in 25 μL of MeOH 
and 75 μL of  H2O (1% of HFor) and injected in the LC–MS/
MS, an Agilent 1200 series ultra-high-performance liquid 
chromatography (UHPLC) system coupled to a 6490 Triple 
Quad mass spectrometer, with electrospray source ionization 
(ESI) operating in negative mode.
Main outcome measures
SBP and DBP were measured twice after 2–5  min of 
respite, with the patient in a seated position, with 1-min 
interval between, using an automatic sphygmomanometer 
(OMRON HEM-907; Peroxfarma, Barcelona, Spain). The 
mean values were used for statistical analyses. Office PP, 
which represents the force that the heart generates each time 
it contracts, was determined by the difference between SBP 
and DBP [25]. The main outcomes were measured in both 
dose–response and sustained consumption studies.
Secondary outcomes
Homocysteine in serum samples was determined by LC–MS/
MS. F2α isoprostanes were determined by a quantitative 
sandwich enzyme-linked immunosorbent assay (ELISA) 
(Caymanchem, MI, USA) in 24-h urine. Soluble Intercel-
lular Adhesion Molecule-1 (ICAM-1) and Soluble Vascu-
lar Cell Adhesion Molecule-1 (VCAM-1) were determined 
in serum by the Luminex™xMAP technology with the 
EPX010-40,232-901 kit eBioscience (Thermo Fisher Scien-
tific, Waltham, Massachusetts, USA), in the the Bio-Plex™ 
200 instrument (Bio-Rad, Hercules, California, USA). Uric 
acid was measured by standardized methods on an autoana-
lyzer 182 (Beckman Coulter-Synchron, Galway, Ireland) in 
serum samples. All biological biomarkers were measured 
in the sustained consumption study. Homocysteine was 
additionally measured after the single 500-mL dose of the 
corresponding intervention product in both dose–response 
studies.
Transcriptomic analyses
Gene expression was assessed in peripheral blood mono-
nuclear cells (PBMCs) with an Agilent Microarray Plat-
form (Agilent Technologies, Santa Clara, California, USA) 
in a subsample (n = 37) of participants (11, 15, and 11, 
in CD, OJ, and EOJ groups, respectively) at baseline and 
after 12 weeks. PBMC RNA was isolated using Ficoll 
gradient separation GE Healthcare Bio Sciences, Barce-
lona, Spain), RNA yield was quantified with a Nanodrop 
UV–VIS Spectrophotometer and integrity was measured 
with an Agilent 2100 Bioanalyzer using the Total RNA 
Nano kit and the Eukaryote Total RNA Nano (Agilent 
Technologies, Santa Clara, California, USA). Total RNA 
from the PBMCs was labeled with one color (Cy3) (ref: 
5190-2305, Agilent Technologies, Santa Clara, California, 
USA) and hybridized using a Gene Expression Hybridi-
zation Kit (ref: 5188-5242, Agilent Technologies, Santa 
Clara, California, USA). Image scanning was performed 
with an Agilent Microarray Scanner System with SureScan 
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High Resolution Technology (Agilent Technologies, Santa 
Clara, California, USA). Differentially expressed genes 
were subjected to functional and biochemical pathway 
analysis using Gene Ontology, Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (https ://www.genom e.jp/
kegg) and PANTHER (protein annotation through evolu-
tionary relationship classification system (https ://www.
panth erdb.org/) [26] biochemical pathway databases. The 
analysis was performed using GeneCodis (https ://www.
genec odis.dacya .ucm.es [27] software.
Selected genes related to hypertension were validated 
by PCR. Briefly, to analyze the expression of the genes 
and validate the DNA array results, cDNA was synthesized 
using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, 4 Barcelona, Spain) and MyGene 
Series Peltier Thermal Cycler (LongGene Scientific, 
Zhejiang, China) and used for reverse transcription. The 
cDNA was subjected to quantitative reverse transcription-
polymerase chain reaction amplification using LightCycler 
480 SYBR Green I Master (Roche Diagnostic, Sant Cugat 
del Vallès, Barcelona, Spain) and a LightCycler 480 II 
system (Roche Diagnostic, Sant Cugat del Vallès, Barce-
lona, Spain).
Sample size and power analyses
A sample size of 159 individuals was calculated assuming an 
expected dropout rate of 20% and a type I error of 0.005 (two 
sided), which allows at least 80% power for the detection of 
statistically significant differences in the SBP of 4 mmHg 
among the groups. The population standard deviation of the 
SBP was estimated to equal 6 mmHg [28].
Statistical analyses
Descriptive data were expressed as the mean 95% confidence 
interval (CI). The normality of variables was assessed by 
the Kolmogorov–Smirnov test. Non-parametric variables 
were log transformed. ANOVA was used to determine dif-
ferences in baseline characteristics. Analyses were made by 
intention-to-treat. Multiple imputation was made by linear 
regression analysis. Intra-treatment comparisons were per-
formed by means of a general linear model with Bonferroni 
correction and age and sex as covariables. Inter-treatment 
comparisons were carried out by analysis of covariance 
(ANCOVA) model adjusted for age and sex. For transcrip-
tomic analyses, quality control was performed through 
principal component analyses. Statistical comparisons were 
performed by Student’s t test or Welch’s t test if proceeded. 
Multiple testing correction was performed using the Benja-
mini–Hochberg False Discovery Rate (FDR) control proce-
dure. Probes were assumed to be differentially expressed if 
they presented a P value < 0.05 and a fold change ≤ −0.58 
or ≥ 0.58 in log2 scale (corresponding to 1.5-fold difference 
in natural scale). Calculations were performed using the R 
statistical language. Comparisons among treatments were 
carried out by an ANCOVA model adjusted by age and sex 
and baseline values. Statistical significance was defined as a 
P value ≤ 0.05 for a two-sided test. Analyses were performed 
using SPSS for Windows, version 21 (IBM corp., Armonk, 




Of the 311 subjects who were assessed for eligibility, 152 
did not meet the inclusion criteria and were excluded. The 
remaining 159 participants were randomly allocated to 
the CD, OJ, and EOJ groups, (n = 53 in each group). Ulti-
mately, 129 participants completed the study (43 in the CD, 
46 in the OJ, and 40 in the EOJ groups) (Fig. 1). For the 
dose–response study, of the 52 allocated participants, three 
discontinued the intervention from the beginning, and six 
were lost for the second dose–response study. Thus, 52 par-
ticipants (17 in the CD, 21 in the OJ, and 14 in the EOJ 
groups) were available for the first dose–response study, and 
43 (13 in the CD, 18 in the OJ, and 12 in the EOJ groups) 
were available for the second dose–response study (Fig. 1). 
No differences in baseline characteristics were observed 
among the groups (Supporting Information Table S2). The 
baseline characteristics of participants in the dose–response 
study were similar to those of the whole sample. No changes 
in the level of physical activity were observed from the 
beginning to the end of the study in any group (data not 
shown). No differences in dietary intake were observed 
among groups with exception of protein (% energy) intake, 
which was greater in the OJ group than in the EOJ one 
(P = 0.031) (Supporting Information Table S3).
Compliance biomarkers
The volunteer compliance intervention was considered 
optimal because all the compliance biomarkers (hesperetin-
7-O-β-d-glucuronide, hesperetin-3-O-β-d-glucuronide, 
hesperetin-7-O-sulfate, naringerine-4-O-β-d-glucuronide, 
naringenin-glucuronide and naringenin-sulfate) increased 
significantly during the OJ and EOJ intervention compared 
with the baseline values and the CD group intervention. At 
12 weeks, the metabolite hesperetin-7-β-d-glucuronide was 
the main differentially expressed metabolite between the OJ 
and EOJ groups and the CD group (P < 0.001).
European Journal of Nutrition 
1 3
After 12 weeks of treatments (Fig. 2a), plasma hesperetin-
7-β-d-glucuronide increased in a dose-dependent manner 
with the hesperidin content of the beverage administered 
(P < 0.001 for linear trend), and the increase in the EOJ 
group was significantly higher than that of the OJ group 
(P < 0.05). In the dose–response studies, plasma hesperetin-
7-β-d-glucuronide increased at 4 and 6 h after OJ and EOJ 
(P < 0.005 versus changes in CD), both at the beginning 
(Fig. 2b) and at the end of the study. The individual changes 
in plasma hesperetin-7-β-d-glucuronide are depicted in Sup-
plementary Fig. 4 .
Main outcomes
Changes in SBP at 2, 6, 10 and 12 weeks are shown in Fig. 3. 
SBP decreased in a dose-dependent manner with the hes-
peridin content of the beverage administered (P < 0.05 for 
linear trend). SBP decreased at weeks 4, 8, and 12 after OJ 
consumption, the decreases reaching significance versus 
changes.
in the CD at week 4 and 12 (P < 0.05) by mean 95% 
IC −5.58 (−9.8; −1.3) mmHg and −5.06 (−8.8; −1.3) 
mmHg, respectively. A borderline significance at week 8 
was also observed (P = 0.056). After consumption of EOJ, 
SBP decreased in all evaluated weeks compared to CD, 
the decreases reaching significance (P < 0.05) at all weeks, 
with the only exception of week 8 in which a borderline 
significance (P = 0.078) was observed. The average of all 
decreases through the study was −6.35 and −7.36 mmHg 
for OJ and EOJ interventions, respectively. DBP decreased 
similarly after all interventions and in all weeks (P < 0.05) 
(data not shown). Changes in PP through the study are 
shown in Fig. 4. PP decreased in a dose-dependent manner 
with the hesperidin content of the beverage administered 
(P < 0.05 for linear trend) in all weeks, but in the 12 week, 
the trend did not reach significance (P = 0.125). Concern-
ing dose–response studies, at the beginning of the study 
(Fig. 5a), significant decreases were observed in SBP at 
2 h and in PP at all evaluated times (P < 0.05) after a sin-
gle dose of 500 mL only in the case of EOJ. No changes 
were observed in DBP values. After 12 weeks of treatment 
(Fig. 5b), a single dose of 500 mL resulted in changes in 
BP and PP also only in the EOJ group (Panel B). DBP 
decreased versus baseline at all evaluated times (P < 0.05), 
and the decrease at 2 h and 6 h reached significance ver-
sus changes in CD (P < 0.05). Additionally, the observed 
Fig. 1  Flow chart of the study
 European Journal of Nutrition
1 3
decreases in SBP at 6 h and those of PP at all evaluated 
times reached significance versus changes in CD (P < 0.05). 
At 4 h and 6 h postprandial after our, an inverse relationship 
was observed between hesperidin-7-β-d-glucuronide values 
and those of PP (R = −0.354, P = 0.023, and R = −0.377, 
P = 0.015, respectively). At 6 h, an inverse relationship was 
also observed between the increase in hesperidin-7-β-d-
glucuronide and SBP values (R = −0.353, P = 0.024).
Secondary outcomes
At week 12 after sustained consumption, homocysteine 
values decreased after OJ and EOJ treatments, and the 
decreases reached significance versus changes after the CD 
treatment. At this time point, homocysteine plasma values 
decreased in the postprandial state at 2 h and 4 h after OJ and 
after 2 h of EOJ ingestion (P < 0.05) (Fig. S2 in the online-
only Data Supplement). Uric acid decreased at 12 weeks 
after EOJ treatment, reaching significance versus changes 
in the CD treatment (P = 0.044). ICAM-1 decreased at week 
12 after EOJ treatment (P = 0.032), but no changes were 
observed between treatments. At week 12 after sustained 
consumption, uric acid concentrations were directly related 
to SBP, DBP, and PP (P < 0.05). No changes were observed 
in other secondary outcomes. After 12 weeks sustained con-
sumption, the values of SBP directly correlated with those 
of ICAM-1 (R = 0.251, P = 0.004) and VCAM (R = 0.185, 
P = 0.036) (Fig. S3 in the online-only Data Supplement), 
and the decrease in F2-isoprostanes, although without sig-
nificance, were directly correlated with the decreases in SBP 
(R = 0.178, P = 0.042).
No adverse events were reported. All products were well 
tolerated.
In transcriptomic analyses, after the sustained consump-
tion study, four genes related to hypertension were identi-
fied: Pentraxin-3 (PTX3); NLR family, pyrin domain con-
taining 3 (NLRP3); neuropeptide S receptor 1(NPSR1); and 
nicotinamide phosphoribosyl transferase (NAMPT), which 
were differentially expressed after 12 weeks of treatment. 
The expressions of the PTX3 and NAMPT genes decreased 
significantly in PBMC after the EOJ intervention versus 
the control treatment (P < 0.05). Figure 6 shows the com-
parisons among interventions considering the dot axis at 
Fig. 2  Changes in plasma hesperitin-7-β-d-glucuronide after inges-
tion of control, orange juice (OJ), and enriched OJ. a After sustained 
consumption for 12  weeks (500  mL/day). b At the beginning of 
the study after a single dose of 500  mL. *P < 0.05 versus baseline; 
†P < 0.05 versus control group; ‡P < 0.001 versus control; ¥P < 0.05 
versus OJ
Fig. 3  Changes in systolic blood pressure (SBP) at 2 (a), 6 (b), 10 (c), 
and 12 (d) weeks after sustained consumption of control drink (CD), 
orange juice (OJ), and hesperidin-enriched OJ (EOJ). *P < 0.05 ver-
sus baseline; †P < 0.05 versus CD
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P < 0.05 to be of significance. The decreases in SBP and 
PP at week 12 were directly related to the decrease in PTX3 
expression (R = 0.393, P = 0.016 and R = 0.487, P = 0.002, 
respectively). The decrease in PP at week 12 was directly 
related to that of NAMPT expression (R = 0.344, P = 0.037). 
Although no significance was observed, changes in NRLP3 
expression were inversely related to those of PP at week 
12 (R = −0.420, P = 0.010). In turn, expression of PTX3 at 
week 12 was directly related to that of NAMPT (R = 0.759, 
P < 0.001).
Discussion
In the present study, on the one hand, SBP and PP decreased 
in a dose-dependent manner with the hesperidin content of 
the beverage administered throughout the 12 weeks of the 
study. On the other hand, a single dose of 500-mL EOJ, but 
no other treatment, reduced SBP, and PP, greater changes 
when the dose was administered at the end of the study after 
12 weeks of sustained treatment where DBP changes were 
also observed. Thus, these suggested that sustained con-
sumption of hesperidin optimizes acute BP-lowering effects.
After 12  weeks, sustained EOJ consumption-related 
decreases in uric acid and ICAM were observed. Homocyst-
eine decreased at 12 weeks after OJ and EOJ, and postpran-
dial decreases in homocysteine were also present after single 
doses of OJ and EOJ at the end of the study. In agreement 
with the decrease in SBP and PP, PTX3 and NAMPT gene 
expression decreased in PBMCs at 12 weeks after sustained 
EOJ treatment.
Currently, the worldwide prevalence of hypertension 
exceeds 1.3 billion [29] and is the main risk factor for death 
and disability-adjusted life-years lost during 2010 [30]. A 
10-mmHg SBP decrease is associated with reductions of 22 
and 41% in coronary heart disease and stroke, respectively 
[31]. Decreases in SBP with medical therapies range from 5 
to 15 mmHg [32]. The average reductions in SBP through-
out our study were −6.35 and −7.36 mmHg for the OJ and 
EOJ interventions, respectively. Our data are in agreement 
with those obtained after 8–12 weeks of a treadmill exercise 
program in hypertensive individuals (6.2 mmHg) [33] and 
after consumption of the Dietary Approaches to Stop Hyper-
tension (DASH) diet (6.74 mmHg) [34] as well as with the 
results of a meta-analysis reporting a mean reduction of 
8 mmHg SBP by regular endurance exercise in hyperten-
sive patients [35]. PP, a surrogate marker of aortic stiffness, 
is recognized as a powerful and independent risk factor for 
CVD with prognostic utility beyond BP measurements [36, 
37]. Throughout our study, the average PP reductions was 
−2.41 mmHg after EOJ. A 10-mmHg increase in PP is asso-
ciated with a 13% increase in all-cause mortality and >20% 
increase in recurrent myocardial infarction [36].
Throughout the 12 weeks of sustained intervention with 
345 mg/day of hesperidin in OJ and 600 mg/day of hesperi-
din EOJ, we observed decreases in SBP and PP, but not in 
DBP. Our results are opposite of those reported in over-
weight men, with a DBP-lowering effect but not an SBP 
one, after 4 weeks of OJ or a hesperidin-rich capsule pro-
viding 292 mg and 146 mg of hesperidin/day, respectively 
[23]. No benefits on BP were reported after sustained high 
hesperidin consumption of 549 mg/L/day over 8 weeks in 
healthy elderly individuals [17]; 6 weeks at 420 mg/day in 
healthy volunteers [18]; or 3 weeks at 500 mg/day in indi-
viduals with metabolic syndrome [38]. In type 2 diabetes 
patients, however, consumption (500 mg/day) of hesperi-
din over 6 weeks led to decreases in SBP and DBP [16]. 
Differences in populations and lengths of treatment could 
account for discrepancies among studies. If the objective of 
a study is to improve a specific cardiovascular risk factor, 
subjects that present symptoms associated with the specific 
cardiovascular risk factor should be included in the study 
[39]. Thus, the present study constitutes the first RCT that 
assesses the effects of hesperidin on BP and PP in pre- and 
Fig. 4  Changes in pulse pressure (PP) at 2 (a), 6 (b), 10 (c), and 12 
(d) weeks after sustained consumption of control drink (CD), orange 
juice (OJ), and hesperidin-enriched OJ (EOJ). *P < 0.05 versus base-
line; †P < 0.05 versus CD; ‡P < 0.05 versus OJ
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stage-1 hypertensive subjects; whereas, the populations stud-
ied in other RCTs were overweight, obese or diabetic with 
no hypertension or elevated BP levels [40]. At present, few 
reports exist concerning the effect of hesperidin on PP. Hes-
peridin reversed aortic stiffness in mice [41]. Although the 
beneficial effect of flavonoids on arterial stiffness is emerg-
ing [42], our data are the first available to supporting the 
effect of dietary flavanones on human arterial stiffness.
Mechanisms by which hesperidin could contribute to 
the control of BP and PP are associated with improvements 
on endothelial function, oxidative stress, and inflammation 
[8]. Homocysteine is associated with these risk factors and 
with a renin–angiotensin system activation to induce a BP 
increase [43]. In agreement with this, we observe a decrease 
in homocysteine concomitant with decreases in BP and PP 
after hesperidin treatments. After 12-week EOJ consump-
tion, ICAM-1 values decreased, and this decrease and those 
of other inflammatory and oxidative markers were directly 
related to the SBP decrease. In our work, plasma uric acid 
decreased after 12-week EOJ consumption. Hyperuricemia 
is strongly associated with hypertension and arterial stiff-
ness through activation of the NLPR3 inflammasome [44]. 
Accordingly, in our study changes in NLPR3 gene expres-
sion after 12 weeks were inversely associated with those 
of PP. After 12 weeks of EOJ consumption, we observed 
a decrease in PBMC expression of two key hypertension-
related genes: PTX3 and NAMPT. Serum levels of PTX3, a 
marker of inflammation activation, are elevated in hyperten-
sive patients [45], and experimental studies reported a direct 
role of PTX3 in vascular function and BP homeostasis [46]. 
NAMPT, also called visfatin, is secreted by visceral fat and 
is a stimulator of proinflammatory cytokines [47]. NAMPT 
is elevated not only in hypertensive patients but also in pre-
hypertensive patients [48, 49], leading to the proposal that 
NAMPT is a marker for damage in the pre-hypertensive state 
[48]. Thus, in our study, the decrease in biochemical and 
transcriptomic markers could account for the decreases in 
BP and PP after intake of hesperidin-rich beverages.
One factor that could minimize differences among sus-
tained hesperidin interventions could be the similar contri-
bution of the narirutin present in these treatments. In experi-
mental and human studies, naringin and narirutin showed 
a hypotensive effect [12, 50, 51]. When comparing the 
dose–response results on the main outcomes, however, only 
Fig. 5  Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) after a single dose of 500 mL of con-
trol drink, orange juice (OJ), and enriched OJ at the beginning (a) and at the end of the study (b)a
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the EOJ single-dose intervention was capable of decreasing 
SBP, DBP, and PP at the postprandial level. At present, few 
reports exist concerning the dose–response effect of hes-
peridin consumption in humans. No changes in SBP or DBP 
have been reported at 5 h after OJ or hesperidin supplemen-
tation (containing 320 mg of hesperidin) in healthy elderly 
individuals, despite an increase in hesperidin at this time 
point [19]. The fact that a unique measurement was obtained 
after a single dose could explain differences between studies. 
To the best of our knowledge, our data are the first to report 
the postprandial benefits of a hesperidin-enriched beverage 
to BP and PP, as well as the fact that its sustained consump-
tion enhances these benefits.
The study has strengths and limitations. As a strength, 
the participants’ diets were monitored throughout the entire 
study, and avoiding hesperidin intake and limiting the con-
sumption of flavonoid-rich foods were given as dietary 
recommendations to all the participants, which is of spe-
cial interest in nutritional RCTs because these guidelines 
would limit confounding between other dietary compounds 
and the dietary intervention [40]. The dietary recommen-
dations were established equally for all the intervention 
groups (CD, OJ and EOJ), and thus, the possible changes in 
the metabolome profile and consequently the downstream 
effects on BP due to these dietary modifications would be 
equally observed in all the groups, which would result in the 
control of these changes. Another important strength is that 
this study constitutes the first human RCT that assessed a 
compliance marker, hesperitin-7-β-d-glucuronide metabo-
lite, which is associated with PP and SBP values, and thus, 
these results add robustness to our study.
Multiple measurements throughout the study permitted 
the assessment of the homogeneity of the results. One limita-
tion is the inability to assess potential interactions between 
the interventions and other dietary components. Addition-
ally, a larger sample size could have permitted detection of 
significant differences between both hesperidin treatments. 
Although BP measurements were performed with maximal 
care, a 24-h ambulatory BP monitoring could have been 
more accurate. The fact that participants were pre- and 
stage-1 hypertensive individuals limits the extrapolation of 
the results to the general population. Whether additional or 
different effects would have been observed over longer time 
periods is unknown, but longer intervention periods could 
have affected the compliance of the individuals.
In summary, our results show that the intake of hesperidin 
in OJ decreases SBP and PP after sustained consumption in 
a dose-dependent manner with the hesperidin content of the 
beverage administered. Chronic consumption of hesperidin-
rich OJ enhances the postprandial response of decreasing 
SBP, DBP and PP. Decreases in homocysteine, uric acid 
and inflammatory markers at the systemic level and in PTX3 
and NAMPT at the transcriptomic level could account for the 
observed changes in BP and PP.
Perspectives
In a randomized, controlled clinical trial with pre- and 
stage-1 hypertensive individuals, we showed that sustained 
consumption of hesperidin promoted a dose-dependent 
decrease in SBP and PP with the hesperidin content of the 
beverage administered. Our data are the first to support an 
effect of dietary flavanones on human arterial stiffness. 
Additionally, we report for the first time the postprandial 
benefits of a hesperidin-enriched beverage to BP and PP, 
as well as the fact that its sustained consumption enhances 
these benefits. Regular consumption of OJ, particularly 
hesperidin-rich OJ, could be a useful co-adjuvant tool for 
BP management in pre- and stage-1 hypertensive individu-
als. This fact has public health implications in preventive 
medicine for reducing the secondary effects of long-term 
medical treatment of mild hypertension.
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Table S1. Composition of the intervention products calculated by 
500 mL/day* 
 Intervention 
 CD OJ EOJ 
Acidity, % 2.49 2.49 2.49 
Sugar, g 43.1 37.7 37.7 
Vitamin C, mg 235.3 235.3 235.3 
Citric acid, g 3.40 3.40 3.40 
Narirutin, mg ND 64 77 
Hesperidin, mg ND 392 670 
*In frozen concentrated canned drink, once diluted 3.4:1 (water to 
syrup). Abbreviations: CD, control drink; OJ, orange juice; EOJ, 










Table S2. Baseline characteristics of participants by intervention group 
Variable CD 






Age, y 45.4 ±13.0 43.3 ± 
12.0 
   43.6 ± 
11.8 
0.629 
Females, % 34.0 32.1 34.0 0.981 
SBP, mm Hg 132 ± 9.94 132 ± 
9.11 
134 ± 9.82 0.687 
DPB, mm Hg 79 ± 8.14 80 ± 8.42 79 ± 10.2 0.868 
Pulse pressure, mm 
Hg 
53 ± 9.09 52 ± 8.05 54 ± 6.74  0.261 




75.9 ± 11.6 0.523 







91.4 ± 10.7 0.766 




0.54 ± 0.07 0.790 




1.39 ± 0.62 0.269 
Glucose, mg/dL 91.6 ± 9.2 93.6 ± 
11.6 
93.6 ± 9.6 0.517 
Cholesterol, mg/dL     
  Total 196 ± 30.1 198 ± 
32.7 
196 ± 31.6 0.937 
   LDL 124 ± 26.4 125 ± 
31.5 
127 ± 25.1 0.900 
   HDL 50.9 ±13.4 51.0 ± 
14.7 
49.8 ± 13.0 0.889 











3.12 ± 1.26 0.986 
 Data are expressed as the mean ± standard deviation, or percentages. CD, control drink; 
 OJ, orange juice; EOJ, enriched orange juice; SBP, systolic blood pressure; DBP, 
 diastolic blood pressure; Pulse pressure = SBP-DBP; BMI, body mass index; LDL, low-
 density lipoproteins; HDL, high-density lipoproteins * median (25th -75th percentiles). 
 AU, arbitrary units: 0, inactive; 1, very low activity; 2, low activity; 3, moderately 
 active; 4, very active. P for ANOVA with logarithmic transformation for triglycerides. 
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Table S3. Energy, nutrients, fibre and alcohol after 12 weeks of intervention. 
Variable Treatment P* 
 Control                  P      OJ                    P            Enriched OJ        P  
Energy, 
kcal/day 





2443 ± 638       




2422 ± 618 




2488 ± 627 








  Baseline 




37.5 ± 6.3 




37.9 ± 5.8 




37.5 ± 6.1 







  Baseline 
  12-week 
 
 
224 ± 55 




190 ± 62             <0.001 
 
 
227 ± 66 











17.6 ± 2.9 
17.9 ± 3.6          0.578 
 
 
16.6 ± 2.4 
17.7 ± 3.5          0.028 
 
 
17.6 ± 3.8 













104 ± 29.5 
100 ± 32.6          0.287 
 
 
99.0 ± 26.0 
93.8 ± 28.6         0.204 
 
 
106 ± 28.9 









  Baseline 
  12-week 
 
 
43.0 ± 5.2 
45.5 ± 7.7          0.036 
 
 
43.1 ± 5.7 
43.8 ± 6.1           0.496 
 
 
41.9 ± 4.8 









  Baseline 




120 ± 42.4 
118 ± 44.8         0.759 
 
 
118 ± 33.8 
107 ± 36.7          0.032 
 
 
118 ± 34.7 









 SFA, % 
energy 
  Baseline 




12.6 ± 3.1          0.233 
 
 
12.4 ± 2.8 
13.3 ± 3.3           0.092 
 
 
12.0 ± 2.7 









  Baseline 




33.8 ± 15.4        0.662 
 
 
34.2 ± 130 
33.1 ± 14.2         0.572 
 
 
34.2 ± 12.0 
30.8 ± 9.2           0.111 
 
 
       
     
 
      NS 
 
 
Table S3 (cont.) 
MUFA ,% 
energy 
  Baseline 
  12-week 
 
 
19.1 ± 4.1 
20.1 ± 4.2            0.217  
 
 
19.9 ± 2.9 
19.6 ± 3,8            0.566 
 
 
19.4 ± 4.3 









  Baseline 
  12-week 
 
 
53.3 ± 21.0 
51.9 ± 21.2          0.641  
 
 
53.8 ± 15.5 
46.5 ± 13.3          0.003 
 
 
53.0 ± 16.6 









   Baseline 
   12-week 
 
 
8.3 ± 3.6 
8.9 ± 2.8              0.140 
 
 
7.4 ± 2.5 
7.6 ± 2.6             0.549 
 
 
7.6 ± 2.3 









  Baseline 
  12-week 
 
 
22.8 ± 9.9 
22.1 ± 9.2              0.612 
 
 
19.8 ± 7.6 
18.9 ± 10.4          0.431 
 
 
21.4 ± 9.4 













  Baseline 




18.5 (13.3-23-.7)   

















  Baseline 



















Data are expressed as the mean ± standard deviation: a median (25-75th percentile). 
H C, carbohydrates; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids. 
Intra-treatment comparisons by Student’s t test and Wilcoxon test for related samples.  
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CD:  control drink 
CVD:  cardiovascular diseases 
CVDR:  cardiovascular diseases risk 
CVDRFs: cardiovascular diseases risk factors  
DBP:   diastolic blood pressure 
EOJ:   hesperidin-enriched orange juice 
IPA:  ingenuity pathway analysis 
LncRNA: long non-coding RNA 
OJ:  orange juice 
PBMCs: peripheral blood mononuclear cells 
SBP:  systolic blood pressure 
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Hesperidin exerts cardiovascular beneficial effects, but its mechanisms 
of action remain undefined. The aim of this work was to determine 
whether the sustained and single dose consumption of hesperidin in 
orange juice (OJ) and hesperidin-enriched orange juice (EOJ) can 
change the transcriptomic profile of subjects with pre- and stage 1 
hypertension to elucidate possible mechanisms of action of the 
hesperidin. 
Methods and results 
For transcriptomic analysis, peripheral blood mononuclear cells were 
obtained from 37 subjects with pre- and stage 1 hypertension from 
CITRUS study who were randomized to receive for 12 weeks: control 
drink (CD; n=11), OJ (containing 392 mg of hesperidin; n=15) or EOJ 
(containing 670 mg of hesperidin; n=11). At baseline, a single dose 6-
hour study in each group was also performed. After the single dose 
consumption, EOJ versus OJ, downregulated DHRS9 gene which is 
related with insulin resistance. Compared to CD, sustained 
consumption of EOJ downregulated 6 proinflammatory while after OJ 
consumption only 1 proinflammatory gene was downregulated. 
Moreover, sustained consumption of EOJ versus OJ, downregulated 
acute coronary syndrome gene related (SELENBP1).  
Conclusion 
A single dose consumption of EOJ could protect from insulin 
resistance. Moreover, EOJ decrease the expression of proinflammatory 
genes after sustained consumption providing a possible mechanism of 





Hesperidin is a naturally occurring flavonoid present in citrus fruits and 
is found at particularly high concentrations in orange fruits and orange 
juice (OJ).(9) The beneficial effects of hesperidin on cardiovascular risk 
factors have been elucidated and integrated in a recently published 
systematic review of animal studies and randomized human clinical 
trials.(130)  The beneficial effects of hesperidin consumption on the 
lipid profile and glucose levels have been observed in rats, but the 
results from human studies remain unclear.(130) Some studies have 
related hesperidin to hypotensive,(98,131) hypolipemiant,(132) anti-
inflammatory(131) and antioxidant(99) effects. Consistently, we 
recently reported that the sustained and acute consumption of 
hesperidin in OJ decreases the systolic blood pressure (SBP) and pulse 
pressures in subjects with pre- and stage 1 hypertension, and the 
sustained consumption of hesperidin-enriched OJ (EOJ) enhances the 
postprandial effect of hesperidin compared with that obtained with a 
single dose.(133) Thus, the consumption of hesperidin via OJ could be 
an interesting strategy for the SBP levels and treatment of 
cardiovascular disease risk factors (CVDRFs).(134) 
 
In contrast, the impacts of different bioactive compounds on gene 
expression have been clearly established and have gained much interest 
in research because better comprehension of these effects can be used 
to prevent, detect and treat chronic diseases.(135) Therefore, 
knowledge about nutrient-gene interactions is key for obtaining more 
information about new mechanisms of action, and transcriptomics can 
provide such knowledge because compares the transcriptomes, which 
are sets of RNA transcripts of cells, tissues or organisms under specific 
conditions. For complex diseases, such as cardiovascular disease 
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(CVD) and cancer, a transcriptomic approach offers the possibility to 
identify novel mechanisms and thus further characterize disease 
pathophysiology.  
 
Different families of phenolic compounds have the ability to modify 
gene expression profiles.(53) Specifically, phenolic compounds from 
virgin olive oil improved cholesterol efflux gene expression in 
humans(12) and can modify the whole transcriptome to exert beneficial 
effects on CVD and cancer.(136) Similarly, other phenolic compounds 
such as flavonoids, such as resveratrol and hesperidin, have been linked 
to effects on the transcriptome. Thus, previous studies have shown that 
resveratrol consumption improves vascular function in older 
adults.(137) Moreover, the chronic consumption of hesperidin can 
change the expression of leucocyte genes to exert an anti-atherogenic 
and anti-inflammatory effects in overweight subjects.(138) However, 
the molecular mechanism through which hesperidin influences 
metabolic pathways via transcriptome changes remains unclear. To the 
best of our knowledge, a transcriptomic analysis that simultaneously 
assesses the impacts of sustained and acute hesperidin consumption in 
human peripheral blood mononuclear cells (PBMCs) of subjects with 
hypertension has not been performed. PBMCs are highly useful for 
demonstrating the capacity of cell systems to interact with nutrients and 
bioactive food compounds.(139,140)  
 
The aim of this work was to determine whether the sustained and single 
dose consumption of hesperidin in OJ and EOJ can change the 
transcriptomic profile of PBMCs of subjects with pre- and stage 1 
hypertension to elucidate possible mechanisms of action of the 




2. EXPERIMENTAL SECTION 
2.1 Subjects 
The study population was included in our previous randomized clinical 
trial.(133) The subjects were 159 men and women with pre and stage 1 
hypertension who did not smoke, had no family history of CVD, SBP 
≥ 120 mm Hg and < 159 mm Hg, diastolic blood pressure (DBP) < 100 
mm Hg,(34) and were not taking any anti-hypertensive medications. 
 
2.2 Test drinks 
The three interventional drinks were provided by the Florida 
Department of Citrus from the USA: a control drink (CD), OJ with the 
natural content of hesperidin, and EOJ, which contains the 2S form of 
hesperidin, the naturally form in OJ and a bioavailable form 
(micronized 2S hesperidin; Ferrer Health Tech, Murcia, Spain).(103) 
The composition of the three test drinks is detailed in Supporting 
Information Table S1. 
 
2.3 Dosage information 
The subjects orally consumed 500 mL/day of the corresponding test 
drink: CD (0 mg/day of hesperidin), OJ (345 mg/day of hesperidin) and 
EOJ (600 mg/day of hesperidin). 
 
2.4 Study design 
A randomized, parallel, double-blind, placebo-controlled clinical trial 
was performed and registered at Clinical-Trials.gov under 
NCT02479568. All volunteers were randomly assigned to one of the 
three intervention groups: CD, OJ and EOJ groups. The sustained 
intervention was conducted for 12 weeks and nested, two 6-hour single 
dose studies, one at baseline and the other after 12 weeks, were 
performed.(133) For the transcriptomic analysis in the sustained study, 
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PBMCs were obtained from blood samples collected under fasting 
conditions at baseline and after 12 weeks. For the transcriptomic 
analysis in the single dose study, PBMCs were obtained at baseline and 
after 6 hours only in the single dose study conducted at the beginning 
of the study. 
 
2.5 Transcriptomic analysis 
Whole gene expression in PBMCs from whole blood samples collected 
under fasting conditions in both the dose-response and sustained studies 
was assessed using the Agilent Microarray Platform (Agilent 
Technologies, Santa Clara, California, USA). Total PBMC RNA was 
isolated by Ficoll gradient separation (GE Healthcare Bio Sciences, 
Barcelona, Spain). The RNA yield was quantified with a Nanodrop UV-
VIS spectrophotometer, and the RNA integrity was measured with an 
Agilent 2100 Bioanalyzer using the Total RNA Nano kit and the 
protocol Eukaryote Total RNA Nano (Agilent Technologies, Santa 
Clara, California, USA). Total RNA (100 ng) from the PBMCs was 
labelled with Cy3 (ref: 5190-2305, Agilent Technologies, Santa Clara, 
California, USA) and hybridized using a Gene Expression 
Hybridization Kit (ref: 5188-5242, Agilent Technologies, Santa Clara, 
California, USA), on an Agilent SurePrint G3 Human Gene Expression 
8x60K v3 Microarray (Design ID 072363) with SurePrint Technology 
(Agilent Technologies, Ref. G4851C). Image scanning was performed 
with a 3 μm resolution using an Agilent Microarray Scanner System 
with SureScan High-Resolution Technology (ref: G2565CA, Agilent 
Technologies, Santa Clara, California, USA). The Feature Extraction 





Gene expression and real-time PCR analysis 
To analyse the gene expression in the samples and validate the DNA 
array results, cDNA was synthesized using the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, 4 Barcelona, Spain). A 
MyGene Series Peltier Thermal Cycler (LongGene Scientific, 
Zhejiang, China) was used for reverse transcription. The reaction was 
performed according to the manufacturer’s instructions. The cDNA was 
amplified by quantitative reverse transcriptase polymerase chain 
reaction using LightCycler 480 SYBR Green I Master (Roche 
Diagnostic, Sant Cugat del Vallès, Barcelona, Spain) and a LightCycler 
480 II system (Roche Diagnostic, Sant Cugat del Vallès, Barcelona, 
Spain). The primers used for the different genes are described in 
Supporting Information Table S2 and were obtained from Biomers.net 
(Ulm, Germany). The fold changes in the mRNA levels were calculated 
as percentages compared with the control group  (CD) using the -2∆∆Ct 
method (141) and the RPLP0 gene was used as an endogenous control. 
Real-time PCR analysis was performed in a subset of six genes: 
DHRS9, DSP, TNF, NAMPT, PTX3 and IER3; and in a subsample of 
the samples collected: 22 samples for DHRS9, 18 for DSP, 24 for TNF, 
19 for NAMPT, 17 for PTX3 and 20 for IER3.  
 
2.7 Data analysis 
Quality control was performed through principal component analyses. 
Statistical comparisons were performed by Student’s t-test or Welch’s 
t-test. Differentially expressed genes were genes with that met the 
following criteria: P-value < 0.05 and fold change <= -0.58 or >= 0.58 
in the log2 scale (corresponding to a 1.5-fold difference in natural 
scale). Treatment comparisons were performed with an ANCOVA 
model adjusted for age, sex and baseline values. Statistical significance 
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was defined by a P value ≤ 0.05 from a two-sided test. SPSS for 
Windows (version 21; IBM Corp., Armonk, New York, USA) was used 
for the analyses. Differentially expressed genes were subjected to 
functional and biochemical pathway analyses using Gene Ontology and 
the KEGG (Kyoto Encyclopedia of Genes and Genomes 
(www.genome.jp/kegg) and PANTHER (protein annotation through 
evolutionary relationship classification system 
(http://www.pantherdb.org/) biochemical pathway databases, 
respectively. The analysis was performed using GeneCodis 
(http://genecodis.dacya.ucm.es) software. For biological interpretation, 
the functions, pathways and networks of the results that showed 
significant differences between the groups were analysed by Ingenuity 
pathway analysis (IPA; www.ingenuity.com), which explores the 
possible metabolic cell signalling pathways that were up- and 
downregulated after the intervention. 
 
3. RESULTS 
3.1 Baseline characteristics of the participants 
PBMC samples were collected from 37 of the 159 subjects included in 
the original randomized clinical trial after both the single dose and 
sustained interventions, and these subjects were thus candidates for 
transcriptomic profile evaluation.(133) These 37 participants were 
assigned to the three groups: CD, N = 11; OJ, N = 15; and EOJ, N = 11. 
The baseline characteristics of the participants of each group are 
detailed in Table 1. The volunteers ranged in age from 41 to 65 years, 
had a normal weight or were overweight, and had pre- and stage 1 
hypertension. No differences in the baseline characteristics were found 




3.2 Clinical results 
In accordance with our previously published results,(133) the 
consumption of hesperidin in OJ and EOJ for 12 weeks decreased the 
SBP of subjects with pre- and stage 1 hypertension by an average of -
6.35 mm Hg and -7.36 mm Hg, respectively. Additionally, the pulse 
pressure, which is a recognized independent risk factor for CVD, 
decreased by -2.41 mm Hg after the consumption of EOJ. No significant 
changes in the DBP were observed. Additionally, the homocysteine and 
uric acid levels decreased after the consumption of OJ and EOJ. In 
contrast, the acute consumption at baseline of a single dose of 
hesperidin in EOJ reduced the SBP, pulse pressure and homocysteine 
levels, and after 12 weeks of treatment resulted in greater changes in 
these variables as well as a decrease in the DBP. 
Moreover, as a new result, the plasminogen activator inhibitor type 1 
(PAI-1) levels decreased after EOJ consumption versus CD (Mean 
change: -0.191; 95% CI: -0.32; -0.06; P=0.004) and also versus 
OJ (Mean change: -0.199; 95% CI: -0.33; -0.07; P=0.002). 
 
3.3 Gene expression profile 
After sustained and acute consumption, the number of statistically or 
borderline differentially expressed genes (P < 0.05 or P < 0.10, 
respectively) after OJ and EOJ compared with the levels obtained with 
the CD are represented in Figure 1. Compared with their expression in 
the CD group, 3 genes were commonly differentially or potentially 
differentially expressed after consumption of a single dose of hesperidin 
in OJ and EOJ. In addition, compared with their expression in the CD 
group, after the consumption of hesperidin in OJ and EOJ for 12 weeks, 
16 genes were commonly differentially or potentially differentially 
expressed compared with their levels in the CD group. 
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Gene expression after dose-response intervention 
Comparisons of the single dose gene expression changes in PBMCs of 
individuals with pre-a and stage 1 hypertension among the three 
treatment groups are shown in Table 2. Three differentially expressed 
genes (P < 0.05) were observed after the single dose consumption of OJ 
compared with the CD. Two of these three genes, DHRS9 and PKDL1, 
were significantly upregulated, while the other gene, TNFAIP3, was 
downregulated. Moreover, 5 genes were borderline differentially 
expressed (P < 0.10) after OJ consumption. The comparison of the EOJ 
and CD groups revealed no differentially expressed genes, but 6 genes 
were borderline differentially expressed (P < 0.10). Finally, the 
comparison of the EOJ with OJ group revealed that DHRS9 gene was 
significantly downregulated (P < 0.05). All these genes are mainly 
related to the inflammation pathways and insulin resistance. 
 
Gene expression after sustained intervention 
Comparisons of the gene expression changes in PBMCs from 
individuals with pre- and stage 1 hypertension among the three 
treatment groups after 12 weeks of sustained consumption of hesperidin 
are shown in Table 3. After 12 weeks, we identified 12 genes that were 
differentially expressed in the OJ group compared with the CD group, 
and these included seven upregulated genes (CCL20, FAM53B, LINC 
01220, lncRNA SNRPD3-2, lncRNA NFKBID-1, lncRNA PDE3B-1, 
and LOC101929524) and five downregulated genes (TNF, TMPO-
AS1, BPIFB3, lncRNA ACOT-13 and CCT8-1). Moreover, 13 genes 
were borderline differentially expressed (P < 0.10) after OJ 
consumption. After 12 weeks, 18 genes showed differential expression 
in the EOJ group compared with the CD group, and these included four 
upregulated genes (DSP, FAM53B, lncRNA SNRPD3-2 and lncRNA 
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SLC39A8-1) and 14 downregulated genes (TNF, IL1B, CCL3L3, 
CXCL2, CXCL8, PTGS2, IER3, PTX3, KMT22-AS1, ATP2B1-AS1, 
lncRNA CCT8-1, lncRNA GRK3-1, lncRNA CCDC117-1 and 
LOC644090). Moreover, 17 genes were borderline differentially 
expressed (P < 0.10) after EOJ consumption. Finally, after 12 weeks, 4 
genes showed differential expression between the EOJ and OJ groups: 
one gene (lncRNA IYD) was upregulated, and 3 genes (SELENBP1, 
ALAS2 and BTBD19) were downregulated. 
The 12 differentially expressed genes after OJ were related to 
inflammation (2 genes), cancer (1 gene) and unknown functions (9 
genes). After EOJ, the 18 differentially expressed genes were related to 
inflammation (6 genes), endothelial function (2 genes), hypertension (1 
gene), and unknown functions (9 genes).  
A summarized table of results are detailed in Supporting Information 
Table S4. 
 
Pathway analysis  
IPAs were performed only with the genes that showed significantly and 
borderline significantly differential expression after sustained 
consumption of hesperidin because the number of differentially 
expressed genes after acute consumption was insufficient for the 
pathway analysis. None of the long noncoding RNAs (lncRNAs) that 
were showed significantly or borderline significantly differential 
expression after 12 weeks of hesperidin consumption could be used for 
the pathway-based IPA due to the scarcity of the related literature. The 
biological networks based on the differentially expressed genes after 
sustained consumption of OJ and EOJ are represented in Figure 2. The 
overlapping graphical representation of the two most important 
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networks identified by the IPAs of the differentially expressed genes 
after OJ and EOJ consumption compared to CD consumption, are 
shown in panels A and B, respectively, and the up- and downregulated 
genes are shown in red and green colours, respectively. The top 
canonical pathways, diseases and functions regulated by sustained 
consumption of OJ and EOJ and the implicated genes are shown in 
Table S3 in the Supplementary Information. The top diseases and 
functions related to the differentially expressed genes identified after 
the consumption of hesperidin in OJ for 12 weeks were the 
inflammatory response, cell-to-cell signalling and interaction, 
organismal injury and abnormalities, and the haematological and 
cardiovascular systems. After the consumption of hesperidin in EOJ for 
12 weeks, the top diseases and functions were the inflammatory 
response, organismal injury and abnormalities, cellular growth and 
proliferation, lipid metabolism and the haematological system. 
 
3.4 Results of the real-time PCR analysis 
Figure 3 shows the real-time PCR validation of the arrays results for a 
subset of 6 genes, which demonstrated that the directions of the 




In the present work, we demonstrated that the consumption of 500 
mL/day for 12 weeks of OJ and EOJ can change the transcriptomic 
profile of PBMCs of subjects with pre- and stage 1 hypertension. Our 
results showed the single dose consumption of EOJ compared to OJ, 
downregulated the gene DHRS9 reducing the insulin resistance. 
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Moreover, the sustained consumption of EOJ, which provides a higher 
dose of hesperidin, can induce greater changes in the expression profile 
of PBMCs, compared with those obtained with the lower dose of 
hesperidin in OJ, since EOJ downregulated more pro-inflammatory 
genes.  
 
Interestingly, the differential expression of a gene related to insulin 
resistance was only observed after the single dose consumption of 
hesperidin in OJ and EOJ but not after sustained consumption for 12 
weeks. The consumption of a single dose of hesperidin in OJ 
significantly upregulated the expression of DHRS9, whereas the 
consumption of a single dose of hesperidin in EOJ downregulated 
DHRS9 gene expression compared to CD. DHRS9, an 
oxidoreductase/decarboxylase, promotes insulin resistance by 
activating lipid metabolism.(142) Accordingly, we hypothesized that 
the presence of fructose in OJ could increase DHRS9 expression and 
thereby increases fructose metabolism, the plasma triglyceride levels 
and insulin resistance;(142) whereas the higher doses of hesperidin in 
EOJ could counteract the effects of the fructose content to induce 
downregulation of the DHRS9 gene. The evidence suggests that the 
consumption of 50-100 mg/kg body weight/day hesperidin improves 
insulin resistance and decreases the glucose plasma levels in 
rats.(143,144) Because this dose range of hesperidin for animals is 
equivalent to the hesperidin dose present in EOJ (670 mg/day), the 
results might explain the different gene expression profiles detected 
after a single dose between the two test drinks, whereas positive results 




Moreover, the consumption of a single dose of hesperidin in EOJ 
induced the borderline significant upregulation of different pro-
inflammatory genes, including the gene encoding the chemokine 
CXCL2. CXCL2, which is also called macrophage inflammatory 
protein 2-alpha, produces endogenous signals during the first steps of 
inflammasome activation to generate pro-inflammatory cytokines(145) 
A recently published review reported that CXCL2 overexpression 
contributes to atherosclerotic plaque formation, inflammation in obesity 
and the induction of diabetes, which demonstrates that CXCL2 might 
be a therapeutic target in CVD.(146) Additionally, the consumption of 
a single dose of EOJ borderline significantly downregulated the 
expression of the CCL3-encoding gene. CCL3 is a chemokine with pro-
inflammatory activity and serves as an independent risk factor in 
subjects with acute coronary syndromes because high levels of CCL3 
are associated with short-term mortality.(147) Additionally, high levels 
of this chemokine are associated with future ischaemia events in 
subjects with acute myocardial infarction (148) Thus, downregulated 
CCL3 gene expression can suggest a role for this chemokine in the 
prevention of inflammation related to cardiovascular disease risk 
(CVDR). 
 
The sustained consumption of hesperidin in OJ and EOJ induces 
significantly differential expression of different pro-inflammatory 
genes. In this sense, the consumption of OJ and EOJ for 12 weeks 
significantly downregulated TNF gene expression. Experimental 
studies have shown that the cytokine TNF is associated with 
hypertension and renal injuries in hypertensive rats and mice.(149) In 
addition, the intracerebroventricular administration of TNF to 
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normotensive and hypertensive rats increases their blood pressure and 
thereby influences angiotensin type 1 receptors.(149) Therefore, the 
downregulation of TNF might be beneficial for the improvement of 
high blood pressure levels and thereby influences the angiotensin II 
levels and oxidative stress in hypertension.(150) If these effects can be 
translated to humans, they can at least partly explain the decrease in 
SBP observed in subjects with pre- and stage 1 hypertension.(133) IL1B 
was also significantly downregulated after 12 weeks of EOJ compared 
with CD consumption. IL1B is a cytokine with cogent links to 
atherosclerosis and other inflammatory diseases.(151) Previous studies 
have shown that high levels of ILB1 promote atherothrombosis and 
thereby increase CVDR.(151) Additionally, increased levels of ILB1 
suggest an important role of this cytokine in hypertension 
pathogenesis.(152) In addition, PTGS2 was borderline significantly 
downregulated after 12 weeks of EOJ consumption. PTGS2 (also 
named COX-2) induces pro-inflammatory cytokines and thereby 
stimulates cell proliferation and increases metastatic potential through 
inflammatory pathways.(153) PTGS2 is also an important enzyme in 
prostaglandin synthesis, and its overexpression increases the risk of 
ischaemic stroke.(154) In this sense, CITRUS study showed decreased 
levels of PAI-1 after EOJ consumption and reduced homocysteine 
levels after OJ and EOJ consumption for 12 weeks(133), and both 
results are related with an improvement of inflammation, that which 
observed also at transcriptome level in the present analysis.  
 
In contrast, unlike our previously positive results regarding decreases 
in the expression of pro-inflammatory genes, some anti-inflammatory-
related genes were significantly, or borderline significantly 
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downregulated after the single dose and sustained consumption of 
hesperidin in OJ and EOJ. Specifically, TNFAIP3, which is related to 
vascular disease, was significantly downregulated after a single dose of 
OJ compared with CD. The overexpression of the TNFAIP3 gene is 
related to suppression of adhesion protein expression at sites of 
atherosclerotic plaque formation; therefore, lower levels of TNFAIP3 
are associated with an increased risk of atherosclerosis in subjects with 
type 2 diabetes.(155) An aspect that should be considered is that the 
decrease in the expression of anti-inflammatory genes could be 
explained by the fructose content of fruit juices, although natural and 
enriched juices were used in the present study. A high consumption of 
fructose can increase CVDR due to increases in inflammation 
pathways,(142) but some controversial studies have only showed an 
association between cardiometabolic risk factors and fructose content 
though the consumption of artificially sweetened beverages rather than 
fruit juices.(156) The unclear conclusions might be due to the presence 
of fibres and phenolic compounds, such as hesperidin, or other 
beneficial bioactive compounds, such as vitamins and minerals, in fruit 
juices, including OJ. Hence, more studies in this field are needed to 
obtain conclusive results regarding the effects of fruit juices and the 
fructose content on inflammation and CVD factors. 
 
Moreover, our results showed that the gene selenium binding protein 1 
(SELEBP1) was downregulated after EOJ consumption for 12 weeks. 
The elevated levels of SELENBP1 was related with a high risk of 
adverse cardiac events and death(157). Thus, the downregulation of 
these gene could be beneficial since it is considered a biomarker for 
cardiac events. Additionally, the genes PTX3 and NAMPT previously 
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published in CITRUS study(133), were changed after 12 weeks of OJ 
and EOJ consumption, related with the improvement of blood pressure 
levels. Also, the genes DSP and IER3, which are related with an 
improvement of endothelial function, were differentially expressed 
after EOJ sustained consumption. 
 
Moreover, our findings suggest that both the single dose and sustained 
consumption of hesperidin in OJ and EOJ for 12 weeks can change the 
expression of several lncRNAs. lncRNAs, which are RNA transcripts 
that do not encode proteins, have been implicated in numerous 
biological processes and diseases.(158) LNCipedia, a comprehensive 
compendium of human lncRNAs with an integrated database that offers 
the annotation of thousands of lncRNA transcript sequences, was 
searched for the differentially expressed lncRNAs, including both up- 
and downregulated lncRNAs, after the consumption of OJ and EOJ 
compared with the CD. However, although some of these lncRNAs 
were identified in previous studies, most of the identified lncRNAs are 
unknown, and their functions and involvement in diseases have not yet 
been assessed. Accordingly, further research is needed in this topic 
because some studies have shown that lncRNAs can act as key 
regulators of the inflammatory response(159) and can play an important 
role in the cardiovascular system.(160) 
 
One strength of the present work is that the study constitutes the first 
evaluation of the transcriptomic profile of human PBMCs after the 
consumption of hesperidin in OJ and EOJ. The assessment of gene 
expression in human PBMCs can demonstrate their capacity to reflect 
the distinct gene expression signatures of several diseases linked to 
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cardiovascular health(140,161) and the gene expression signatures after 
interaction with bioactive food compounds, such as flavonoids. In 
contrast, this work provides the first evaluation of the transcriptomic 
profile of human PBMCs after the acute consumption of hesperidin in 
OJ and EOJ. The evidence demonstrates the capacity of phenolic 
compounds to exert postprandial effects on several systems, and the 
accumulation of acute functional changes can induce chronic 
physiological alterations,(162) and thus has a positive impact on the 
target systems. The insights on postprandial actions can offer the 
possibility to study unknown mechanisms for the beneficial effects of 
hesperidin in human health. However, whether the changes in the 
transcriptomic profile of PBMCs are maintained over time and whether 
the observed changes might improve long-term CVDRFs remain 
unclear. Therefore, larger clinical trials and trials that include patients 
with hypertension and other CVDRFs are needed to better understand 
these clinical findings. Moreover, in the present work, the 
transcriptomic analysis of the single dose intervention was only 
performed at the beginning of the clinical trial. Thus, a second PBMC 
analysis in the second single dose study conducted at 12 weeks could 
provide evidence regarding the effects of chronic phenolic compounds 
intake on the possible optimization of the acute intake observed in 
previous studies.(133) 
 
In conclusion, the single dose and sustained consumption of hesperidin 
in OJ and EOJ changed the transcriptome of PBMCs of subjects with 
pre- and stage 1 hypertension. The single dose consumption of higher 
doses of hesperidin could induce a better response than the consumption 
of the naturally occurring doses of hesperidin in OJ because of their 
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improvement of insulin resistance. Moreover, the sustained 
consumption of hesperidin in EOJ decrease the expression of 
proinflammatory genes providing a possible mechanism of action on 
inflammation pathway and thereby could induces beneficial effects on 
the cardiovascular system. However, some results are unclear and 
controversial; therefore, more studies are needed to confirm and clarify 
the biological effects of hesperidin consumption on the transcriptomic 
profile. 
 
5. REFERENCES  
[1] D. Del Rio, A. Rodriguez-Mateos, J. P. E. Spencer, M. 
Tognolini, G. Borges, A. Crozier, Antioxid. Redox Signal. 2013, 
DOI 10.1089/ars.2012.4581. 
[2] L. Pla-Paga, J. Companys, L. Calderon-Perez, E. Llaurado, R. 
Sola, R. M. Valls, A. Pedret, Nutr. Rev. 2019, 77, 1–20. 
[3] F. Homayouni, F. Haidari, M. Hedayati, M. Zakerkish, K. 
Ahmadi, Phyther. Res. 2018, 32, 1073–1079. 
[4] C. Wunpathe, P. Potue, P. Maneesai, S. Bunbupha, P. 
Prachaney, U. Kukongviriyapan, V. Kukongviriyapan, P. 
Pakdeechote, Am. J. Chin. Med. 2018, 46, 1–17. 
[5] J. Shen, K. A. Wilmot, N. Ghasemzadeh, D. L. Molloy, G. 
Burkman, G. Mekonnen, M. C. Gongora, A. A. Quyyumi, L. S. 
Sperling, Annu. Rev. Nutr. 2015, DOI 10.1146/annurev-nutr-
011215-025104. 
[6] P. Maneesai, S. Bunbupha, P. Potue, T. Berkban, U. 
Kukongviriyapan, V. Kukongviriyapan, P. Prachaney, P. 
Pakdeechote, Nutrients 2018, 10, 1–15. 
[7] R. M. Valls, A. Pedret, L. Calderón-Pérez, E. Llauradó, L. Pla-
183 
 
Pagà, J. Companys, A. Moragas, F. Martín-Luján, Y. Ortega, M. 
Giralt, M. Romeu, L. Rubió, J. Mayneris-Perxachs, N. Canela, 
F. Puiggrós, A. Caimari, J. M. Del Bas, L. Arola, R. Solà, Eur. 
J. Nutr. 2020, DOI 10.1007/s00394-020-02279-0. 
[8] A. Ahmadi, A. Shadboorestan, Nutr. Cancer 2016, 68, 29–39. 
[9] L. Bordoni, R. Gabbianelli, Biochimie 2019, 160, 156–171. 
[10] V. Tufarelli, E. Casalino, A. G. D’Alessandro, V. Laudadio, 
Curr. Drug Metab. 2017, DOI 
10.2174/1389200218666170925124004. 
[11] M. Farràs, S. Arranz, S. Carrión, I. Subirana, D. Muñoz-
Aguayo, G. Blanchart, M. Kool, R. Solà, M. J. Motilva, J. C. 
Escolà-Gil, L. Rubió, S. Fernández-Castillejo, A. Pedret, R. 
Estruch, M. I. Covas, M. Fitó, Á. Hernáez, O. Castañer, 
Nutrients 2019, 11, 1–10. 
[12] S. D’Amore, M. Vacca, M. Cariello, G. Graziano, A. D’Orazio, 
R. Salvia, R. C. Sasso, C. Sabbà, G. Palasciano, A. Moschetta, 
Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 2016, 1861, 
1671–1680. 
[13] R. M. Pollack, N. Barzilai, V. Anghel, A. S. Kulkarni, A. 
Golden, P. O’Broin, D. A. Sinclair, M. S. Bonkowski, A. J. 
Coleville, D. Powell, S. Kim, R. Moaddel, D. Stein, K. Zhang, 
M. Hawkins, J. P. Crandall, Journals Gerontol. - Ser. A Biol. 
Sci. Med. Sci. 2017, 72, 1703–1709. 
[14] D. Milenkovic, C. Deval, C. Dubray, A. Mazur, C. Morand, 
PLoS One 2011, 6, 1–9. 
[15] C. Cappuzzello, M. Napolitano, D. Arcelli, G. Melillo, R. 
Melchionna, L. Di Vito, D. Carlini, L. Silvestri, S. Brugaletta, 




[16] S. D’Amore, M. Vacca, G. Graziano, A. D’Orazio, M. Cariello, 
N. Martelli, G. Di Tullio, R. Salvia, G. Grandaliano, A. Belfiore, 
F. Pellegrini, G. Palasciano, A. Moschetta, Biochim. Biophys. 
Acta - Mol. Basis Dis. 2013, 1832, 2289–2301. 
[17] M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons, A. 
L. Catapano, M. T. Cooney, U. Corrà, B. Cosyns, C. Deaton, I. 
Graham, M. S. Hall, F. D. R. Hobbs, M. L. Løchen, H. Löllgen, 
P. Marques-Vidal, J. Perk, E. Prescott, J. Redon, D. J. Richter, 
N. Sattar, Y. Smulders, M. Tiberi, H. B. Van Der Worp, I. Van 
Dis, W. M. M. Verschuren, S. Binno, G. De Backer, M. Roffi, 
V. Aboyans, N. Bachl, S. Carerj, L. Cho, J. Cox, J. De Sutter, 
G. Egidi, M. Fisher, D. Fitzsimons, O. H. Franco, M. Guenoun, 
C. Jennings, B. Jug, P. Kirchhof, K. Kotseva, G. Y. H. Lip, F. 
Mach, G. Mancia, F. M. Bermudo, A. Mezzani, A. Niessner, P. 
Ponikowski, B. Rauch, A. Stauder, G. Turc, O. Wiklund, S. 
Windecker, J. L. Zamorano, S. Achenbach, L. Badimon, G. 
Barón-Esquivias, H. Baumgartner, J. J. Bax, V. Dean, Ç. Erol, 
O. Gaemperli, P. Kolh, P. Lancellotti, P. Nihoyannopoulos, A. 
Torbicki, A. V. Carneiro, B. Metzler, R. Najafov, V. 
Stelmashok, C. De Maeyer, M. Dilić, I. Gruev, D. Miličić, H. 
Vaverkova, I. Gustafsson, I. Attia, D. Duishvili, J. Ferrières, N. 
Kostova, Z. Klimiashvili, R. Hambrecht, K. Tsioufis, E. 
Szabados, K. Andersen, C. Vaughan, B. Zafrir, S. Novo, K. 
Davletov, F. Jashari, A. Kerimkulova, I. Mintale, G. Saade, Z. 
Petrulioniene, C. Delagardelle, C. J. Magri, V. Rudi, L. 
Oukerraj, B. E. Çölkesen, H. Schirmer, R. P. Dos Reis, D. 
Gherasim, S. Nedogoda, M. Zavatta, V. Giga, S. Filipova, L. R. 
185 
 
Padial, A. Kiessling, A. Mahdhaoui, D. Ural, E. Nesukay, C. 
Gale, Eur. Heart J. 2016, 37, 2315–2381. 
[18] B. N. Salden, F. J. Troost, E. de Groot, Y. R. Stevens, M. 
Garcés-Rimón, S. Possemiers, B. Winkens, A. A. Masclee, Am. 
J. Clin. Nutr. 2016, 104, 1523–1533. 
[19] K. J. Livak, T. D. Schmittgen, Methods 2001, 25, 402–408. 
[20] M. Boro, K. N. Balaji, J. Immunol. 2017, 199, 1660–1671. 
[21] L. Y. Guo, F. Yang, L. J. Peng, Y. B. Li, A. P. Wang, Clin. Exp. 
Hypertens. 2019, 00, 1–10. 
[22] S. C. A. de Jager, B. W. C. Bongaerts, M. Weber, A. O. 
Kraaijeveld, M. Rousch, S. Dimmeler, M. P. van Dieijen-Visser, 
K. B. J. M. Cleutjens, P. J. Nelemans, T. J. C. van Berkel, E. A. 
L. Biessen, PLoS One 2012, 7, DOI 
10.1371/journal.pone.0045804. 
[23] S. C. A. de Jager, A. O. Kraaijeveld, R. W. Grauss, W. de Jager, 
S. S. Liem, B. L. van der Hoeven, B. J. Prakken, H. Putter, T. J. 
C. van Berkel, D. E. Atsma, M. J. Schalij, J. W. Jukema, E. A. 
L. Biessen, J. Mol. Cell. Cardiol. 2008, 45, 446–452. 
[24] A. Segiet, P. Smykiewicz, P. Kwiatkowski, T. Żera, Cytokine 
2019, 113, 185–194. 
[25] E. Mehaffey, D. S. A. Majid, Am. J. Physiol. - Ren. Physiol. 
2017, 313, F1005–F1008. 
[26] P. Libby, J. Am. Coll. Cardiol. 2017, 70, 2278–2289. 
[27] J. Qi, X. F. Zhao, X. J. Yu, Q. Y. Yi, X. L. Shi, H. Tan, X. Y. 
Fan, H. L. Gao, L. Y. Yue, Z. P. Feng, Y. M. Kang, Cardiovasc. 
Toxicol. 2016, 16, 298–306. 




[29] Z. Miao, M. Guo, S. Zhou, X. Sun, F. Wang, H. Lu, Z. Cui, Exp. 
Ther. Med. 2018, 16, 61–66. 
[30] R. Chen, J. Yan, P. Liu, Z. Wang, C. Wang, Metab. Brain Dis. 
2017, 32, 667–673. 
[31] H. Lai, Q. Chen, X. Li, Y. Ma, R. Xu, H. Zhai, F. Liu, B. Chen, 
Y. Yang, Int. J. Clin. Exp. Med. 2015, 8, 21487–21496. 
[32] A. Seidi, S. Mirzaahmadi, K. Mahmoodi, M. Soleiman-
Soltanpour, Mol. Biol. Res. Commun. 2018, 7, 17–24. 
[33] A. Ma, B. A. Malynn, Nat. Rev. Immunol. 2012, 12, 774–785. 
[34] Vasanti S Malik, F. B. Hu, J Am Coll Cardiol 2015, 66, 1615–
1624. 
[35] T. A. Khan, J. L. Sievenpiper, Eur. J. Nutr. 2016, 55, 25–43. 
[36] R. Sundaram, E. Nandhakumar, H. Haseena Banu, Toxicol. 
Mech. Methods 2019, 29, 644–653. 
[37] H. Xuguang, T. Aofei, L. Tao, Z. Longyan, B. Weijian, G. Jiao, 
Phyther. Res. 2019, 33, 1697–1705. 
[38] E. C. Kühn, A. Slagman, E. C. D. Kühn-Heid, J. Seelig, C. 
Schwiebert, W. B. Minich, C. Stoppe, M. Möckel, L. 
Schomburg, J. Trace Elem. Med. Biol. 2019, 52, 247–253. 
[39] X. Sun, M. S. S. Haider Ali, M. Moran, Biochem. J. 2017, 474, 
2925–2935. 
[40] N. W. Mathy, X. M. Chen, J. Biol. Chem. 2017, 292, 12375–
12382. 
[41] C. Jiang, N. Ding, J. Li, X. Jin, L. Li, T. Pan, C. Huo, Y. Li, J. 
Xu, X. Li, Brief. Bioinform. 2019, 20, 1812–1825. 
[42] D. Esser, J. M. Geleijnse, J. C. Matualatupauw, J. I. Dower, D. 










The human randomized clinical trial was conducted by LP-P, LCP, EL, 
JC, RMV, AP and RS. LP-P wrote the manuscript and RMV, AP and 
RS provided feedback on the manuscript. CD and LP-P realized the 
qRT-PCR analysis. All the authors have read the manuscript. We thank 
the Centre for Omics Sciences (COS) Joint Unit of the Universitat 
Rovira i Virgili-Eurecat, for their contribution to the processing of the 
samples and transcriptomic analysis. We thank Nutritional Projects 




The Florida Department of Citrus, an executive agency of the state of 
Florida, USA, provided a grant and study drinks to the Eurecat, Centre 
Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. AP 
has Torres Quevedo contract (Subprograma Estatal de Incorporación, 
Plan Estatal de Investigación Científica y Técnica y de Innovación).  
 
Declaration of interest  
The authors declare that they have not conflicts of interest with the 














Age  51.9 ± 12.8 41.0 ± 14.2 49.3 ± 5.9 0.061 
Females, % 18.2 33.3 7.3 0.691 
SBP, mm Hg 130.4 ± 9.8 134.9 ± 11.9 139.9 ± 11.8 0.156 
DBP, mm Hg 74.6 ± 9.8 79.9 ± 9.2 82.1 ± 9.8 0.182 
Pulse pressure, mm Hg 58.4 ± 9.7 55.0 ± 10.7 57.8 ± 7.2 0.623 
Weight, kg 75.6 ± 10.0 76.9 ± 11.9 77.8 ± 11.8 0.905 
BMI, kg/m2 25.5 ± 3.2 26.3 ± 3.5 26.3 ± 3.1 0.812 
Waist circumference, 
cm 
92.3 ± 9.1 91.8 ± 11.8 92.8 ± 7.7 0.966 






201 ± 42 
134 ± 33 
49.2 ± 11.9 
 
187 ± 28 
111 ± 27 
54.6 ± 21.5 
 
194 ± 19 
129 ± 16 





Triglycerides, mg/dL 88 ± 20 104 ± 49 102 ± 39 0.594 
Physical activity, UA 2.91 ± 1.7 3.33 ± 1.2 3.63 ± 0.5 0.398 
Data expressed as mean ± standard deviation, or percentages. Abbreviations: 
CD, control drink; OJ, orange juice; EOJ, hesperidin-enriched orange juice; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass 
index; LDL, low density lipoprotein; HDL, high density lipoprotein; UA, 
arbitrary units: 0, inactive. 1, very low activity. 2, low activity. 3, moderately 
active. 4, very active. 
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Table 2. Comparisons of dose-response gene expression changes among treatments in PBMCs of mildly hypertensive individuals. 
Gene 
Symbol 















Inflammation related genes 
Anti-inflammatory 
NFKB1A Nuclear factor of kappa 
light polypeptide gene 


















TNFAIP3 Tumor necrosis factor, 





















TNFAIP6 Tumor necrosis factor, 



















DUSP2 Dual specify 


































TMIGD3 Transmembrane and 
immunoglobulin 

















CCL3 Chemokine (C-C 



















CCL3L3 Chemokine (C-C 














CCL4L2 Chemokine (C-C 














CXCL2 Chemokine (C-X-C 































CLEC5A C-type lectin domain 







































































Obesity related  















Insulin resistance  
DHRS9 Dehydrogenase/reduct
ase (SDR family) 


















Others (Unknown function)          
SLED1 Proteogly can 3 
pseudogene non-

































PKDL1 Polycystic kidney 






































Long non coding RNA 





















































Data expressed as mean ± standard error (ES) or mean (95% confidence interval, CI). Inter treatment comparisons by ANCOVA Model adjusted by sex and age. Analyses performed 












Table 3. Comparisons of gene expression changes among treatments after 12 weeks of sustained consumption in PBMCs of mildly hypertensive individuals. 
Gene Symbol Gene Name Post-intervention values 
mean (SE) 



















Nuclear factor kappa light 
polypeptide 

















NFKBIZ Nuclear factor kappa light 
polypeptide gene enhancer 









































































































































































CCL3L3 Chemokine (C-C motif) 
















CCL4L2 Chemokine (C-C motif) 
















CXCL1 Chemokine (C-X-C motif) 


































CXCL3 Chemokine (C-X-C motif) 










































































RasGEF1B Ras GEF domain family 














Cardiovascular disease related 
FMN1 
 




















Acute coronary syndrome 


















Homo sapiens protein 



































































































Solute carrier family 
















































TMPO-AS1 TMPO antisense RNA 1 




















Esophageal squamous cell 
CFLAR-AS1 CFLAR antisense RNA 1 



















































FAM53B Family with 
sequence similarity 

































GOS2 G0 /G1 switch gene 2 4.28 3.66 3.64 -0.620 0.171 -0.635 0.155 -0.015 0.972 
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(0.32) (0.27) (0.31) (-1.5;0.28)  (-1.5;0.25) (-0.87;0.84) 
BPIFB3 BPI fold containing family 




































Long intergenic non-protein 


























































Long non-coding BTB 










































Long non-coding arresting 




































































Long non-coding solute 

































Long non-coding NFKB 







































































Long non-coding leucine 
















Long non-coding G protein-
















Long non-coding RNA 





































Long non-coding coiled-coil 












































Data expressed as mean ± standard error (SE) or mean (95% confidence interval, CI). *logarithmic transformation of the variable. Inter treatment comparisons by ANCOVA 













Figure 1. Venn diagram of the number of differentially (P < 0.05) and borderline (P > 0.10) expressed genes in PBMC of stage 1 and pre-
hypertensive individuals: 6 h after the consumption of 500 mL (A) and after 12-week consumption of orange juice (OJ) and hesperidin-
enriched orange juice (EOJ) (B) compared to control drink, and the differentially expressed genes after both consumptions (C). Yellow, 
postprandial OJ; pink, postprandial EOJ; brown, sustained OJ; red, sustained EOJ.
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Figure 3. Biological networks based on the differentially expressed gens after sustained 
consumption of orange juice (panel A) and hesperidin-enriched orange juice (panel B). 
Interaction between the differently expressed genes and other important related gens. Down- and 

























Supporting Information Table S1. Composition of the three test 
drinks. 
 Dose per day in mg/500 mL 
Control drink Orange juice Hesperidin-enriched 
orange juice 
Hesperidin  ND 392 670 
Narirutin  ND 64 77 
Vitamin C 235 235.3 235 
Glucose 14407 938.2 9382 
Fructose 7357 10123 10123 
Sucrose  13197 18158 18158 
Composition determined by State of Florida, Department of Citrus. 




Supporting Information Table S2. Nucleotide sequences of primers used for PCR amplification. 
Gene 
Forward primer Reverse primer 
Ref. or Acc. No. 
(5’ to 3’) (5’ to 3’) 
DHRS9 TGGACCACGCTCTAACAAGT CACACTGCCTTGGGATTAGC NM_001142270.2 
DSP TACCCCTGCGACAAGAACAT TCTGGGTTACGAGGCTTCAG NM_004415.4 
IER3 GGCTTCTCTTTCTGCTGCTC GAGGGCTCCGAAGTCAGATT NM_003897.4 
NAMPT TGGAGGAAGGAAAAGGAGACC CACACAACACACACCCAGTC NM_005746.3 
PTX3 GGTAAATGGTGAACTGGCGG TGACAAGACTCTGCTCCTCC NM_002852.4 
RPLP0 ATGGCAGCATCTACAACCCT AGGACTCGTTTGTACCCGTT NM_001002.4 




Supporting Information Table S3. Top canonical pathways, diseases and 
functions regulated by sustained consumption (12 weeks) of orange juice and 
hesperidin-enriched orange juice in PBMCs of pre- and stage 1 hypertensive 











EOJ Granulocyte adhesion 




CXCL8, IL1B, TNF. 
8.85-17 Inflammatory response: 
CXCL1, CXCL2, 
CXCL3, CXCL8, IL1B, 












CXCL8, IL1B, TNF. 
1.71-16 Cell–to-cell signaling 
and interaction: CCL20, 
CCL3, CCL3L3, 
CXCL1, CXCL2, 
CXCL3, CXCL8, IL1B, 
PTGS2, TNF, CD83, 









8.20-12 Organismal injury and 
abnormalities: CCL20, 








CCL3, CD83, CXCL8, 
IL1B, TNF. 










between innate and 
adaptive immune cells: 
CCL3, CCL3L3, CD83, 
CXCL8, IL1B, TNF. 
1.40-10 Cardiovascular system: 
CCL3, CXCL1, 
CXCL2, CXCL8, IL1B, 




OJ Dendritic cell 
maturation: CD83, 
IL1B, NFKB1A, TNF. 
1.84-07 Inflammatory response: 













CD83, IL1B, NFKB1A, 
TNF. 
IL-10 signaling: IL1B, 
NFKB1A, TNF. 
1.33-06 Cellular growth and 
proliferation: CCL20, 





CD83, IL1B, TNF. 
1.39-06 Lipid metabolism: 







1.71-06 Hematological system: 




Analysis performed with the Ingenuity Pathway Analysis (IPA). Abbreviations: 
PBMCs, peripheral blood mononuclear cells; EOJ, hesperidin-enriched orange juice; 






















Supporting information Table S4. Statistically significant and borderline 
differentially expressed genes after the single dose study and after 12 
weeks of OJ, EOJ and CD consumption. 
 After 6h  
(single dose 
study) 






















 NFKB1A ↓b ↓ b  ↓ b ↓ b  
 TNFAIP3 ↓a ↓ b     
Pro-inflammatory 
 TNF    ↓a ↓a  
 IL1B    ↓ b ↓a  
 ICAM     ↓ b  
 CCL3  ↓b   ↓ b  
 CCL20    ↑a ↑ b  
 CCL3L3  ↓ b   ↓a  
 CCL4L2 ↓ b ↓ b   ↑ b  
 CXCL1     ↓ b  
 CXCL2  ↓ b   ↓a  
 CXCL3     ↓ b  
 CXCL8     ↓ a  
 CLEC5 ↑ b      
 PTGS2     ↓a  
Insulin resistance       
 DHRS9 ↑a  ↓a    
Acute coronary syndrome 
 SELENBP1      ↓a 
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Endothelial function related 
 DSP     ↑a  
 IER3     ↓a  
Improvement of hypertension  
 PTX3     ↓a  
 NAMPT     ↓b  
Obesity related       
 PPP1R15AGADD34     ↓b  
Hemoglobin related  
 ALAS2      ↓a 
Neuronal differentiation 
 CD83    ↓b ↓b  
Cancer: prostate  
 TMPO-AS1    ↓a ↓b  
Unknown function 
 SLED1 ↓ b   ↓b   
 BPIFB3    ↓a ↓b  
 PKDL1 ↑ a      
 ATP2B1-AS1     ↓a  
 PLA1A    ↓b ↓b  
 FAM53B    ↑a ↑a  
 BTBD19      ↓a 
 KMT2E-AS1     ↓a  
 LINC01220    ↑a   
 LncRNA ATOH8-2 ↑ b      
 LncRNA ACOT-13    ↓a ↓b  
 LncRNA KDM5A-3     ↓b  
 LncRNA SNRPD3-2    ↑a ↑a  
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 LncRNA SLC39A8-1    ↑b ↑a  
 LncRNA CCT8-1    ↓a ↓a  
 LncRNA GRK3-1     ↓a  
 LncRNA RP11- 
 701P16.2.1-2 
   ↓b ↓b  
 LncRNA  CCDCC117-1    ↓b ↓a  
 LOC101929524    ↑a   
 LOC644090    ↓b ↓a  
 LncRNA IYD    ↓b  ↑a 
 LncRNA BTBD19-1     ↓b  
 LncRNA IL1B1    ↑b   
 LncRNA NFKBID-1    ↑a   
 LncRNA PDE3B-1    ↑a   
 LncRNA LRRC61-2    ↓b   
 LncRNA TOMM20-2    ↓b   
a, p<0.05; b, p<0.10. Abbreviations: OJ, orange juice; EOJ, hesperidin-











Project 4: The consumption of hesperidin 
in orange juice modulates the plasma and 
urine metabolic profiles in pre- and stage 1 
hypertensive subjects to promote beneficial 
effects on the cardiovascular system: 
targeted and nontargeted metabolomic 


















The consumption of hesperidin in orange juice modulates the 
plasma and urine metabolomic profiles in pre- and stage 1 
hypertensive subjects to promote beneficial effects on the 
cardiovascular system: targeted and nontargeted metabolomic 
approaches (CITRUS study) 
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CD:  control drink 
CVDs:  cardiovascular diseases 
CVDRFs: cardiovascular diseases risk factors 
DMA:  dimethylamine  
DMG:  dimethylglycine 
EOJ:  hesperidin-enriched orange juice 
GPC:  glycerophosphocholine  
NAG:  N-acetylglycoproteins 
OJ:  orange juice 
PAG:  phenylacetylglutamine 






The aim of the present work was to determine new biomarkers of the 
biological effects of hesperidin in orange juice (OJ) applying a 
nontargeted metabolomics approach validated by targeted 
metabolomics analyses of compliance biomarkers. 
Methods and results 
Plasma/serum and urine targeted (HPLC-MS/MS) and untargeted (1H-
NMR) metabolomics signatures were explored in a subsample with pre- 
and stage-1 hypertension subjects of the CITRUS study (N=159). 
Volunteers received 500 mL/day of control drink, OJ, or hesperidin-
enriched OJ (EOJ) for 12-weeks. A 6-h postprandial study was 
performed at baseline. Targeted analyses revealed plasma and urine 
hesperetin 7-O- -D-glucuronide as the only metabolite differing 
between OJ and EOJ groups after both single dose and 12-weeks 
consumption, and in urine is correlated with a decreased systolic blood 
pressure level. The nontargeted approach showed that after single dose 
and12-weeks consumption of OJ and EOJ changed several metabolites 
related with an anti-inflammatory and antioxidant actions, lower blood 
pressure levels and uraemic toxins. 
Conclusions 
Hesperetin 7-O- -D-glucuronide could be a candidate marker for 
distinguishing between the consumption of different hesperidin doses 
as well as a potential agent mediating blood pressure reduction. 
Moreover, changes in different endogenous metabolites could explain 






The metabolome comprises all the metabolites found in an organ, cell, 
biofluid or organism under certain conditions. Metabolites have several 
functions in cells and systems,(69) and their levels in organism are 
directly associated with human health.(163) Notably, changes at the 
metabolome level can appear in biofluids before the appearance of 
clinical symptoms.(164) Therefore, when assessing nutritional studies, 
metabolomics approaches provide information about changes in diet-
derived and endogenous metabolites to allow the identification of novel 
biomarkers related to dietary intake and biological effects.(165) 
 
The relationship between bioactive compounds in food and the 
development of several chronic conditions has been widely studied. In 
this sense, the effects of phenolic compounds, that are naturally present 
in plant-based foods, have emerged as potential nutritional strategy 
against on cardiovascular disease (CVD). In particular, hesperidin, 
which is the main flavanone in citrus fruits and is present mainly in 
oranges and orange juice (OJ), has demonstrated beneficial effects on 
different cardiovascular risk biomarkers in animal and human 
studies.(130) Nevertheless, the bioavailability of the flavanone 
hesperidin depends on the body’s capacity to absorb this metabolite, 
and subjects can be stratified into three categories: low, moderate and 
high absorbers.(110) 
Through omics analyses, our research group recently showed that 
hesperidin consumption can modify the heart and kidney tissue 
proteome(166) and the plasma metabolome profile of rats with 
metabolic syndrome.(167) Specifically, our metabolomics analysis 
showed that hesperidin consumption decrease the levels of several 
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plasma metabolites related to inflammation and oxidative stress and 
thereby, reduces the blood pressure levels, influences on the 
cardiovascular system, and improves the conditions of metabolic 
syndrome in rats.(167) In humans, hesperidin consumption decreases 
the body weight(94) and diastolic blood pressure levels,(107) and 
improves lipid profile(93) and postprandial microvascular endothelial 
reactivity.(107) In fact, our research group recently demonstrated a 
beneficial effect of hesperidin consumption in OJ on blood pressure 
levels in subjects with pre- and stage 1 hypertension.(133) 
 
The study of the metabolic profiles can offer important insights into 
cardiovascular system and CVDs pathogenesis as well as the possible 
identification of new CVDs biomarkers. However, to the best of our 
knowledge, no study has combined a targeted and nontargeted 
metabolomics approach after the consumption of hesperidin in OJ in 
humans with cardiovascular disease risk factors (CVDRFs).  
Therefore, the aim of the present work was to determine new 
biomarkers of the biological effects of hesperidin in OJ applying 
nontargeted metabolomics approach in plasma/serum and urine 
samples after both single dose (6 hours) and sustained (12 weeks) 
consumption, validated through targeted metabolomics analyses of 
compliance biomarkers in subjects with pre- and stage 1 hypertension. 
 
2. METHODS 
2.1 Study population and study design  
The study population was obtained from the CITRUS study (N= 159), 
a randomized, parallel, double-blind and placebo controlled clinical 
trial (registration number in Clinical-Trials.gov: NCT02479568).(133) 
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Moreover, the targeted metabolomics analysis was performed in 129 
subjects who completed sustained study, and nontargeted metabolomics 
was performed in 52 subjects who completed both the single dose and 
sustained studies. The subjects were women and men with pre- or stage 
1 hypertension, systolic blood pressure ≥ 120 mm Hg and < 159 mm 
Hg and diastolic blood pressure < 100 mm Hg, who are not taking any 
anti-hypertensive or anti-hyperlipemia medication. The subjects, who 
were recruited between January 2016 and June 2017, were randomly 
assigned to one group of the three intervention groups: control drink 
(CD), OJ and hesperidin-enriched orange juice (EOJ) groups. Detailed 
information on the study population and the design of the study are 
described in Supplementary Information Methods S1. 
 
2.2 Test drinks  
The following three test drinks were provided by The Florida 
Department of Citrus from the USA: the CD (without hesperidin), OJ 
containing hesperidin at its natural level, and EOJ, which was OJ 
enriched with hesperidin. The intervention drinks were similar in smell 
and appearance and can be differentiated by a code assigned by an 
independent researcher not related directly to the clinical trial.   
 
2.3. Dosage information 
All subjects drank 500 mL of the corresponding test drink daily: the 
CD, provided 0 mg/day of hesperidin, OJ provided 345 mg/day of 
hesperidin, and EOJ provided 600 mg/day of hesperidin. The 
composition of the three test drinks is detailed in Supporting 





2.4 Targeted metabolomics analysis of compliance biomarkers 
Sample collection 
To assess whether the compliance biomarkers in plasma supply more 
information than those in urine, plasma samples were collected at 
baseline and after 2, 4 and 6 h in the single dose study. In the sustained 
study, plasma samples were collected at baseline and at 4, 8 and 12 
weeks after sustained consumption. Moreover, 24-h urine samples were 
collected at the beginning of the study and after 12 weeks of treatment. 
 
Determination of hesperidin and naringenin metabolites in urine 
and plasma samples by UHPLC-MS/MS 
Urine and plasma samples were thawed at 4 °C. Subsequently, 50 µL 
of the urine samples was mixed with 100 μL of water containing 1% 
HF or the internal standard (rac-hesperetin-d3). This dilution was 
performed through a semi-automated process using the Agilent Bravo 
Automated Liquid Handling Platform. In contrast, 20 internal standards 
(hesperetin-d4) were mixed with 125 μL of the plasma samples and 750 
μL of methanol, and then, mixture was then vortexed for 10 mins and 
centrifuged at 4700 rpm at 4°C for 10 min. A total of 900 μL was 
transferred and evaporated in a Speed-Vac at ambient temperature. The 
residues were reconstituted in 25 μL of MeOH and 75 μL of H2O (1% 
HFor) and injected into an LC-MS/MS instrument. The extraction was 
performed through a semi-automated process using the Agilent Bravo 
Automated Liquid Handling Platform. The analyses were performed 
with an Agilent 1200 series UHPLC coupled to a 6490 Triple Quad LC-
MS mass spectrometer, and the source electrospray source ionization 
(ESI) was operated in the negative mode. A reversed-phase Eclipse Plus 
column (C18, 1.8 μm, 2.1 mm × 150 mm) from Agilent Technologies 
was used for chromatographic separation. 
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The assignment of the hesperetin and naringenin metabolites was 
performed by direct comparison with commercial standards 
(hesperidin, narirutin, hesperetin, naringenin, hesperetin 3-O-β-D-
glucuronide, hesperetin 7-O- β -D-glucuronide, naringenin 4'-O-β-D-
glucuronide and hesperetin 7-O-sulfate). The tentative identification of 
the other hesperetin and naringenin metabolites was based on the 
precursor ion mass, chromatographic behaviour on a similar system, 
and published data from plasma samples. The method was validated 
using a pool of samples collected during the study and was based on 
standard addition. The method was validated by determining the limit 
of detection (MDL), and the limit of quantification (MQL), the 
repeatability (expressed as relative standard deviation, RSD), the 
accuracy (%) and the coefficient of determination of the calibration 
curve (Supplementary Information Table S2). The total flavanone 
content was obtained by summing the plasma or urine levels of all 
identified hesperidin and naringenin metabolites.  
 
 
2.5 Nontargeted metabolomics analysis of biological effects 
biomarkers 
Sample collection 
Serum samples were collected at baseline and 6 h after treatment in the 
single dose study (N=129). Nontargeted metabolomics analyses were 
performed at 6-h, corresponding with the reported maximal flavanone 
plasma concentration.(168) For the sustained study, serum samples 
were collected at the beginning and after 12 weeks of treatments only 
for those subjects that participated in single dose study (N=52). Twenty-
four hours urine samples were also collected at the beginning of the 




NMR sample preparation and acquisition 
Urine and serum samples were allowed to reach room temperature. 
Subsequently, 400 μL of urine was mixed with 200 μL of phosphate 
buffer (pH 7.4; 100% D2O) containing the internal standard/L, 3-
trimethylsilyl-1-[2,2,3,3-2H4] propionate (TSP), at a concentration of 
1 mM and 2 mM sodium azide. In addition, 200 μL of each serum 
sample was mixed with 400 μL of phosphate buffer containing 2 mM 
TSP, and the resulting mixture was vortexed and centrifuged at 10,000 
x g for 10 min. A 550-μL aliquot was then transferred into a 5-mm 
NMR tube. 
All NMR spectra were recorded at 300 K with a Bruker Avance III 600 
spectrometer operating at 600.20 MHz for protons and equipped with a 
5-mm PABBO BB-1H/D Z-GRD probe and an automatic sample 
changer with a cooling rack at 4°C. For the urine samples, a standard 
one-dimensional (1D) NOESY presaturation pulse sequence (RD-90°-
t1-90°-tm-90°-acquire) was used with water suppression. The data from 
all the samples were acquired using a recycle delay (RD) of 5 s, a 
mixing time (tm) of 100 ms, an acquisition time of 3.41 s, and a 90° 
pulse of 10.99 μs. For each sample, 128 scans were collected after four 
dummy scans to obtain 64K data points with a spectral width of 16 ppm. 
For all serum samples, 1D-NOESY and Carr-Purcell-Meiboom-Gill 
(CPMG) spin echo experiments with water suppression were performed 
to obtain the corresponding metabolic profile. The settings for the 
NOESY experiments were the same as those used for the urine samples. 
Low-molecular-weight-filter CPMG spectra were then obtained using 
a CPMG sequence (RD [90°x-(t-180°y-t)n-collect FID) with a spin-
echo delay of 400 μs (for a total T2 filter of 210 ms), which allowed 
efficient attenuation of the lipid NMR signals. The total acquisition time 
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was 2.73 s with an RD of 2 s, and the 90° pulse length was automatically 
calibrated for each sample at approximately 11.1 μs. For each sample, 
eight dummy scans were followed by 128 scans, and 64K points over a 
spectral width of 20 ppm were collected. 
 
NMR spectra processing 
Prior to the data analysis, all FIDs were multiplied by an exponential 
function equivalent to a 0.3-Hz line broadening factor before applying 
a Fourier transform. The transformed spectra were phased, corrected for 
baseline distortions, and calibrated using the reference standard TSP in 
Topspin 3.5 (Bruker). Each spectrum in the range between 0 and 10.0 
ppm was digitized into consecutive integrated spectral regions (32.768) 
of equal width (0.00033 ppm) using MATLAB (MathWorks). The 
region containing the residual water in both the urine and serum 
samples was removed to minimize the baseline effects arising from 
improper water suppression. Chemical shift variation was minimized 
across the dataset by applying a recursive segment-wise peak alignment 
algorithm to each spectrum. Each spectrum was then normalized using 
a probabilistic quotient normalization. 
 
 
2.6 Statistical analysis 
To express the changes in plasma compliance biomarkers after 4, 8 and 
12 weeks of the treatments, intra-treatment comparisons were evaluated 
by a general linear model with Bonferroni correction and age and sex 
as covariables, and inter-treatment comparisons were evaluated with the 
ANCOVA model adjusted by sex and age. To express the changes in 
urine compliance biomarkers after 12 weeks of the treatments, intra-
treatment comparisons were evaluated by Wilcoxon test and inter-
treatment comparison by Mann-Whitney test for independent samples. 
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The relationship of hesperetin 7-O-B-glucuronide and systolic blood 
pressure levels was assessed by Pearson's and Spearman's correlation 
coefficients since this metabolite seems to be the responsible of 
hypotensive, vasodilatory and anti-inflammatory activities in 
literature.(15) 
 
Multivariate modelling of the results from the nontargeted 
metabolomics analysis was performed in MATLAB using in-house 
scripts. First, outlying samples were identified by PCA, and the 
significant metabolites that can be used to discriminate between groups 
were identified using orthogonal partial least squares discriminant 
analysis (O-PLS-DA). Hence, NMR metabolic profiles served as the 
descriptor matrix (X) and the experimental groups were used as the 
response variable (Y). The O-PLS model loadings were back-
transformed by multiplying all the values by their standard deviation 
(covariance) and colour-plotted based on their model weights (R2). The 
important variables for between-class discrimination are highlighted by 
the correlation colour scale, and the red colour indicates high 
significance. The predictive performance (Q2Y) of the models was 
calculated using a 7-fold cross-validation approach, and the model 
significance was assessed using 1000 permutations. Large 
interindividual variability has been observed in the bioavailability and 
excretion of hesperidin among subjects.(169,170) Therefore, we also 
build O-PLS models using the maximum total flavanone (hesperidin + 
naringenin metabolites) content, independently from the intervention 






3.1 Volunteer characteristics and results from the human 
randomized clinical trial 
Of the 159 volunteers with pre- and stage 1 hypertension who were 
randomly allocated, 129 completed the sustained study (N = 43, 46 and 
40 in CD, OJ and EOJ groups, respectively), and 52 of these volunteers 
participated in the baseline single-dose study (N = 17, 21 and 14 in the 
CD, OJ and EOJ groups, respectively). The flow diagram of the 
volunteers is detailed in Figure S1 in the Supplementary Information, 
and the basal characteristics of the volunteers are detailed in Table S3 
in the Supplementary Information. 
 
3.2 Targeted metabolomics for compliance biomarkers 
Plasma targeted metabolomics analysis  
The changes in the six studied plasma metabolites, namely, hesperetin 
7-O-β-D-glucuronide, hesperetin 3-O-β-D-glucuronide, hesperetin 7-
O-sulfate, naringenin 4-O-β-D-glucuronide, naringenin glucuronide 
and naringenin sulfate, after 4, 8 and 12 weeks of the treatments are 
detailed in Table 1 (N = 129). Compared with those observed in the CD 
group, significantly increased levels of the six exposure biomarkers 
were observed after 12 weeks of OJ and EOJ consumption. In 
particular, the metabolite hesperetin 7-O-B-D-glucuronide was the 
main metabolite that showed differential expression between the OJ and 
EOJ groups. 
The changes in the six studied plasma metabolites, namely, hesperetin 
7-O-B-D-glucuronide, hesperetin 3-O-B-D-glucuronide, hesperetin 7-
O-sulfate, naringenin 4-O-B-D-glucuronide, naringenin glucuronide 
and naringenin sulfate, detected after 2, 4 and 6 h in the single dose 
study are presented in Figure 1 (N = 52). After 6 h, OJ and EOJ 
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consumption significantly increased the plasma levels of hesperetin 7-
O-B-D-glucuronide, hesperetin 3-O-B-D-glucuronide, hesperetin 7-O-
sulfate, naringenin glucuronide and naringenin sulfate compared with 
the levels obtained with the CD. 
High interindividual variability has been observed in absorption and 
excretion in hesperidin-based acute and chronic interventions.(112) 
Consistently, we also observed a large interindividual variability in total 
plasma flavanone pharmacokinetics upon beverage intake in each 
treatment group (Supplementary Information Figure S2). Some 
participants had the maximal total flavanone concentration after 6-h of 
consumption, while other had the maximum peak at 4-h or even earlier 
(2-h). In addition, the total amount of flavanones absorbed in each 
hesperidin supplemented group had a high variability, with high-, 
medium-, and low-absorbers in each group.  
 
 
Urine targeted metabolomics analysis: 
The changes in the six studied urine metabolites, namely, hesperetin 7-
O-β-D-glucuronide, hesperetin 3-O-β-D-glucuronide, hesperetin 7-O-
sulfate, naringenin 4-O-β-D-glucuronide, naringenin glucuronide and 
naringenin sulfate, after sustained consumption of the intervention 
drinks are detailed in Table 2 (N = 129). After 12 weeks of CD 
intervention, no differences were observed in the six studied urine 
metabolites. Compared to CD, after OJ and EOJ interventions, 
significant increased levels of the six studied metabolites were 
observed. Moreover, the EOJ consumption compared to OJ, increased 
the levels of only one metabolite in urine: the hesperetin 7-O-β-D-
glucuronide.  
In Figure 2 is represented the relationship between the levels of urine 
hesperetin 7-O-β-D-glucuronide and changes on blood pressure levels 
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of the participants of CITRUS study. Our results showed that increased 
levels of hesperetin 7-O-β-D-glucuronide in urine are correlated with 
lower blood pressure levels after 12 weeks of treatment (R=-0.223; 
P=0.011). 
 
3.3 Nontargeted metabolomics analysis of biomarkers of the 
biological effect in the serum and urine samples 
Pairwise O-PLS-DA models were built to compare the metabolic 
profiles of the three study groups at 6-h in the single dose study. 
Significant models were obtained for the comparison of the metabolic 
profiles between CD and OJ group (Q2Y=0.36, P=0.001) and between 
CD and EOJ groups (Q2Y=0.35, P=0.001) after the 6 hours of the single 
dose consumption. The serum levels of proline betaine and 
dimethylglycine (DMG) were significantly increased and the level of 
leucine were significantly decreased after 6 h, in the OJ and EOJ groups 
compared with the CD group. Moreover, 6 h after EOJ consumption, 
the isoleucine urine levels were also significantly decreased compared 
with those in the CD group (Figure 3, panels A and B). 
To take into account that hesperidin absorption varied largely in both 
OJ and EOJ groups (Figure 3, panel C), we also built an O-PLS model 
considering the the maximal total flavanone concentration observed 
during the single dose study for each participant independent of the 
treatment group. Interestingly, we obtained a more significant model 
(Q2Y=0.20, P<0.001) that revealed additional differences between high 
and low absorbers (Figure 3, panel D). Consistent with the previous 
models, high hesperidin absorbers had higher plasma levels of DMG 
and proline betaine. However, this model also revealed that high 
absorbers had higher levels of ketone bodies (3-hydroxybutyrate, 




Pairwise O-PLS-DA models were also constructed to compare the 
metabolic profiles between treatment groups at the end of the study 
(week 12) for those participants that completed the single dose study. 
Again, we obtained significant models differentiating the metabolic 
profiles of CD vs OJ (Q2Y=0.35, P=0.02) and CD vs EOJ (Q2Y=0.28, 
P=0.05) (Figure 4). After the sustained consumption study, a 
nontargeted metabolomics was performed with a subsample of 52 
subjects (N = 17 in CD, 21 in OJ and 14 in EOJ) who completed both 
the single dose study and the sustained study, and differences in the 
metabolic profiles were observed after sustained consumption. As a 
result, increased serum levels of proline betaine and decreased serum 
levels of glycerophosphocholine (GPC), N-acetyl glycoproteins 
(NAGs), acetate, valine, isoleucine, and leucine were observed after 12 
weeks of OJ consumption compared with the levels founded in the CD 
group (Figure 4, panel A). Similarly, increased serum levels of proline 
betaine and decreased plasma levels of GPC, aspartate, glutamate, 
valine, isoleucine, and leucine were observed after 12 weeks of EOJ 
consumption compared with the levels detected in the CD group (Figure 
4, panel B). 
 
The nontargeted analysis of urine samples from the sustained study 
(N=129) also revealed significant differences between the metabolic 
profiles of the OJ and CD (Q2Y=0.79, P<0.001) and between the EOJ 
and CD (Q2Y=0.80, P<0.001) groups after 12 weeks. Significantly 
increased levels of proline betaine in urine were observed after 12 
weeks of OJ consumption compared with the levels found in the CD 
group, whereas the levels of 4-hydroxyhippurate, pseudouridine, 
phenylacetylglutamine (PAG), 4-cresyl sulfate, creatinine, 
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dimethylamine (DMA), NAGs, alanine and 3-methyl-2-oxovalerate 
were significantly decreased (Figure 5, panel A). Compared with the 
levels found in the CD group, significantly increased levels of proline 
betaine in urine were observed after 12 weeks of EOJ consumption, and 
the levels of 4-cresyl sulfate, pseudouridine, uracil, creatinine, creatine, 
NAGs, alanine, 2-hydroxyisobutyrate (2-HIB) and 3-MOV were 
significantly decreased (Figure 5, panel B).  
No differences were found between the OJ and EOJ groups in any of 
the untargeted analyses.  
 
4. DISCUSSION  
The current study comprises the first evaluation of the effects on the 
metabolome of single dose and sustained consumption of hesperidin in 
OJ and EOJ on subjects with pre- and stage 1 hypertension through 
targeted and nontargeted approaches to finally determine new 
biomarkers of the biological effects of hesperidin. Both targeted and 
nontargeted analyses revealed that OJ and EOJ consumption induced 
significant changes on plasma/serum and urine metabolome compared 
to the CD group. 
 
The targeted metabolomics approach for compliance biomarkers 
revealed increased plasma and urine of six flavanone catabolites after 
12 weeks of OJ and EOJ consumption and 6 h after consumption of the 
single dose. As previously reported in plasma(133) and in the present 
work also in urine, the six compliance biomarkers were significantly 
increased after OJ and EOJ consumption, which demonstrate 
compliance with the interventions Moreover, hesperetin 7-O-B-D-
glucuronide, both in plasma and urine, was the only metabolite that 
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showed differences between the OJ and EOJ groups, which indicated 
that hesperetin 7-O-B-D-glucuronide could be a candidate marker for 
distinguishing between different doses of hesperidin consumed for at 
least 12 weeks. Additionally, urine levels of hesperetin 7-O-B-D-
glucuronide was correlated with lower systolic blood pressure levels, 
demonstrating a possible role on blood pressure control in humans. In 
this sense, its appreciation was only previously observed in rat models, 
where hesperetin 7-O-B-D-glucuronide exerts antihypertensive effects 
and exhibits vasodilatory and anti-inflammatory activities.(15) Thus, to 
the best of our knowledge, this is the first study to show a negative 
correlation between the urine metabolite hesperetin 7-O-B-D-
glucuronide and the levels of systolic blood pressure. 
 
Metabolic profiles provide a direct functional read-out of the 
physiological status of an individual. As a result, they are closely related 
to the phenotype. Therefore, we also applied an NMR-based untargeted 
metabolomics approach to identify metabolites and metabolic pathways 
associated with the phenotypes after hesperidin consumption to 
understand the mechanisms underlying these phenotypes. We found a 
significant increase in plasma and urine levels of proline betaine after 
both the single dose study and sustained consumption of OJ and EOJ 
compared to CD. Proline betaine is a direct marker of citrus fruit intake 
and it reflects a good treatment adherence.(171) Moreover, the levels of 
leucine, valine and isoleucine were significantly decreased in the serum 
and urine samples collected after 12 weeks of sustained consumption of 
OJ and EOJ and after consumption of a single dose of OJ and EOJ, 
which supported the effect of hesperidin consumption independent of 
the dose. Valine, leucine and isoleucine are branched-chain amino acids 
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(BCAA) associated with several cardiometabolic risk factors such as 
insulin resistance,(125) obesity, atherogenic dyslipidaemia, elevated 
blood pressure,(172,173) and increased incident of CVDs events.(124) 
The effects of BCAA in general, and leucine in particular, on mTOR 
activation could partly explain these associations.(172,173) 
Intracerebroventricular administration of leucine has shown to active 
the mTORC1 signalling pathway specifically in the mice hypothalamus 
and cause a significant increase in arterial pressure.(174) In this sense, 
previous studies have reported elevated circulating leucine levels in 
hypertensive subjects.(175) Notably, the circulating levels of BCAA, 
and leucine in particular, were significantly decreased after 12 weeks of 
OJ or EOJ consumption compared to the CD. In addition, the urinary 
levels of 3-methyl-2-oxovalerate (3-MOV), a microbial-derived 
metabolite from leucine degradation, were also decreased after chronic 
consumption of both OJ and EOJ treatments. These findings could 
partly explain the decrease in systolic blood pressure that we observed 
in the participants consuming OJ or EOJ. Therefore, decreased plasma 
levels of BCAA could point to a possible protective role of hesperidin 
in OJ on hypertension.  
Another potential mechanism by which hesperidin could reduce 
systolic blood pressure involves an improvement of the inflammatory 
and oxidative stress status. We observed decreased serum and urine 
levels of N-acetyl glycoproteins (NAGs) after 12 weeks of OJ and EOJ 
consumption. NAGs is considered a novel biomarker of systemic 
inflammation and cardiovascular disease risk.(176) In addition, the 
levels of pseudouridine, a metabolite used as a biomarker of oxidative 
stress in DNA,(177) were decreased in the urine samples collected after 
12 weeks of OJ and EOJ consumption. Higher pseudouridine excretion 
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increases oxidative stress and inflammatory processes.(178) As a result, 
hesperidin in OJ and EOJ could improve the inflammatory state of 
subjects with pre- or stage 1 hypertension. Moreover, decreased plasma 
levels of GPC, which are related to decreases in oxidative and 
inflammatory tissue damage, were also observed after 12 weeks of OJ 
and EOJ consumption.(179) However, few studies have broadly 
discussed its role as a CVD risk factor. Therefore, decreased levels of 
NAG, pseudouridine and GPC, following hesperidin consumption 
reflects an improvement in the oxidative and inflammatory status of 
pre- and stage 1 hypertensive subjects, which could contribute to the 
amelioration of systolic blood pressure.  
 
Hesperidin consumption also resulted in significant alterations in 
choline metabolism. Choline is rapidly absorbed in the small intestine 
and catabolized to betaine. Betaine plays a pivotal role in the one-
carbon metabolism as a methyl-donor by reacting with homocysteine to 
generate methionine and DMG. However, gut bacteria compete with 
the host for choline. Hence, choline can be alternatively metabolized by 
the gut microbiota to TMA and dimethylamine (DMA), thereby 
depleting metabolites involved in one-carbon metabolism. Alterations 
in one-carbon metabolism has been related with metabolic diseases and 
hypertension-related health outcomes.(180)  Notably, OJ and EOJ 
participants had higher plasma levels of DMG and lower urinary 
excretions of DMA, which suggests a lower microbial metabolism of 
choline following hesperidin consumption, that could explain the 
improvement of systolic blood pressure in these patients.  
DMA is also a microbial-derived uremic toxin that has shown to 
contribute to CVD(181)  and is considered a potential uraemic 
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cardiovascular toxin according to the European Uraemic Toxin 
Working Group.(182) Other uraemic toxins, namely, 4-cresyl sulfate, 
creatinine and PAG, were significantly decreased in urine after OJ and 
EOJ consumption compared with their levels in the CD group. Lower 
serum levels of these toxins are beneficial to the cardiovascular and 
renal systems because the accumulation of their metabolites could 
produce vascular inflammation, endothelial dysfunction and vascular 
calcifications.(183) Moreover, PAG have also been negatively 
associated with systolic blood pressure (184) and with increased risk of 
incident of coronary artery disease.(185) In this sense, the lower urinary 
excretion of uraemic toxins observed after 12 weeks of OJ and EOJ 
consumption could be due to the minor serum levels derived from their 
lower production, which is likely related to an improvement in 
oxidative stress.(186) Thus, the lower oxidative stress obtained after OJ 
and EOJ consumption could result in the production of uraemic toxins. 
 
Additionally, our results suggest that the individual capacity of 
flavanone absorption is an important aspect to consider. We observed a 
large interindividual variability in flavanone absorption, as reported in 
the literature,(111) and identify high and low total flavanone absorbers 
regardless of their consumption of OJ or EOJ. We considered the 
maximum absorption values of total flavanones in all the samples 
regardless of their intervention group at the end of the single dose study 
(6 h) and found that the subjects who absorbed more flavanones showed 
significant changes in their proline betaine, 3-hydroxybutyrate, leucine, 
isoleucine, valine, lysine, and alanine levels compared with the levels 
found in the CD group. This subanalysis was performed because a large 
interindividual variability was observed after the single-dose study, 
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which resulted in the identification of high and low absorbers in the OJ 
and EOJ groups. Moreover, this large interindividual variability in the 
absorption of flavanones, which includes the group of phenolic 
compounds to which hesperidin belongs, could at least partly explain 
why similar and non-significant changes in biomarkers of the biological 
effects of hesperidin were observed after OJ and EOJ consumption, 
although the doses of hesperidin consumed were different. 
Consistently, the volunteers who participated in the single dose study 
(N = 52) and presented higher plasma levels of total flavanones, showed 
higher plasma levels of ketone bodies, such as 3-hydroxybutyrate and 
acetoacetate. The decrease in the activation of mTORC1 activity in the 
hypothalamus achieved with ketogenic diets and induced by ketone 
bodies plays a critical role in blood pressure control, which results in 
vasodilation and improvements in the blood pressure levels.(187) 
Therefore, this findings could indicate another possible mechanism 
through which hesperidin induced blood pressure improvements in 
subjects with pre- and stage 1 hypertension. 
Moreover, participants consuming hesperidin also excreted lower 
urinary amounts of 2-HIB compared to those consuming the CD. This 
metabolite is also a microbial-derived metabolites resulting from the 
degradation of dietary proteins.(188) Higher levels of 2-HIB have been 
identified in the urine of obese people and have been associated with a 
reduced microbiota diversity. Recently, 2-HIB has also been associated 
with an increased risk of type 2 diabetes.(189)  
 
In this sense, the present study has a limitation and it is that stool 
samples were not collected in the CITRUS randomized clinical trial, 
and the use of these type of samples would have provided more 
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information about metabolites related to microbiota, such as 2-HIB and 
PAG, and their relationship with the cardiovascular system. In contrast, 
the subanalysis performed considering the absorption of flavanones is 
a strength of the study because not all of the subjects have the same 
characteristics, such as their nutritional status, medication, and 
microbiota, which could influence the absorption of hesperidin by 
increasing or decreasing the bioavailability of hesperidin. Thus, 
whether high hesperidin levels in plasma exert a stronger effect than 
lower hesperidin levels should be investigated. Moreover, these results 
highlight the importance of volunteer stratification in clinical trials with 
hesperidin due to the large interindividual variability in flavanone 
absorption. 
 
In conclusion, the plasma and urine metabolite hesperetin 7-O-B-D-
glucuronide is the only metabolite that differentiated between responses 
to different hesperidin doses, while urine hesperetin 7-O-B-D-
glucuronide metabolite is correlated with low systolic blood pressure 
levels. In addition, independent of the hesperidin dose, the consumption 
of hesperidin in OJ and EOJ for 12 weeks has an impact on the serum 
metabolomic profile by decreasing the levels of endogenous 
metabolites related to blood pressure (leucine and isoleucine) and 
inflammation (NAGs). In contrast, hesperidin in OJ and EOJ can also 
decrease the urinary excretion of uraemic toxins (DMA, NAG and 4-
cresuyl sulfate) and endogenous metabolites suggesting an antioxidant 
effect (pseudouridine). Moreover, 6 h after the consumption of a single 
dose of hesperidin in OJ and EOJ, changes in the serum levels of 
metabolites related to reduced blood pressure levels and anti-
inflammatory effects (proline betaine, DMG, leucine and isoleucine) 
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were detected. Thus, the nontargeted metabolomics approach offered 
the possibility of identifying changes in different endogenous 
metabolites induced by hesperidin consumption that could indicate a 
beneficial cardiovascular effect of hesperidin and expand our 
knowledge regarding its potential mechanism of action or biological 
effects. 
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Table 1. Changes in plasma compliance biomarkers at 4, 8 and 12 weeks after treatments.  
Treatment Changes among treatments 
 Control drink OJ EOJ OJ vs Control drink EOJ vs Control drink EOJ vs OJ 
Variable  Post-int Change Post-int Change Post-int Change Mean  
(95% CI) 
P  Mean  
(95% CI) 
P  Mean  
(95% CI) 
P  
Hesperetin 7-O-B-D glucuronide, nM/L, (log)  
Week 4  1.26 ± 0.05 -0.032  
(-0.15;0.08) 













Week 8 1.23 ± 0.03 -0.031  
(-0.15;0.08) 













Week 12  1.21 ± 0.02 -0.048  
(-0.19;0.09) 













Hesperetin 3-O-B-D glucuronide, nM/L, (log)  
Week 4  0.50 ± 0.00 -0.049  
(-0.18;0.09) 














Week 8 0.54 ± 0.04 -0.06  
(-0.19; 0.18) 










<0.001 -0.217  
(-0.78;0.35) 
0.448 
Week 12  0.50 ± 0.00 -0.048  
(-0.18; 0.09) 















Hesperetin 7-O-sulfate, nM/L, (log)  




















































Naringerin 4-O-B-D glucuronide, nM/L, (log)  
Week 4  1.22 ± 0.00 -0.074 (-
0.22;0.07) 













Week 8 1.21 ± 0.03 -0.073 (-
0.14;0.08) 













Week 12  1.22 ± 0.00 -0.074 (-
0.22;0.07) 













Naringerin glucuronide, nM/L, (log)  
Week 4  1.24 ± 0.00 -0.074 
(-0.22;0.07) 













Week 8 1.21 ± 0.03 -0.073 
(-0.14;0.08) 















Week 12  1.22 ± 0.00 -0.074 
(-0.22;0.07) 













Naringerin sulfate, nM/L, (log)  

























































Data expressed as mean ± standard error or mean (95% confidence interval, CI). Intra treatment comparisons evaluated by General Lineal Model with Bonferroni correction and age and 
sex as covariables. Inter treatment comparisons by ANCOVA Model adjusted by sex and age. P<0.05. Abbreviations: Post-in, post-treatment values; Change, change from baseline; OJ, 









































Figure 1. Targeted metabolomics results in plasma samples after the single dose 
consumption of control drink, orange juice and hesperidin-enriched orange juice 










Table 2. Changes in urine of compliance biomarkers after sustained consumption of treatments (N=129). 
 Treatment Changes among treatments  
 CD OJ EOJ OJ vs CD EOJ vs CD EOJ vs OJ 
 Change  Post-int Change  Post-int Change  Post-int Median  
(25th-75th p) 
P Median  
(25th-75th p) 
P Median  
(25th-75th p) 
P 


































































































































           
Data expressed as median (25th-75th percentiles) /median (minimum-maximum) Intra-treatment comparisons by Wilcoxon test, * P<0.05; †P<0.005, ‡P<0.001. Inter-









Figure 2. Relationship between levels of hesperetin-7-O-β-d glucuronide in urine and 






















Figure 3. O-PLS coefficients plots for the nontargeted plasma metabolomics analyses after 
6-h of beverage consumption in the single dose study (N=52). (A) Orange juice vs control 
drink. (B) Hesperidin-enriched orange juice vs CD. (C) Maximal total flavanone 
concentration during the single dose study for each participant in the three treatment 
groups. (D) O-PLS coefficients plot considering the maximal total flavanone concentration 
as the response variable. Abbreviations: OJ, orange juice; DMG, dimethylglycine; EOJ, 



















Figure 4. O-PLS-DA coefficient plots for the plasma nontargeted metabolomics analyses at 
the end of the chronic study (N=52). (A) Orange juice vs Control Drink. (B) Hesperidin-
enriched orange juice vs Control Drink. Abbreviations: OJ, orange juice; GPC, 


















Figure 5. O-PLS-DA coefficient plots for the urine nontargeted metabolomics analyses at the 
end of the chronic study (N=129). (A) Orange juice vs Control Drink. (B) Hesperidin-
enriched orange juice vs Control Drink. Abbreviations: OJ, orange juice; PAG, 
phenylacetylglutamine; DMA, dimethylamine; NAG, N-acetylglycoproteins; EOJ, hesperidin-









Supplementary Information Methods S1 
 
Study population: 
Participants were recruited between January 2016 and June 2017 
thought social networks and newspapers in the Hospital Universitari 
Sant Joan of Reus (Spain). The inclusion criteria were adults from 18 
years to 65 years, with systolic blood pressure level ≥ 120 mm Hg and 
no family history of CVDs or other chronic diseases. The exclusion 
criteria were subjects with: body mass index ≥35 kg/m2, fasting glucose 
>125 mg/dL, hemoglobin ≤13 mg/dL in men and ≤12 mg/dL in women, 
systolic blood pressure ≥160 mm Hg and diastolic blood pressure >100 
mm Hg or taking anti-hypertensive medications, smoking, alcoholism, 
pregnancy, use of antioxidants or vitamin supplements, and following 
a vegetarian diet. 
 
All the volunteers signed the informed consent before their inclusion in 
the clinical trial. The randomized clinical trial received the approbation 
by the Clinical Research Ethical Committee of Hospital Universitari 
Sant Joan of Reus (14-12-18/12aclaassN1). The study was conducted 
in accordance with Helsinki Declaration and Good Clinical Practice 
Guidelines of the International Conference of Harmonization and was 
registered at Clinical-Trials.gov: NCT02479568.  
 
Study design: 
The study was a randomized, parallel, double-blind, and placebo-
controlled clinical trial. The subjects were randomly assigned by a 
computerized random-number generator to 1 group of the 3 intervention 
groups: control drink (CD), orange juice (OJ) and hesperidin-enriched 
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orange juice (EOJ). All the participants consume daily 500 mL of the 
corresponding test drink for 12 weeks, and 2 dose-responses studies 
were performed at baseline and after 12 weeks. Only in the baseline 















Supplemental Information Figure S2. Total absorption of flavanones in 
baseline conditions and at 2, 4 and 6 hours after each treatment. 





Supporting Information Table S1. Composition of the 3 test drinks. 
 Test drink (for 500 mL/day) 
 Control drink Orange juice Hesperidin-enriched 
orange juice 
Acidity, % 2.49 2.49 2.49 
Sugar, g 43.1 37.7 37.7 
Vitamin C, mg 235.3 235.3 235.3 
Citric acid, g 3.40 3.40 3.40 
Narirutin, mg ND 64 77 
Hesperidin, mg ND 392 670 
The 3 test drinks were in frozen concentrated canned drink, once diluted 3.4:1 (water to 






Supplementary Information Table S2. Results from the method validation for 
targeted metabolomics by UHPLC-MS/MS. 









H7G 20.9 62.8 10.8 
Hesperetin 3-O-beta-D-
glucuronide 
H3G 85.3 255.9 6.7 
Hesperetin 7-O-sulfate H7S 0.2 0.45 4.6 
Naringenin 4'-O-beta-D-
glucuronide 
N4G 51.4 154.1 10.1 
Naringenin-glucuronide NG - - 7.5 








Supplementary Information Table S3. Baseline characteristics of participants by intervention 
group. 
Variable CD (n=53) OJ (n=53) EOJ (n=53) P  
Age, y 45.4 ±13.0 43.3 ± 12.0    43.6 ± 11.8 0.629 
Females, % 34.0 32.1 34.0 0.981 
SBP, mm Hg 132 ± 9.94 132 ± 9.11 134 ± 9.82 0.687 
DPB, mm Hg 79 ± 8.14 80 ± 8.42 79 ± 10.2 0.868 
Pulse pressure, mm Hg 53 ± 9.09 52 ± 8.05 54 ± 6.74  0.261 
Weight, kg 77.3 ± 15.4 78.8 ± 12.2 75.9 ± 11.6 0.523 
BMI, kg/m2 26.1 ± 3.8 26.4 ± 3.6 26.1 ± 3.3 0.858 
Waist circumference, cm 93.0 ± 11.0 91.7 ± 10.9 91.4 ± 10.7 0.766 
Waist/height, cm 0.54 ± 0.06 0.53 ± 0.07 0.54 ± 0.07 0.790 
Conicity index 1.50 ± 0.76 1.30 ± 0.35 1.39 ± 0.62 0.269 
Glucose, mg/dL 91.6 ± 9.2 93.6 ± 11.6 93.6 ± 9.6 0.517 
Cholesterol, mg/dL     
  Total 196 ± 30.1 198 ± 32.7 196 ± 31.6 0.937 
   LDL 124 ± 26.4 125 ± 31.5 127 ± 25.1 0.900 
   HDL 50.9 ±13.4 51.0 ± 14.7 49.8 ± 13.0 0.889 
Triglycerides*, mg/dL 82 (67-118) 85 (65-121) 81 (63-116) 0.624 
Physical activity, A 3.08 ± 0.06 3.12 ± 1.38 3.12 ± 1.26 0.986 
Data are expressed as the mean ± standard deviation, or percentages. CD, control drink; OJ, orange juice; EOJ, hesperidin-
enriched orange juice; SBP, systolic blood pressure; DBP, diastolic blood pressure; Pulse pressure = SBP-DBP; BMI, body 
mass index; LDL, low-density lipoproteins; HDL, high-density lipoproteins * median (25th -75th percentiles). AU, arbitrary 
units: 0, inactive; 1, very low activity; 2, low activity; 3, moderately active; 4, very active. P for ANOVA with logarithmic 







Project 5: Proteomic analysis of heart and 
kidney tissues in healthy and metabolic 




























Proteomic Analysis of Heart and Kidney Tissues in Healthy
and Metabolic Syndrome Rats after Hesperidin
Supplementation
Laura Pla-Pagà, Maria Guirro, Andreu Gual-Grau, Albert Gibert-Ramos,
Elisabet Foguet-Romero, Úrsula Catalán, Jordi Mayneris-Perxachs,* Nuria Canela,
Rosa M. Valls,* Lluís Arola, Rosa Solà, and Anna Pedret
Scope: Proteomics has provided new strategies to elucidate the mechanistic
action of hesperidin, a flavonoid present in citrus fruits. Thus, the aim of the
present study is to determine the effects of hesperidin supplementation (HS)
on the proteomic profiles of heart and kidney tissue samples from healthy and
metabolic syndrome (MS) rats.
Methods and results: 24 Sprague Dawley rats are randomized into four
groups: healthy rats fed with a standard diet without HS, healthy rats
administered with HS (100 mg kg−1 day−1), MS rats without HS, and MS rats
administered with HS (100 mg kg−1 day−1) for eight weeks. Heart and kidney
samples are obtained, and proteomic analysis is performed by mass
spectrometry. Multivariate, univariate, and ingenuity pathways analyses are
performed. Comparative and semiquantitative proteomic analyses of heart
and kidney tissues reveal differential protein expression between MS rats with
and without HS. The top diseases and functions implicated are related to the
cardiovascular system, free radical scavenging, lipid metabolism, glucose
metabolism, and renal and urological diseases.
Conclusion: This study is the first to demonstrate the protective capacity of
hesperidin to change to the proteomic profiles in relation to different
cardiovascular risk biomarkers in the heart and kidney tissues of MS rats.
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1. Introduction
Diets rich in fruits and vegetables are
known to protect against cardiovascu-
lar diseases (CVDs),[1,2] which include
heart failure, stroke, and chronic kidney
diseases and are the leading cause ofmor-
tality worldwide.[3] Several studies have
aimed to elucidate the beneficial role of
bioactive compounds present in food,
such as phenolic compounds, which have
shown beneficial effects on different car-
diovascular risk factors (CVRFs)[4] and on
the prevention of CVDs,[5] to determine
their mechanisms of action and iden-
tify biomarkers of disease or treatment
response. In this sense, omics sciences
have gained attention since they can
provide important biological information
on many biomolecules. Proteomics, one
of the most common omics sciences
involves large-scale protein identifica-
tion to study the proteome of a tissue
or organ under certain conditions. In
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cardiovascular research, proteomics can help to elucidate the sig-
naling mechanisms involved in CVDs[6] and facilitate prevention
and drug development.[7]
In recent years, citrus, particularly orange and orange juice,
has been investigated in cardiovascular research. Citrus is
rich in polyphenols, mainly flavonoids, and lignans, with hes-
peridin (hesperetin-7-O-rutinoside) being the most abundant.
Hesperidin has been assessed in studies on rats and humans and
shown to have beneficial effects on several parameters related
to the cardiovascular system and the improvement of CVRFs,
such as decreasing blood pressure,[8–11] improving endothelium-
dependent vasodilation during hypertension,[12] decreasing to-
tal cholesterol and triglyceride levels,[13] improving glucose and
insulin levels and the homeostasis model assessment index,[14]
decreasing inflammatory markers,[9] decreasing kidney damage
markers,[15] and decreasing oxidative stress.[16]
However, proteomic analyses of the effects of citrus on health
are scarce. Some studies analyzed the orange proteome but only
for technological purposes.[17,18] To the best of our knowledge,
only one study performed an interventional analysis of orange
juice consumption in humans to evaluate the proteomic changes
in the peripheral blood mononuclear cells of healthy humans
after consumption of a high-fat and high-carbohydrate meal to
evaluate oxidative stress and inflammatory markers.[19] In this
study, orange juice suppressed diet-induced inflammation. Fur-
thermore, only one study evaluated the effects of hesperidin on
the proteomic profile of human HepG2 cells in relation to cell
death.[20] Therefore, no studies have examined the effects of hes-
peridin on the human or rat tissue proteome in relation toCVDor
CVRFs despite several publications reporting a beneficial effect of
hesperidin. Furthermore, the biological processes by which hes-
peridin can induce cardioprotective effects have not been eluci-
dated through proteomic analyses.
Therefore, the aim of this work was to determine the changes
in the proteomic profiles of heart and kidney tissues in healthy
and metabolic syndrome (MS) rats after hesperidin supplemen-
tation to shed light on the hesperidin mechanism of action.
2. Experimental Section
2.1. Animals and Experimental Design
The animal procedures were conducted in accordance with the
guidelines of the EU Directive 2010/63/EU for animal experi-
ments and approved by the Government of Catalonia and the
Animal Ethics Committee of the University Rovira i Virgili (num-
ber 10 061). 24 eight-week-oldmale SpragueDawley rats (Charles
River Laboratories, Wilmington, Massachusetts, USA) were ran-
domly assigned to one of the following four groups (n = 6 per
group): healthy rats fed a standard diet and supplemented with
milk as a vehicle (STDV), healthy rats fed a standard diet and
supplemented withmilk containing hesperidin (STDH),MS-rats
fed a cafeteria diet supplemented with milk as a vehicle (CAFV),
andMS-rats fed a cafeteria diet supplemented with milk contain-
ing hesperidin (CAFH); all of the treatments occurred over eight
weeks. The experimental design was the same as that described
by Guirro M et al.[21]
2.2. Dosage Information
Hesperidin was administered daily and orally via low-fat con-
densed milk over eight weeks at a dose of 100 mg kg−1 of body
weight per day. The rationale for choosing this dose was based on
the beneficial effects of hesperidin reported in previous works fo-
cused on MS factors in rat models.[14,22] Accordingly, the human
equivalent dose of 100 mg kg−1 hesperidin was 1350 mg per day
for a 60 kg human,[21,23] a dose achievable with hesperidin-rich
orange juice.
2.3. Kidney and Heart Proteomic Analysis
Heart and kidney tissue samples were obtained immediately after
the animals were sacrificed, snap-frozen in liquid nitrogen, and
stored at −80 °C until the analyses were performed.
2.3.1. Protein Extraction and Quantification
Sample tissue was weighed (25–30 mg) to perform cell lysis, re-
alized according to the radioimmunoprecipitation assay buffer
(RIPA) protocol (ThermoFisher Scientific, Barcelona, Spain).
First, the samples were frozen in liquid nitrogen for complete
lysis. The samples were thenmixed with 1mL of RIPA buffer, ho-
mogenized completely with a BlueBender via freeze thaw cycles,
agitated for 1 h at 4 °C, and centrifuged. After centrifugation, the
samples were sonicated with a 30 s pulse at 50% amplitude. The
samples were then centrifuged at 21 130 relative centrifugal force
for 15 min, and the supernatants were collected for protein pre-
cipitation with the addition of 10% trichloroacetic acid/acetone.
The protein pellets were resuspended in 6 m urea per 50 mm am-
monium bicarbonate and quantified by Bradford’s method.
2.3.2. Protein Digestion and Peptide 10-Plex Tandem Mass Tag
Labeling
Thirty micrograms of total protein was reduced with 4 mm 1.4-
dithiothreitol for 1 h at 37 °C and alkylated with 8 mm iodoac-
etamide for 30 min at 25 °C in the dark. Afterward, the sam-
ples were digested overnight (pH 8, 37 °C) with sequencing-grade
trypsin (Promega,Wisconsin, USA) at an enzyme:protein ratio of
1:50. Digestion was quenched by acidification with 1% v/v formic
acid, and peptides were desalted on an Oasis HLB SPE column
(Waters, California, USA) before TMT 10-plex labeling (Thermo
Fisher, Scientific, Massachusetts, USA) according to the manu-
facturer’s instructions.
For normalization of all samples in the study alongwith the dif-
ferent TMT-multiplexed batches, a pool containing all the sam-
ples was labeled with a TMT-126 tag and included in each TMT
batch. The different TMT 10-plex batches were desalted on Oasis
HLB SPE columns before nanoLC-MS analysis.
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2.3.3. Off Gel-NanoLC-(Orbitrap) MS/MS Analysis
Labeled and multiplexed samples were fractionated by off-gel
technology (Agilent, California, USA) according to the manufac-
turer’s protocol. Samples were fractioned on 12 cm non-linear
pH 3–10 strips in 12 fractions. Thus, fraction 1 (F1) was mixed
with fraction 7 (F7), F2 was mixed with F8, and this protocol
was repeated with all fractions. In total, 6 fractions were ob-
tained, and they were separated on a C-18 reversed-phase (RP)
nanocolumn (75 𝜇m I.D; 15 cm length; 3 𝜇m particle diameter,
Nikkyo Technos Co., Ltd., Japan) on an EASY-II nanoLCmade by
Thermo Fisher Scientific (Massachusetts, USA). The chromato-
graphic separation was performed with a 90-min gradient using
Milli-Q water (0.10% formic acid) and acetonitrile (0.10% formic
acid) as the mobile phase at a flow rate of 300 nL min−1.
Mass spectrometry analyses were performed on an LTQ-
Orbitrap Velos Pro made by Thermo Fisher via an enhanced
FT-resolution MS spectrum (R = 30 000 FHMW) followed by a
data-dependent FT-MS/MS acquisition (R = 15 000 FHMW, 40%
HCD) of the 10 most intense parent ions with a charge state re-
jection of one and a dynamic exclusion of 0.5 min.
2.3.4. Protein Identification and Quantification
Protein identification and quantification were performed with
Proteome Discoverer software v.1.4.0.288 (Thermo Fisher Sci-
entific, Massachusetts, USA) using multidimensional protein
identification technology, combining the six raw data files ob-
tained after off-gel fractionation. For protein identification, allMS
and MS/MS spectra were analyzed using the Mascot search en-
gine (v.2.5). Mascot was set up to search SwissProt_2018_03.fasta
database (557 012 entries), restricted to Rattus norvegicus tax-
onomy (8003 sequences) and assuming trypsin digestion. Two
missed cleavages were allowed, and errors of 0.02 Da for an
FT-MS/MS fragmentation mass and 10 ppm for an FT-MS par-
ent ion mass were allowed. TMT-10plex was set as the quan-
tification modification, oxidation of methionine and acetyla-
tion of N-termini were set as dynamic modifications, and car-
bamidomethylation of cysteine was set as the static modification.
For protein quantification, the ratios between each TMT-label
and the 126-TMT label were used, and quantification results were
normalized based on the protein median.
2.4. Statistical Analysis
The proteins present in ≥67% of the samples in the four groups
were considered for the statistical analysis. After the proteomic
analysis, the data were log base 2 transformed, mean centered,
and Pareto scaled. The multivariate statistical analysis was per-
formed using Metaboanalyst 4.0 (https://www.metaboanalyst.
ca/). The modeling included the use of unsupervised methods
such as principal component analysis (PCA), supervised meth-
ods such as partial least squares discriminant analysis (PLS-DA),
and an orthogonal projection to latent structures discriminant
analysis (OPLS-DA). For the univariate statistical analysis, the
distribution of normality was assessed by Kolmogorov-Smirnov
tests, and a t-test or a Wilcoxon test was performed for pairwise
comparisons. The proteins that were statistically significant in
univariate analysis with a p-value < 0.01 and a PLS-DA variable
importance on projection (VIP) score > 1.5 in multivariate anal-
ysis were considered differentially expressed between groups.
2.5. Pathway Analysis
The UniProt Database was used to obtain the gene symbols
and protein description (https://www.uniprot.org/). Ingenuity
pathway analysis (IPA; www.ingenuity.com) was used to ana-
lyze the protein networks via the statistically significant results
from both multivariate and univariate analyses for biological in-
terpretation. IPA was used to explore the possible metabolic cell




In previous studies,[21,24] the feeding of a cafeteria diet to Sprague
Dawley rats induced an obesogenic pattern with significant in-
creases in body weight and fat mass, elevated systolic blood
pressure, hypertriglyceridemia, hyperglycemia, and high levels
of low-density lipoprotein cholesterol (LDL-c), which are crite-
ria required for MS diagnosis. Consequently, when applying the
harmonized human definition of MS to Sprague Dawley rats
consuming a cafeteria diet, the rats exhibited a reflex of fat
mass, elevated triglyceride (TG) levels (drug treatment for ele-
vated TG is an alternate indicator), reduced high-density lipopro-
tein cholesterol (HDL-c) levels (drug treatment for reducedHDL-
c is an alternate indicator), elevated blood pressure (systolic or
diastolic (antihypertensive drug treatment in a person with a his-
tory of hypertension is an alternate indicator), and/or elevated
fasting plasma glucose levels (drug treatment of elevated glucose
is an alternate indicator).[25]
We also report that the consumption of hesperidin (100 mg
kg−1 body weight per day) for eight weeks improved lipid
metabolism and the insulin response and decreased the systolic
blood pressure in MS rats. In this sense, hesperidin supplemen-
tation can improve most of the MS criteria.[24]
3.2. Proteomic Analysis Results
From the proteomic analysis of heart and kidney tissue rat sam-
ples, 1127 and 1753 proteins were identified, respectively, and the
total proteins identified from each tissue are detailed in Tables
S1 and S2, Supporting Information. The tables contain informa-
tion on the protein IDs from UniProt, descriptions of the pro-
teins, coverage, unique peptides identified, total peptides iden-
tified, peptide-to-spectrum matches, molecular weights, and the
value for each protein.
3.2.1. Proteomic Analysis of Heart Rat Tissue
For statistical analyses only those proteins that were present
in ≥67% of the samples in the four groups were considered.
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After filtering, a total of 872 proteins were considered for statis-
tical analysis. The identified proteins with a p-value < 0.01 and a
VIP score from PLS-DA > 1.5 were considered significantly dif-
ferent between the STDV and STDH groups, and between the
CAFV and CAFH groups.
Hesperidin Effects in Healthy Rats Fed with a Standard Diet: In
multivariate analysis, no clear differences were observed between
the two STD treatment groups (STDV vs STDH) in the unsuper-
vised analysis. The supervised analysis showed that none of the
assessed models was significant due to the negative performance
measurement Q2, indicating that the models were not predictive
at all or were overfitted and that a random model would perform
better. Moreover, the univariate analysis showed no significant
differences between the treatment groups (STDV vs STDH) in
any of the 872 considered proteins.
Hesperidin Effects inMSRats Fed with a Cafeteria Diet: Inmul-
tivariate analysis, no clear differences between the two treatment
groups (CAFV vs CAFH) were observed in CAF rats from the un-
supervised analysis. The PLS-DA from the supervised analysis
showed that a model including one component provided the best
performance, as determined by the Q2 measure. However, after
permutation testing, the model was not found to be significant.
Nevertheless, a borderline significant model with a strong pre-
dictive ability (Q2Y = 0.58, p = 0.053) was obtained for the com-
parison between CAFH and CAFV rats. The univariate analysis
showed 65 differentially expressed proteins between CAF groups
with a p-value < 0.01.
The proteins with a p-value < 0.01 and a VIP score from PLS-
DA > 1.5 were considered to be differentially expressed between
the group without hesperidin supplementation (CAFV) and the
group with hesperidin supplementation (CAFH). A total of 35
proteins considered to be significantly different between the two
groups met the two criteria of univariate and multivariate analy-
ses. The information about the 35 proteins is detailed in Table 1.
In total, 19 proteinswere downregulated and 16were upregulated
after hesperidin treatment for eight weeks compared to those in
the CAFV group.
Pathway Analysis of the Heart Tissue Proteome: IPA analysis
was performed and the top signaling pathways that were sig-
nificantly affected after hesperidin supplementation were ob-
tained. The top five significant signaling pathways were: produc-
tion of nitric oxide and reactive oxygen species in macrophages
(p = 4.08E−04; ratio = 0.021), which involved: APOA4, APOC2,
CDC42, and RBP4; clathrin-mediated endocytosis signalling
(p = 4.50E−04; ratio = 0021), which involved: APOA4, APOC2,
CLTC, and RBP4; LXR/RXR activation (p = 1.07E−03; ratio =
0.028), atherosclerosis signaling (p = 1.19E−03; ratio = 0.027);
and FXR/RXR activation (p = 1.25E−03; ratio = 0.026) which in-
volved: APOA4, APOC2, and RBP4 in the last three canonical
pathways.
Network of the Heart Tissue Proteome: The top networks found
by IPAwere “Molecular transport, carbohydratemetabolism, and
small molecule biochemistry” (score = 16), “Cardiac arrhyth-
mia, cardiovascular disease, and metabolic disease” network
(score = 2), and “Cancer, cardiovascular disease, and cell cycle”
(score = 2). The graphical representation of the top overlapping
networks and the up- and downregulated proteins, symbolized
in red or green, respectively, is shown in Figure 1. The proteins
implicated in the top networks after hesperidin treatment for
eight weeks were: APOA4, SOD1, ATP5F1D, ATPA1A, SLC27A1,
SLC25A3, OGDH, FLNA, ALDH7A1, CLTC, and CDC42. The
other proteins implicated in the top networks related to the pro-
teins analyzed in the present study were: IL-1B, LAMC1, TNF,
KCNJ11, ATP1B1, OTOF, SLC1A2, AP2B1, EPB41L2, GRM4,
CACNA1B, F11R, TNFRSF1B, KCNJ2, CPT1A, PIN, MYO1C,
PP2A, PRKCD, STAT3, NEFH, ITSN1, SRC, ABR, PRKCZ,
CAMKII, FILIP1, AR, RCAN1, GSK3B, NFKB complex, and
SIPI.
3.2.2. Proteomic Analysis of Kidney Rat Tissue
After filtering, a total of 1341 proteins were considered for
the statistical analysis of kidney tissue samples. The identi-
fied proteins with a p-value < 0.01 and a VIP score from PLS-
DA > 1.5 were considered significantly different between the
STDV and STDH groups, and between the CAFV and CAFH
groups.
Hesperidin Effects in Healthy Rats Fed a Standard Diet: From
the multivariate analysis no clear separation between the two
STD groups (STDV versus STDH) was evident from the un-
supervised or supervised analysis. From the univariate anal-
ysis, no statistically significant proteins were observed be-
tween the two STD groups among any of the 872 considered
proteins.
Hesperidin Effects in MS Rats Fed a Cafeteria Diet: From un-
supervised analysis, a clear separation between the two CAF
groups (CAFV versus CAFH) was evident from the PCA, al-
though it was not very clear in the hierarchical clustering anal-
ysis. A PLS-DA from the supervised analysis showed that a
model including one component provided the best performance,
as determined by the Q2 measurement. The OPLS-DA analy-
sis showed a significant model with a strong predictive abil-
ity (Q2Y = 0.70, p = 0.046) for the comparison between CAFH
and CAFV rats. The univariate analysis showed 75 proteins that
were differentially expressed between the two CAF groups with a
p-value < 0.01.
The proteins with a p-value < 0.01 and a VIP score from PLS-
DA > 1.5 were considered to be differentially expressed between
the groups with and without hesperidin supplementation. A to-
tal of 53 proteins were considered to be significantly different be-
tween the two groups met the two criteria from univariate and
multivariate analyses. The information on the 53 proteins is de-
tailed in Table 2. In total, 33 proteins were downregulated and
20 were upregulated after hesperidin treatment for eight weeks
compared to those in the CAFV group.
Pathway Analysis of the Kidney Tissue Proteome: IPA analysis
was performed and the top signaling pathways that were signifi-
cantly affected in kidney tissue after hesperidin supplementation
were obtained. The top five significant signaling pathways were:
mitochondrial dysfunction (p = 4.65E−06; ratio = 0.039), which
involved ATP5PF, COX6B1, CPT1A, OGDH, TXN2, and VDAC3;
the sirtuin signalling pathway (p = 9.37E−05; ratio = 0.023),
which involved: ATP5PF, CPT1A, HIST2H3C, SOD1, TIMM8B,
and VDAC3; xanthine and xanthosine salvage (p = 2.82E−03;
ratio = 1), guanine and guanosine salvage I (p = 5.62E−03;
ratio = 0.5); and adenine and adenosine salvage I (p = 5.62E−03;
ratio = 0.5), which involved PNP.
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Table 1. 35 proteins differentially expressed in heart tissue after hesperidin treatment in CAFH compared to CAFV rats.
UniProt code Gene symbol Protein description MW [kDa] Univariate analysis Multivariate analysis
FC p-valuea) VIPb)
M0RDK9 ACAD8 Acyl-CoA dehydrogenase family, member 8 45.10 1.4409 0.0044 1.8469
F1LN92 AFG3L2 AFG3-like matrix AAA peptidase subunit 2 89.30 1.3967 0.0060 1.7448
Q64057 ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 58.70 1.2888 0.0004 1.6283
P02651 APO A4 Apolipoprotein A-IV 44.40 −1.5095 0.0093 1.9047
P19939 APO C1 Apolipoprotein C-I 9.90 1.7180 0.0033 2.2661
G3V8D4 APO C2 Apolipoprotein C-II 10.70 −1.8310 0.0006 2.4926
P06685 ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 113.00 1.3297 0.0020 1.6668
G3V7Y3 ATP5F1D ATP synthase subunit delta, mitochondrial 17.60 −1.3813 0.0047 1.7317
D4A305 CCDC58 Coiled-coil domain containing 58, isoform CRA_c 16.70 1.7327 0.0065 2.2324
Q8CFN2 CDC42 Cell division control protein 42 homolog 21.20 1.2746 0.0025 1.5289
Q5XIM5 CDV3 Protein CDV3 homolog 24.30 −1.6055 0.0040 2.1074
M0RC65 CFL2 Cofilin 2 18.70 −1.3380 0.0054 1.635
F1M779 CLTC Clathrin heavy chain 191.40 1.2960 0.0024 1.5829
Q5BJQ0 COQ8A Atypical kinase COQ8A, mitochondrial 72.20 −1.2667 0.0012 1.5373
P11240 COX5A Cytochrome c oxidase subunit 5A, mitochondrial 16.10 −1.5030 0.0056 1.9324
P60841 ENSA Alpha-endosulfine NA −1.2770 0.0034 1.5225
C0JPT7 FLNA Filamin A 280.30 1.5440 0.0007 2.1071
D3ZT90 GCDH Glutaryl-CoA dehydrogenase 49.70 1.2996 0.0050 1.5552
Q5I0P2 GCSH Glycine cleavage system H protein, mitochondrial 18.50 −1.5136 0.0097 1.9064
D4ADD7 GLRX5 Glutaredoxin 5 16.40 −1.2978 0.0019 1.5977
D4A4L5 ISCA2 Iron-sulfur cluster assembly 2 16.70 −1.3870 0.0098 1.6936
G3V6P7 MYH9 Myosin, heavy polypeptide 9, nonmuscle 226.30 1.8328 0.0019 2.4356
A0A0G2KAQ5 MYOZ2 Myozenin 2 29.80 −1.4006 0.0084 1.7298
Q5XI78 OGDH 2-oxoglutarate dehydrogenase, mitochondrial 116.20 1.3004 0.0043 1.5656
P04916 RBP4 Retinol-binding protein 4 23.20 −1.3708 0.0037 1.7246
G3V8R0 RGD1311703 Similar to sid2057p 19.90 −1.5060 0.0053 1.9425
F1LSW7 RPL14 60S ribosomal protein L14 23.30 1.3440 0.0021 1.6981
Q6IRH6 SLC25A3 Phosphate carrier protein, mitochondrial 39.60 1.3677 0.0098 1.5331
P97849 SLC27A1 Long-chain fatty acid transport protein 1 71.20 1.2016 0.0037 1.5028
P07632 SOD1 Superoxide dismutase[Cu-Zn] 15.90 −1.39760 0.0040 1.7717
P62078 TIMM8B Mitochondrial import inner membrane translocase subunit Tim8 B 9.30 −1.5168 0.0073 1.9335
P62074 TIMM10 Mitochondrial import inner membrane translocase subunit Tim10 10.30 −1.2840 0.0043 1.5285
Q5XIK2 TMX2 Thioredoxin-related transmembrane protein 2 33.80 1.4949 0.0031 1.9565
B0K010 TXNDC17 Thioredoxin domain-containing 17 14.10 −1.3020 0.0052 1.5612
Q5M9I5 UQCRH Cytochrome b-c1 complex subunit 6 mitochondrial 10.40 −1.4631 0.0037 1.8937
CAFH, metabolic syndrome rats with hesperidin supplementation; CAFV, metabolic syndrome rats without hesperidin supplementation; MW, molecular weight; FC, fold
change; NA, not available. a)Results from Wilcoxon tests and t-test. A p-value < 0.01 was considered statistically significant. b)VIP score was from PLS-DA.
Network of the Kidney Tissue Proteome: The top network found
by IPA was “Cellular compromise, free radical scavenging, cell
death, and survival” (score = 14), followed by “Cell death and
survival, free radical scavenging, organismal injury, and abnor-
malities” (score = 6), and “Cardiovascular system development
and function, immunological disease, inflammatory disease”
(score = 1). The overlapping graphical representation of the two
more important networks “Cellular compromise, free rad-
ical scavenging, cell death, and survival” and “Cardiovas-
cular system development and function, immunological
disease, inflammatory disease”, as well as the up- and
downregulated proteins (in red and green, respectively) are
represented in Figure 2. The proteins implicated in the top
networks after hesperidin treatment for eight weeks were
EPB41L3, TXN2, SOD1, TPM3, NUCB2, VDAC3, MYO1D,
SLC25A3, OGDH, CPT1A, MME, CDC42, ABCG2, and RACK1.
The other proteins implicated in the top networks related
to the proteins analyzed in the present study were TNF,
AGT, INSULIN, OTOF, SLC27A1, FRIN2B, TPM1, CD36,
ITGB1, KCNJ11, CHMP2B, PLEC, KRT8, TPM2, MAPK14,
HSPA5, PRKCZ, PAR6, NCF1, ERN1, EIF2AK3, CTSV, and
TP53.
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Figure 1. Graphical representation of the top networks of the heart tissue proteome after hesperidin supplementation. Interaction between the differen-
tially expressed proteins and other important proteins. Down- and upregulated proteins are symbolized in red and green, respectively. ABR, active break-
point cluster region-related protein; ALDH7A1, aldehyde dehydrogenase 7 family member 1; AP2B1, AP-2 complex subunit beta; APOA4, apolipoprotein
A4; ATP1A1, ATPase Na+/K+ transporting subunit alpha 1; ATP1B1, sodium/potassium-transporting ATPase subunit beta-1; ATP5F1D, ATP synthase
F1 subunit delta; CACNA1B, voltage-dependent N-type calcium channel subunit alpha-1B; CAMKII, calcium/calmodulin-dependent protein kinase type
II alpha chain; CDC42, cell division cycle 42; CLTC, clathrin heavy chain; CPT1A, carnitine palmitoyltransferase 1A; EPB41L2, erythrocyte membrane
protein band 4.1-like 2; F11R, junctional adhesion molecule A; FILIP1, filamin-A-interacting protein 1; GRM4, metabotropic glutamate receptor 4; IL1B,
interleukin-1 beta; ITSN1, intersection-1; FLNA, filamin A; KCNJ11, ATP-sensitive inward rectifier potassium channel 11; KCNJ2, inward rectifier potas-
sium channel 2; LAMC1, laminin subunit gamma 1; MYO1C, unconventional myosin-Ic; NEFH, neurofilament heavy polypeptide; NFKB, nuclear factor
NF-kappa-B p105 subunit; OGDH, oxoglutarate dehydrogenase; OTOF, otoferlin; PIN, peptidyl-propyl cis-trans isomerase NIMA-interacting 1; PP2A,
serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform; PRKCD, protein kinase C delta type; SRC, proto-oncogene tyrosine-
protein kinase Src; PRKCZ, protein kinase C zeta type; RCAN1, calcipressin-1; GSK3B, glycogen synthase kinase-3 beta; SIPI, secretory leukocyte protease
inhibitor; AR, androgen receptor; SLC1A2, excitatory amino acid transporter 2; SLC25A3, solute carrier family 25member 3; SLC27A1, long-chain fatty acid
transport protein 1; SOD1, superoxide dismutase 1; STAT3, signal transducer and activator of transcription 3; TNF, tumor necrosis factor; TNFRSF11B,
tumor necrosis factor receptor superfamily member 11B. Figure reproduced with permission under the terms of the CC-BY 4.0 license. Copyright 2019,
QIAGEN Silicon Valley.
3.3. Top Diseases and Functions Determined from the Heart and
Kidney Tissue Proteomes
Table 3 details the top relevant diseases and functions involving
the significant proteins in both heart and kidney tissues. The top
categories are the cardiovascular system, free radical scavenging,
lipid metabolism, glucose metabolism, and renal and urological
diseases.
4. Discussion
The current study presents the effects of hesperidin supplemen-
tation of 100 mg kg−1 body weight per day for eight weeks on
the proteomic profiles of heart and kidney tissues in rats with or
without MS. Proteomic analysis revealed significant changes in
the proteomic profiles of MS rats fed a cafeteria diet with and
without hesperidin supplementation in both tissues after eight
weeks.
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Table 2. 53 proteins differentially expressed in kidney tissue after hesperidin treatment in CAFH compared to CAFV rats.
UniProt code Gene symbol Protein description MW [kDa] Univariate analysis Multivariate analysis
FC p-valuea) VIPb)
Q80W57 ABCG2 ATP-binding cassette subfamily G member 2 72.90 1.2570 0.0031 1.6966
Q6P2A5 AK3 GTP:AMP phosphotransferase AK3, mitochondrial 25.50 −1.2561 0.0094 1.7174
Q9WUC4 ATOX1 Copper transport protein ATOX1 7.30 −1.2888 0.0021 1.8082
Q03344 ATP5IF1 ATPase inhibitor, mitochondrial 12.20 −1.3651 0.0005 2.0549
P21571 ATP5PF ATP synthase−coupling factor 6, mitochondrial 12.50 −1.6119 0.0028 2.4703
B2GUV5 ATP6V1G1 V−type proton ATPase subunit G 13.70 −1.4949 0.0014 2.2956
Q5I0M1 APO H Apolipoprotein H 38.40 −1.5042 0.0008 2.3359
F1LRS8 CD2AP CD2−associated protein 70.40 −1.2746 0.0088 1.6887
D3ZD09 COX6B1 Cytochrome c oxidase subunit 10.10 −1.4006 0.009 1.9883
P32198 CPT1A Carnitine O−palmitoyltransferase 1, liver isoform 88.10 1.4794 0.0043 2.1983
P97829 CD47 Leukocyte surface antigen CD47 33.00 1.2059 0.0038 1.5247
Q8CFN2 CDC42 Cell division control protein 42 homolog 21.20 1.2033 0.0033 1.5261
D3ZUX5 CHCHD3 MICOS complex subunit 26.40 −1.3168 0.0022 1.8771
A0A0H2UHL6 CTSH Pro−cathepsin H 32.90 −1.6982 0.0038 2.5675
P07154 CTSL Cathepsin L1 37.60 1.5305 0.0035 2.3057
Q68FR9 EEF1D Elongation factor 1−delta 31.30 −1.2527 0.0035 1.6775
A3E0T0 EPB41L3 Erythrocyte membrane protein band 4.1−like 3 96.90 −1.5757 0.0065 2.3375
P80299 EPHX2 Bifunctional epoxide hydrolase 2 62.30 4.2663 0.0087 4.1318
C0JPT7 FLNA Filamin A 280.30 1.2067 0.005 1.5157
P19468 GCLC Glutamate-cysteine ligase catalytic subunit 72.60 1.3370 0.0008 1.9709
D3ZK97 H3F3C Histone H3 15.30 1.2772 0.0097 1.691
F1M9B2 IGFBP7 Insulin-like growth factor binding protein 7, isoform CRA_b 28.90 −1.6947 0.0024 2.593
D4A4L5 ISCA2 Iron-sulfur cluster assembly 2 16.70 −1.3918 0.0055 2.0032
B2RZ79 ISCU Iron-sulfur cluster assembly enzyme 18.00 −1.3077 0.0013 1.8767
D3ZCZ9 LOC100912599 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6,
mitochondrial
13.00 −1.2978 0.0037 1.8041
Q562C6 LZTFL1 Leucine zipper transcription factor-like protein 1 34.60 −1.5810 0.0012 2.4546
D3Z900 MARC2 Mitochondrial amidoxime reducing component 2 38.20 1.2501 0.0009 1.7259
A0A0H2UHX5 MME Neprilysin 78.60 1.2870 0.0062 1.745
Q63357 MYO1D Unconventional myosin-Id 116.00 1.4044 0.0072 2.0134
G3V8R1 NUCB2 Nucleobindin 2. isoform CRA_b 50.10 −1.3538 0.0042 1.9359
Q5XI78 OGDH 2-oxoglutarate dehydrogenase, mitochondrial 116.20 1.2142 0.0003 1.6381
P51583 PAICS Multifunctional protein ADE2 47.10 1.4550 0.0078 2.1091
D3ZD40 PAPLN Papilin. proteoglycan-like sulfated glycoprotein 138.50 −1.4040 0.0046 2.0433
B0BN18 PFDN2 Prefoldin subunit 2 16.60 −1.2527 0.0065 1.6467
P85973 PNP Purine nucleoside phosphorylase 32.30 1.3718 0.0005 2.0718
P10960 PSAP Prosaposin 61.10 −1.4641 0.0057 2.151
P63245 RACK1 Receptor of activated protein C kinase 1 35.10 1.2130 0.0005 1.6195
Q6TXG7 SHMT1 Serine hydroxymethyltransferase 75.30 1.2142 0.0042 1.5493
F1LZW6 SLC25A13 Solute carrier family 25 member 13 54.10 1.2303 0.0023 1.6277
G3V741 SLC25A3 Phosphate carrier protein. mitochondrial 39.50 1.2050 0.0057 1.5022
Q9JJ19 SLC9A3R1 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 38.80 −1.2588 0.0093 1.6398
G3V6D9 SLC9A3R2 Na(+)/H(+) exchange regulatory cofactor NHE-RF 37.30 −1.2467 0.0061 1.6295
P07632 SOD1 Superoxide dismutase[Cu-Zn] 15.90 −1.5801 0.0036 2.3891
A0A0G2K9 × 1 SPP2 Secreted phosphoprotein 24 14.90 −1.5094 0.004 2.2601
O70257 STX7 Syntaxin-7 28.80 −1.3122 0.0085 1.7901
P62078 TIMM8B Mitochondrial import inner membrane translocase
subunit Tim8 B
9.30 −1.5241 0.0058 2.2588
Q63610 TPM3 Tropomyosin alpha-3 chain 29.00 −1.4241 0.0036 2.1009
(Continued)
Mol. Nutr. Food Res. 2020, 64, 1901063 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901063 (7 of 12)
www.advancedsciencenews.com www.mnf-journal.com
Table 2. Continued.
UniProt code Gene symbol Protein description MW [kDa] Univariate analysis Multivariate analysis
FC p-valuea) VIPb)
P09495 TPM4 Tropomyosin alpha-4 chain 28.50 −1.3918 0.0056 2.0044
P63029 TPT1 Translationally controlled tumor protein 19.40 −1.4459 0.0027 2.163
P97615 TXN2 Thioredoxin. mitochondrial 18.20 −1.3698 0.0075 1.9353
Q5M9I5 UQCRH Cytochrome b-c1 complex subunit 6, mitochondrial 10.40 −1.4015 0.0027 2.0703
Q9Z269 VAPB Vesicle-associated membrane protein-associated protein B 26.90 −1.3168 0.0097 1.7924
A0A0G2JSR0 VDAC3 Voltage-dependent anion-selective channel protein 3 30.80 1.2226 0.0006 1.6488
CAFH, metabolic syndrome rats with hesperidin supplementation; CAFV, metabolic syndrome rats without hesperidin supplementation; MW, molecular weight; FC, fold
change. a)Results from Wilcoxon tests and t-tests. A p-value < 0.01 was considered statistically significant. b)VIP score was from PLS-DA.
In the heart tissues of MS rats, 35 proteins were differentially
expressed: 19 proteins were downregulated and 16 were upregu-
lated.Moreover, in the kidney tissues ofMS rats, 53 proteins were
differentially expressed: 33 proteins were downregulated and 20
were upregulated.
Currently, there are no data on the effects of hesperidin
polyphenol on the proteomes of heart and kidney tissues in
healthy or MS rats. However, several studies have shown that
polyphenols, such as resveratrol found in red wine and grapes
and secoiridiods and hydroxytyrosol present in olive oil, can
change the proteomes of cells, in rats and humans, improving
different cardiovascular risk parameters such as inflammation,
cholesterol homeostasis, oxidation, and blood coagulation.[26–28]
Our results suggest that, in MS rats, hesperidin supplementa-
tion could exert cardioprotective effects by upregulating the ex-
pression of proteins related to the cardiovascular system such
as ATP1A1 (1.32-fold). ATP1A1, found in heart tissue, is asso-
ciated with ischemic acute renal failure when it is downregu-
lated and with a decrease in blood pressure levels when it is
upregulated.[29] In addition, hesperidin can be cardioprotective
by downregulating the expression levels of proteins known to af-
fect blood pressure, such as ATP5PF (−1.61-fold), which is found
in kidney tissue and related to vasoconstriction, hypertension,
and cardiac hypertrophy in rats and humans.[30,31] Another re-
lated protein that appeared to be downregulated in the kidney
tissues of MS rats was TPT1 (−1.44-fold). TPT is implicated in
the pathogenesis of atherosclerosis and pulmonary artery hyper-
tension to prevent macrophage apoptosis in the artery intima.[32]
IGFBP7 was also downregulated by hesperidin in kidney tissue
(−1.69-fold). At high concentrations, this molecule is related to
poor diastolic function and ventricular systolic pressure. Thus,
elevated IGFBP7 levels could be a biomarker of diastolic dysfunc-
tion and functional capacity in humans with heart failure.[33]
Moreover, our findings suggest that hesperidin could also ex-
ert cardioprotective effects inMS rats by upregulating the expres-
sion levels of proteins related to free radical scavenging, such as
ALDH7A1 (1.28-fold). ALDH7A1, found in heart tissue, protects
cells against oxidative stress by metabolizing lipid peroxidation-
derived aldehydes produced during oxidative stress and xeno-
biotics metabolism.[34] During lipid peroxidation, large quanti-
ties of aldehydes are produced, and they can covalently bind to
proteins and DNA, inactivating different proteins and damaging
DNA. However, aldehydes are related to several diseases, such
as atherosclerosis.[35] In the heart and kidney tissues of MS rats,
another protein upregulated by hesperidin was FLNA, a large
cytoplasmic protein (1.54-fold in heart tissue and 1.20-fold in
kidney tissue). FLNA can promote or suppress cell processes
important for heart development.[36] FLNA is downregulated in
rats with coronary microembolization,[37] and the lack of FLNA
demonstrates its importance duringmorphogenesis of several or-
gans, such as the heart; the lack of FLNA can result in cardiovas-
cular malformations.[38] Moreover, the lack of editing in FLNA
increased RhoA/Rock and PLC/PKC signaling, increased aortic
hypercontraction and induced cardiomyocyte hypertrophy, in-
creasing the diastolic blood pressure.[39]
Our results suggested that hesperidin downregulated CD2AP
inducing changes in the expression of proteins related to glu-
cose metabolism. CD2AP, a cytosolic protein that interacts with
signaling molecules,[40] was downregulated in the kidney tis-
sues (−1.27-fold) of MS rats. Evidence suggests that high lev-
els of CD2AP increase the risk of renal disease in patients
with diabetes.[41] Another differentially expressed and upregu-
lated protein in kidney tissue was EPHX2 (4.26-fold). Decreased
EPHX2 expression is related to increased insulin sensitivity in
humans with MS.[42] Accordingly, hesperidin supplementation
could exert preventive effects on glucose metabolism in MS rats,
but the effects of hesperidin intake on humans with CVRFs such
as diabetes and MS need to be confirmed.
Although the present study showed that hesperidin supple-
mentation can change the proteomic profile to exert positive ef-
fects on different parameters in MS rats, some differentially ex-
pressed proteins showed negative effects. For example, in MS
rats, the following two antioxidant proteins were downregu-
lated: SOD1 (−1.39-fold in heart tissue; 1.58-fold in kidney tis-
sue) and TXN2 (−1.36-fold in kidney tissue), which likely de-
creased the protection against oxidative stress in MS rats. In
addition, SLC9A3R1 was downregulated in kidney tissue (−1.25-
fold). Decreased expression of SLC9A3R1 was found in hyper-
tensive rats,[43] indicating that hesperidin supplementation does
not exert a beneficial effect on it, at least not by this pathway.
However, in MS rats, some proteins related to lipid metabolism
were downregulated in the heart, such as APOA4 (−1.50-fold)
and APOC2 (−1.83-fold). APOA4 increases triglyceride pro-
duction and reduces hepatic lipids;[44] therefore, a decrease in
its expression would be expected to interfere with the cor-
rect absorption and elimination of dietary fats. However, actual
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Figure 2. Graphical representation of the top networks of the kidney tissue proteome after hesperidin supplementation. Interaction between the dif-
ferentially expressed proteins and other important proteins. Down- and upregulated proteins are symbolized in red and green, respectively. ABCG2,
ATP binding cassette subfamily G member 2; AGT, angiotensinogen; CD36, CD36 molecule (trombospondin receptor); CDC42, cell division cycle 42;
CHMP2B, charged multivesicular body protein 2B; CPT1A, carnitine palmitoyltransferase 1A; CTSV, cathepsin V; EIF2AK3, eukaryotic translation initi-
ation factor 2-alpha kinase 3; EPB41IL3, erythrocyte membrane protein band 4.1-like 3; ERN1, endoplasmic reticulum to nucleus-signaling 1; GRIN2B,
glutamate receptor ionotropic NMDA 2B; HSPA5, endoplasmic reticulum chaperone BiP; ITGB1, integrin beta-1; KCNJ11, ATP-sensitive inward rectifier
potassium channel 11; KRT8, keratin type II cytoskeletal 8; MAPK14, mitogen-activated protein kinase 14; MME, neprilysin; MYO1D, unconventional
myosin-Id; NCF1, neutrophil cytosolic factor 1; NUCB2, nucleobindin 2; OGDH, oxoglutarate dehydrogenase; OTOF, otoferlin; PAR6, partitioning de-
fective 6 homolog alpha; PLEC, plectin; PRKCZ, protein kinase C zeta type; RACK1, receptor of activated protein C kinase 1; SLC25A3, solute carrier
family 25 member 3; SLC27A1, solute carrier family 27 member 1; SOD1, superoxide dismutase 1; TNF, tumor necrosis factor; TP53, cellular tumor
antigen o53; TPM1, tropomyosin alpha-1 chain; TPM2, tropomyosin beta chain; TPM3, tropomyosin alpha-3 chain; TXN2, thioredoxin mitochondrial;
VDAC3, voltage-dependent anion-selective channel protein 3. Figure reproduced with permission under the terms of the CC-BY 4.0 license. Copyright
2019, QIAGEN Silicon Valley.
evidence has demonstrated that decreased levels of APOA4 in-
crease the chylomicron size, delaying its clearance from the blood
and indicating it is not required for triglyceride absorption in
the mouse intestine.[45] Thus, more studies of hesperidin sup-
plementation are needed to clarify these effects on the proteomic
profile.
Additionally, in MS rats after administered hesperidin sup-
plementation, some of the proteins differentially expressed in
the heart and kidney tissues were related to cancer. In the heart
tissues of MS rats, CCDC58 and SLC25A3 were upregulated
(1.73-fold and 1.36-fold, respectively). CCDC58 is a biomarker
of breast, endometrial, and urethral cancer, and SLC25A3 is
Mol. Nutr. Food Res. 2020, 64, 1901063 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901063 (9 of 12)
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Table 3. Top diseases and functions determined by heart and kidney tissue proteomic analyses in CAFH compared to CAFV rats.
Categories Heart tissue proteins Kidney tissue proteins
Cardiovascular system Development of neointima – ↓TPT1
Blood pressure – ↓ATP5PF, ↑EPHX2, ↓SOD1
Density of microvessel – ↑EPHX2
Angiogenesis – ↑Cdc42, ↑EPHX2, ↓TPT1
Binding of endothelial cells – ↑CD47
Sprouting angiogenesis ↑Cdc42 ↑CDC42
Heart rate ↑ATP1A1, ↓SOD1 –
Ischemic acute renal failure ↑ATP1A1 –
Free radical scavenging Metabolism, removal, and quantity of
superoxide
↓SOD1 ↓SOD1
Biosynthesis of hydrogen peroxide ↓SOD1 –
Lipid metabolism Fatty acid metabolism
↑OGDH, ↓APOA4, ↑APOC1, ↑GCDH,
↓RBP4, ↑SLC27A1
↑OGDH, ↓APOH, ↓ATP5PF, ↑CPT1A,
↑EPHX2, ↓IGFBP7
Transport of lipid ↓APOA4, ↑APOC1, ↓RBP4, ↑SLC27A1 –
Metabolism of lipoprotein ↑APOC1 –
Synthesis of epoprostenol – ↓ATP5PF, ↓IGFBP7
Synthesis of prostaglandin – ↓ATP5PF, ↑EPHX2, ↓IGFBP7
Binding of eicosapentenoic acid and
malonyl-coenzyme A
– ↑CPT1A
Beta-oxidation of oleic acid – ↑CPT1A
Transport of triacylglycerol – ↓APOH
Quantity of long-chain acyl-coenzyme A – ↑CPT1A
Metabolism of succinyl-coenzyme A ↑OGDH ↑OGDH
Accumulation of triacylglycerol – ↑CPT1A
Oxidation of fatty acid ↑GCDH, ↑SLC27A1 ↑CPT1A, ↓NUCB2
Metabolism of long chain fatty acids – ↑CPT1A
Esterification, transport and oxidation of
palmitic acid
↑SLC27A1 ↑CPT1A
Synthesis and metabolism of acyl-coenzyme A ↑GCDH, ↑OGDH –
Transport of retinol ↓RBP4 –
Glucose metabolism Insulin sensitivity index – ↓NUCB2
Secretion of glucagon – ↓NUCB2
Renal and urological disease Nephrosis ↑CLTC –
Apoptosis of kidney cells ↑ATP1A1, ↑CDC42 –
CAFH, metabolic syndrome rats with hesperidin supplementation; CAFV, metabolic syndrome rats without hesperidin supplementation; —, no protein identified; ↑, protein
upregulated; ↓, protein downregulated.
overexpressed in cervical carcinomas.[46] In the kidney tissues
of MS rats, the proteins UQCRH and LZTFL1 were downregu-
lated (−1.40-fold and −1.58-fold, respectively). In the literature,
UQCRH overexpression is associated with a poor prognosis for
lung cancer and hepatocellular carcinoma patients.[47,48] Finally,
LZTFL1 is a tumor suppressor and an independent prognos-
tic marker for the survival of gastric cancer patients when it
is elevated.[49] In this sense, several studies in cancer models
have shown that hesperidin can delay cell proliferation,[50] in-
hibit cell viability, and induce apoptosis in cancer cells.[51] There-
fore, studies of hesperidin supplementation in rats with cancer
and its effects on the proteome are needed to provide more ro-
bust evidence and to clarify whether hesperidin could be a tumor
suppressor.
The present study has several limitations that warrant discus-
sion. One limitation is the small sample size. Based on the results
obtained in the present work, further studies with larger sample
sizes and other experimental models, such as diabetes and can-
cer, will be performed to confirm the observed effects. Addition-
ally, the dose of hesperidin should be increased or decreased to
observe the different effects of various doses, which will be based
on the natural doses of hesperidin present in citrus fruits or juice
to extrapolate the results from rats to humans.
In conclusion, hesperidin supplementation for eight weeks
can change the proteomic profiles of the heart and kidney tissues
in MS rats and has a beneficial impact on the cardiovascular sys-
tem, free radical scavenging, and lipid and glucose metabolism.
Therefore, the identification of proteins involved in metabolic
Mol. Nutr. Food Res. 2020, 64, 1901063 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1901063 (10 of 12)
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pathways can help to understand the molecular basis of hes-
peridin in MS rats. However, further research is needed to con-
firm the results reported in the present study in humans.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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5. 1 Project 1. Effects of hesperidin consumption on 
cardiovascular risk biomarkers: a systematic review of 
animal studies and human randomized clinical trials.  
 From 698 articles, after the study selection according to our 
eligibility criteria and search strategy, twelve animal studies conducted 
in rats and mice published between January 2003 and January 2018 
were included in the systematic review. All the animals (N= from 4 to 
16) had at least one CVDRF (hypertension, type 2 diabetes, systemic 
inflammation, myocardial ischaemia, hypercholesterolaemia) and they 
consumed a daily dose of hesperidin of 5-200 mg/kg/body weight from 
7 days to 24 weeks. Further details of each study are presented in Table 
3 of the published version. 
The results for anthropometry parameters showed that 6 studies 
evaluated these parameters, and only 1 of them showed a significant 
decrease in body weight after 4.6% of the total calories in the diet was 
composed of hesperidin. 
The results for inflammation and oxidation biomarkers showed that 2 
studies evaluated these parameters, and they showed a significant 
decrease in interleukin-6 (IL-6) levels after treatment with 100 mg/kg 
body weight hesperidin for 4 weeks in rats with in systemic 
inflammation, and showed significant decreases in NO levels after 
treatment with 50 mg/kg body weight hesperidin for 30 days in type 2 
diabetic rats.  
The results for glucose and insulin levels showed that 7 studies 
evaluated these parameters and 6 of them showed significantly lowered 
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blood glucose levels in type 2 diabetic rats and mice after 50-200 mg/kg 
body weight hesperidin for 15-24 days. On the other hand, no 
significant changes were observed in insulin levels after hesperidin 
consumption. 
The results for the lipid profile showed that 4 studies evaluated these 
parameters and 3 and 2 studies showed significant decreases in TC 
levels and LDL-c levels, respectively, after 50-200 mg/kg body weight 
of hesperidin. Moreover, no significant changes were observed in HDL-
c levels after hesperidin consumption. 
From 1917 articles, after the study selection according to our eligibility 
criteria and search strategy, eleven human randomized controlled 
clinical trials with nutritional intervention published between January 
2003 and January 2018 were included in the systematic review. All the 
subjects (N= from 22 to 194) had at least one CVDRF (overweight, 
obesity, metabolic syndrome, hypercholesterolaemia) and they 
consumed a dose of hesperidin of 50-200 mg/kg body weight for 1.5-
13 weeks. Further details of each study are presented in Table 4 and 
Table 5 of the published version (page 103 of the present doctoral 
thesis). 
The results for anthropometric parameters showed that 3 studies 
evaluated the effects of hesperidin consumption on body weight, and 2 
of them reported significant decreases after 54.60-582.50 mg/day of 
hesperidin in OJ for 12-13 weeks. Moreover, 5 studies evaluated the 
effects of hesperidin consumption on BMI and 2 of them reported 
significant decreases after 54.60-582.50 mg/day of hesperidin in OJ for 
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12-13 weeks in hypercholesterolaemic and overweight or obese 
subjects.  
Finally, 1 study evaluated the effect of hesperidin consumption on body 
fat and significant decreases were observed after 13 weeks of 54.60 
mg/day hesperidin in OJ in hypercholesteremic subjects. 
The results for vascular parameters showed that 5 studies evaluated 
systolic and diastolic BP levels, and 2 of them reported significant 
decreases after 12 weeks of 237-292 mg/day of hesperidin consumption 
in OJ but also in the form of pure hesperidin capsules in overweight or 
obese subjects. On the other hand, 5 studies evaluated the effects of 
hesperidin consumption on endothelial function and 2 of them reported 
significant increases after 1.5-3 weeks of 159.60-500 mg/day 
hesperidin in OJ in subjects with metabolic syndrome.  
The results for glucose and insulin levels showed that 5 and 4 studies 
evaluated plasma glucose levels and plasma insulin levels, respectively, 
and no significant changes were reported.  
The results for lipid profile parameters showed that 8 studies evaluated 
the effect of hesperidin consumption on TC levels and LDL-c and 2 of 
them reported significant decreases in both parameters after 42-64.50 
mg/day hesperidin or hesperetin in OJ for 8-13 weeks in overweight 
and hypercholesterolaemic subjects. Moreover, the effect of hesperidin 
consumption on HDL-c levels was evaluated in 8 studies and 1 of them 
reported a significant increase after 54.60 mg/day of hesperetin in OJ 
for 13 weeks in overweight subjects. Furthermore, 8 studies evaluated 
the effects of hesperidin consumption on TG levels and 1 of them 
reported a significant decrease after 237 mg/day of hesperidin in orange 
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juice for 12 weeks in overweight or obese subjects. Finally, the effect 
of hesperidin consumption on apolipoprotein A-1 and B was evaluated 
in 3 studies and 1 of them observed a significant increase after 213 
mg/day of hesperidin in OJ for 4 weeks in hypercholesterolaemic 
subjects; while 1 of them reported a significant decrease after 237 
mg/day of hesperidin in OJ for 12 weeks in overweight or obese 
subjects.  
The results for coagulation biomarkers showed that 2 studies evaluated 
the plasma levels of fibrinogen and homocysteine after hesperidin 
consumption and no significant changes were observed.  
The results for inflammation biomarkers showed that 1 study evaluated 
the effect of hesperidin consumption on plasma protein serum amyloid 
A, sVCAM-1, sICAM-1, sE-selectin and sP-selectin, and no significant 
changes were observed. On the other hand, 1 study evaluated the effect 
of hesperidin consumption on plasma IL-6 levels and after 159.50 
mg/day of hesperidin in OJ for 1.5 weeks, the levels significantly 
decreased in subjects with metabolic syndrome.  
Finally, the results for oxidative biomarkers showed that 2 studies 






5. 2 Project 2. Effects of hesperidin in orange juice in 
blood pressure and pulse pressure in mildly hypertensive 
individuals: a randomized clinical trial (CITRUS study).  
 
Participants and intervention compliance: 
A total of 159 adult participants with pre- and stage 1 hypertension 
completed the 12 weeks of the randomized clinical trial: N=43 in the 
control group, N=46 in the OJ group and N=40 in the EOJ group; 52 
participants completed the single dose study: N= 17 in CD, N=21 in OJ 
and N=14 in EOJ. Further details with the flow diagram are presented 
in Figure 1 of the published version. 
 
Regarding the baseline characteristics, no differences were observed 
among the groups or in the level of physical activity at the end of the 
study. Regarding dietary intake, only an increased intake of protein was 
observed in the OJ group compared with the EOJ group. 
All the subjects complied with the nutritional intervention since 6 
compliance biomarkers namely hesperetin-7-O-β-d-glucuronide, 
hesperetin-3-O-β-d-glucuronide, hesperetin-7-O-sulfate, naringerine-
4-O-β-d-glucuronide, naringenin-glucuronide and naringenin-sulfate, 
were significantly increased with OJ and EOJ consumption compared 
with the control group.  
Changes in blood pressure, the main outcome: 
Hesperidin consumption in the OJ and EOJ groups significantly 
decreased the SBP levels compared to the control group. The average 
decreases in all SBP levels during the 12 weeks of hesperidin 
consumption in OJ and EOJ were -6.35- and 7.36-mm Hg, respectively. 
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Additionally, PP decreased in a dose-dependent manner with the 
hesperidin dose of the drinks consumed.  
On the other hand, after the first single dose study significant decreases 
were observed in SBP levels at 2 hours after EOJ, and no effects were 
observed for DBP levels. After the second single dose study realized 
after 12 weeks of nutritional intervention, EOJ showed decreases in BP 
and PP levels. 
Changes in secondary outcomes: homocysteine, uric acid, ICAM-1 
and VCAM levels: 
After 12 weeks of OJ and EOJ consumption, the levels of homocysteine 
decreased significantly compared to CD. After the second single dose 
study, the homocysteine levels also decreased after 2 hours and 4 hours 
of OJ consumption and after 2 hours of EOJ consumption. Additionally, 
after 12 weeks of EOJ consumption, uric acid levels significantly 
decreased compared to CD. Moreover, after 12 weeks of EOJ the levels 
of ICAM-1, VCAM and F2-isoprostanes significantly decreased.  
All these changes were observed without changes in body weight and 
blood glucose levels. 
Transcriptomic analysis: 
After 12 weeks of EOJ the expression of the genes PTX3 and NAMPT 
in PBMCs was significantly decreased compared to CD. The decreases 
in SBP and PP were directly correlated with the decreased expression 
of both genes. 
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5. 3 Project 3. Effect of hesperidin consumption in orange 
juice on the transcriptomic profile of subjects with pre- 
and stage 1 hypertension: a randomized controlled trial 
(CITRUS study). 
Baseline characteristics of the participants: 
Of the 159 subjects included in the original clinical trial, 37 subjects 
had PBMCs collected and completed both single dose and sustained 
studies, making them candidates for transcriptomic profile evaluation. 
The 37 subjects were 41-65 years old and had pre- or stage 1 
hypertension. They were from the 3 intervention groups: N=11 in the 
CD, N=15 in the OJ group and N=11 in the EOJ group. 
 
Gene expression profile after single dose intervention: 
After 6 hours of OJ consumption in the single dose study, 3 genes were 
significantly different (P < 0.05) compared to CD. Of these, 2 genes 
were upregulated (DHRS9, related with an increase of insulin 
resistance; and PKDL1, with unknown function) and 1 gene was 
downregulated (TNFAIP3, an anti-inflammatory gene). Moreover, 
several genes were borderline (P < 0.10) differentially expressed (such 
as NFKBIA, CCL3 and CCL4L2) after OJ and EOJ consumption 
related to the inflammation pathways.  
 
Gene expression profile after sustained intervention: 
After 12 weeks of hesperidin consumption in OJ, 12 genes were 
significantly different compared to CD. From these, 7 genes were 
upregulated: CCL20, FAM53B, LINC 01220, LncRNA SNRPD3-2, 
LncRNA NFKBID-1, LncRNA PDE3B-1, LOC101929524; and 5 
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genes downregulated: TNF, TMPO-AS1, BPIFB3, LncRNA ACOT-13 
and CCT8-1. Moreover, 13 genes were borderline differentially 
expressed after OJ consumption (such as NFKBIA and IL1B). 
After 12 weeks of hesperidin consumption in EOJ, 18 genes were 
significantly different compared to CD. From these, 4 genes were 
upregulated: DSP, FAM53B, LncRNA SNRPD3-2 and LncRNA 
SLC39A8-1; and 14 genes downregulated: TNF, IL1B, CCL3L3, 
CXCL2, CXCL8, PTGS2, IER3, PTX3, KMT22-AS1, ATP2B1-AS1, 
LncRNA CCT8-1, LncRNA GRK3-1, LncRNA CCDC117-1 and 
LOC644090. Moreover, 17 genes were borderline differentially 
expressed after OJ consumption (such as ICAM, CCL20 and CXCL3). 
 
The significant changes observed in the genes after OJ and EOJ 
consumption were related to an improvement in the following top 
diseases and functions: inflammation, cardiovascular system, acute 






5. 4 Project 4. Hesperidin consumption in orange juice 
modulates plasma and urine metabolic profiles in pre- 
and stage 1 hypertensive subjects promoting beneficial 
effects on cardiovascular system: targeted and non-
targeted metabolomic approach (CITRUS study).   
 
Volunteers: 
A total of 159 subjects with pre- and stage 1 hypertension completed 
the 12 weeks of the CITRUS randomized clinical trial: N=43 in the CD, 
N=46 in the OJ group and N=40 in the EOJ group; 52 participants 
completed the single dose study: N= 17 in CD, N=21 in OJ and N=14 
in EOJ. However, the targeted metabolomics analysis was performed in 
plasma and urine samples of 129 subjects who completed the sustained 
study. Nontargeted metabolomics was performed in serum samples of 
52 subjects who completed both the single dose and sustained studies 
and in urine samples of 129 subjects.  
Results of targeted metabolomics in plasma and urine samples: 
After 12 weeks of OJ and EOJ consumption, the plasma and urine 
metabolites hesperetin 7-O-B-D-glucuronide, hesperetin 3-O-B-D-
glucuronide, hesperetin 7-O-sulfate, naringenin 4-O-B-D-glucuronide, 
naringenin glucuronide and naringenin sulfate were statistical 
significantly increased. Moreover, plasma and urine hesperetin 7-O-B-
D-glucuronide was the main differentially expressed metabolite 
between both OJ and EOJ interventions. Additionally, urine hesperetin 





Nontargeted metabolomics in serum:  
Single dose study: After 6 hours of OJ and EOJ consumption, increased 
levels of proline betaine and dimethylglycine, and decreased levels of 
leucine were observed. Moreover, after single-dose EOJ consumption, 
decreased levels of urine isoleucine were observed. On the other hand, 
after an analysis to classify the subjects into low- and high-flavanones 
absorbers, increased serum levels of proline betaine, 3-
hydroxybutyrate, DMG, acetoacetate and glutamine and decreased 
serum levels of leucine, isoleucine, valine, lysine, and alanine were 
observed in high flavanone absorbers.  
Chronic study: After the analysis performed in a subsample of 52 
subjects, who completed both the single dose study and the sustained 
study, increased serum levels of proline betaine and decreased serum 
levels of glycerophosphocholine (GPC), N-acetylglycoproteins (NAG), 
acetate, valine, isoleucine, and leucine were observed after OJ and EOJ 
consumption compared to CD. 
Nontargeted metabolomics in urine:  
After the analysis performed in a sample of 129 subjects, the 
consumption of OJ for 12 weeks increased urine levels of proline 
betaine and decreased levels of hydroxyhippurate, pseudouridine, PAG, 
4-cresyl sulfate, creatinine, DMA, NAG, alanine and 3-methyl-2-
oxovalerate were observed compared to CD. After 12 weeks of EOJ 
consumption increased urine levels of proline betaine and decreased 
levels of 4-cresyl sulfate, pseudouridine, uracil, creatinine, creatine, 




5. 5 Project 5. Proteomic analysis of heart and kidney tissues in 
healthy and metabolic syndrome rats after hesperidin 
supplementation.  
 
The feeding of a cafeteria diet to Sprague Dawley rats produces an 
obesogenic dietary pattern and increases body weight, fat mass, SBP, 
TG, glucose, and LDL-c, producing metabolic syndrome. 
After proteomic analysis of heart tissue samples, 1127 proteins were 
identified. After filtering, 872 proteins were candidates for the 
statistical analysis. After the analysis, in healthy rats fed a standard diet 
no significant differences were observed between the treatment groups 
(between the group that received hesperidin by the vehicle and the 
group that did not receive hesperidin). On the other hand, in metabolic 
syndrome rats (the rats fed with cafeteria diet) 35 proteins were 
differentially expressed between the treatment groups (p<0.01 and VIP 
score from PLS-DA >1.5). After hesperidin consumption in metabolic 
syndrome rats, 19 proteins were downregulated in heart tissue samples: 
APOC2, COQ8A, GLRX5, ENSA, RBP4, UQCRH, SOD1, CDV3, 
TIMM10, ATP5F1D, TXNDC17, RGD1311703, CFL2, COX5A, 
TIMM8B, MYOZ2, APOA4, GCSH, ISCA2; and 16 proteins were 
upregulated: ALDH7A1, FLNA, MYH9, ATP1A1, RP114, CLTC, 
CDC42, TMX2, APOC1, SLC27A1, OGDH, ACAD8, GCDH, 
AFG312, CDC58 and SLC25A3.  
The most important and significantly affected pathways for hesperidin 
supplementation in heart tissue of metabolic syndrome rats, analysed 
by Ingenuity Pathway Analysis (IPA), were the following:  
- Production of NO and reactive oxygen species in macrophages. 
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- Clathrin-mediated endocytosis signaling. 
- LXR/RXR activation. 
- Atherosclerosis signaling. 
- FXR/RXR activation. 
On the other hand, the top networks founded by IPA were the following: 
- Molecular transport, carbohydrate metabolism and small 
molecule biochemistry. 
- Cardiac arrhythmia, CVD and metabolic disease.  
- Cancer, cardiovascular and cell cycle. 
After proteomic analysis of kidney tissue samples, 1753 proteins were 
identified. After filtering, 1341 proteins were candidates for the 
statistical analysis. After the analysis, in healthy rats fed a standard diet 
no significant differences were observed between the treatment groups. 
On the other hand, in metabolic syndrome rats, 53 proteins were 
differentially expressed between the treatment groups (p<0.01 and VIP 
score from PLS-DA >1.5). After hesperidin consumption in metabolic 
syndrome rats, 33 proteins were downregulated in kidney tissue 
samples: ATP5IF1, APOH, LZTFL1, ISCU, ATP6V1G1, ATOX1, 
CHCHD3, IGFBP7, TPT1, UQCRH, ATP5PF, EF1D, SOD1, TPM3, 
LOC100912599, CTSH, SPP2, NUCB2, PAPLN, ISCA2, TPM4, 
PSAP, TIMM8B, SLC9A3R2, EPB4113, PFDN2, TXN2, STX7, 
CD2AP, COX6B1, SLC9A3R1, AK3, VAPB; and 20 proteins were 
upregulated: OGDH, RACK1, PNP, VDAC3, GCLC, MARC2, 
SLC25A13, ABCG2, CDC42, CTSL, CD47, SHTM1, CPT1A, FLNA, 
SLC25A3, MME, MYOLD, PAICS, EPHX2 and H3F3C. The detailed 




The most important and significantly affected pathways for hesperidin 
supplementation in kidney tissue of metabolic syndrome rats, analysed 
by IPA, were the following:  
- Mitochondrial dysfunction. 
- Xanthine and xanthosine salvage. 
- Guanine and guanosine salvage I. 
- Adenine and adenosine salvage I. 
 
On the other hand, the top networks founded by IPA were the following: 
- Cellular compromise, free radical scavenging, cell death and 
survival. 
- Cell death and survival, free radical scavenging, organismal 
injury and abnormalities. 
- Cardiovascular system development and function, 
immunological disease, inflammatory disease. 
 
Finally, the significant changes observed in the expressed proteins in 
both heart and kidney tissues of metabolic syndrome rats after 
hesperidin consumption were related with to an improvement in these 
top diseases and functions:  
- Cardiovascular system. 
- Free radical scavenging. 
- Lipid metabolism. 
- Glucose metabolism. 






















 The present work provides evidence that hesperidin 
consumption has beneficial effects reducing BP in humans, whereas 
genes expression and metabolites changes suggests effects also on 
others CVD risk biomarkers having protective capacity on 
cardiovascular health.  
In this sense, the CITRUS randomized controlled trial showed the 
capacity of hesperidin to decrease SBP and PP, in a dose-dependent 
manner,  in subjects with pre- and stage 1 hypertension after 12 weeks 
of OJ (392 mg/day of hesperidin) and EOJ (670 mg/day of hesperidin) 
consumption. Additionally, after single dose studies hesperidin 
decreased SBP and PP levels. On the other hand, markers of oxidation 
and inflammation (homocysteine, uric acid, ICAM-1 and VCAM) were 
reduced after 12 weeks of hesperidin consumption, and uric acid 
concentrations were directly related to SBP, DBP and PP at week 12. 
Moreover, daily consumption for 12 weeks and single dose 
consumption of hesperidin in OJ and EOJ significantly changed the 
transcriptome profile of PBMCs of subjects with pre- and stage 1 
hypertension, with hesperidin being an anti-inflammatory agent 
because its capacity to downregulate pro-inflammatory genes and 
decrease the insulin resistance in higher doses. Furthermore, daily 
consumption for 12 weeks of hesperidin in OJ and EOJ changed the 
metabolome profile of urine and plasma/serum samples in subjects with 
pre- and stage 1 hypertension. Hesperidin changes endogenous 
metabolites related to BP, oxidative stress, inflammation and uraemic 
toxins, indicating anti-inflammatory and antioxidant actions, and lower 
SBP levels and ureamic toxins, providing beneficial effects on the 
cardiovascular system. Finally, daily hesperidin consumption for 8 
weeks changes the proteome profile of kidney and heart tissue samples 
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of experimental rat models with metabolic syndrome, which has 
beneficial effects on the cardiovascular system, free radical scavenging 
and lipid and glucose metabolism. 
 
In Project 1, we summarize by a systematic review the available 
scientific evidence of the effects of hesperidin consumption on 
cardiovascular risk biomarkers. Animal studies and human RCT 
published between January 2003 and January 2017 were included in the 
systematic review. Mice and rats and human subjects had at least one 
CVDRF, they participated in sustained and single dose studies and 
consumed a hesperidin dose through OJ or capsule; and orally, by 
gavage and intravenous administration in the case of animal models.  
 
In animal studies, hesperidin consumption improves blood glucose, TC, 
LDL-c, and TG levels. No significant changes were observed in 
anthropometric parameters, BP, inflammation, or oxidative biomarkers. 
However, the sample size in some of the studies may be insufficient to 
obtain conclusive results. On the other hand, a conclusive inference 
cannot be drawn from the included RCT: most of the studies did not 
have the most appropriate population to evaluate the effects of different 
CVDRFs, and only 3 of the 11 included articles evaluated the diet of 
the subjects through a validated method and no one used consumption 
biomarkers. There may be factors that influence hesperidin 
bioavailability or other phenolic compounds of the diet that can 
influence the observed effects. Therefore, further RCT with higher 




To the best of our knowledge, the present study is the first to 
systematically review the effects of hesperidin on CVD risk biomarkers 
in animal studies and human RCT. In this sense, no systematic review 
or meta-analysis about the effects of hesperidin on CVDs was published 
after our work. However, in 2020, a review has been published 
reporting the scientific evidence of hesperidin consumption on 
CVDRFs and its role in intestinal microbiota.(112) In this review the 
mechanism of action by which hesperidin can exert beneficial effects 
was discussed together with the results of in vivo, in vitro and human 
clinical trial studies. In this work, although they demonstrate the 
influence of the intestinal microbiota on the absorption and subsequent 
effects of hesperidin consumption, more animal and human studies are 
needed to clarify this relationship. In this sense, their conclusion about 
the actual evidence of the hesperidin effects is the same as what we 
reported in our systematic review.  
As there is a need to realize more randomized and controlled clinical 
trials to confirm the effects of hesperidin on CVD risk biomarkers, the 
CITRUS study was carried out. 
 
In Project 2, we assessed the sustained and single dose effects of 
hesperidin consumption in OJ and EOJ on BP levels and PP in pre- and 
stage 1 hypertensive subjects. After 12 weeks of daily hesperidin 
consumption in 500 mL of OJ (392 mg of hesperidin) and EOJ (670 mg 
of hesperidin), decreased SBP and PP levels were observed in a dose-
dependent manner. Therefore, regular consumption of OJ, especially 




Similarly, an open-labelled randomized controlled trial that evaluated 
the clinical effects of hesperidin in metabolic syndrome subjects was 
recently published.(190) In this study, after 12 weeks of hesperidin 
powder consumption (1 g/day), significant reductions in SBP of -5.68 
mm Hg and serum TG of 50.06 mg/dL were observed. Moreover, a 
randomized, double-blinded, placebo-controlled clinical trial also 
performed in patients with metabolic syndrome showed that the 
consumption of 500 mg/day hesperidin by 2 capsules for 12 weeks 
significantly decreased the levels of blood glucose, TG, SBP and 
TNFα.(191) Therefore, hesperidin can improve metabolic 
abnormalities and inflammatory status in subjects with metabolic 
syndrome. Moreover, hesperidin can exerts anti-hypertensive effects 
increasing NO production,(192) improving endothelium-dependent 
vasodilatation and improving potassium channel activity.(193)  
 
Furthermore, in the CITRUS study the genes that were significantly and 
differently decreased after 12 weeks of hesperidin consumption in EOJ 
related to BP levels were PTX3 and NAMPT. PTX3 is a marker of 
inflammation activation and is increased in hypertensive subjects.(194) 
Additionally, NAMPT is implicated in inflammation since it is a 
stimulator of pro-inflammatory cytokines, and it is increased in subjects 
with prehypertension.(195) Therefore, NAMPT could be a marker of 
risk and damage in prehypertensive subjects. Accordingly, the 
decreased expression of both genes could be partially responsible for 
the decreased BP and PP levels after hesperidin consumption because 




Therefore, the CITRUS study provides further evidence of the effects 
of hesperidin consumption on CVDRFs such as BP. However, more in-
depth analyses are necessary to better understand how hesperidin can 
exert its beneficial effects and understand its mechanisms of action. In 
this sense, an omics science approach through transcriptomics and 
metabolomics analysis was performed in subjects with pre- and stage 1 
hypertension from the CITRUS study.  
 
In Project 3, additionally, we determined whether the sustained and 
single dose consumption of hesperidin in OJ and EOJ can change the 
transcriptome profile of PBMCs of pre- and stage 1 hypertensive 
subjects. According to our results, after 12 weeks of OJ and EOJ 
consumption, pro-inflammatory genes were downregulated. However, 
after EOJ consumption more pro-inflammatory genes were 
differentially and borderline downregulated than after the consumption 
of OJ (such as CXCL2, CCL3, TNF, IL1B and PTGS2). These 
differentially expressed genes after hesperidin consumption influence 
the inflammatory response and the communication between immune 
cells preventing atherosclerotic plaque formation, inflammation in 
obesity, short-term mortality and hypertension, thus decreasing the risk 
of developing CVDs.  
Additionally, the differential expression of a gene related to insulin 
resistance was only observed after the single dose consumption of 
hesperidin in OJ and EOJ. The OJ upregulated the DHRS9 gene 
compared to CD, increasing insulin resistance, but EOJ downregulated 
it compared to OJ. The different behaviour between the two hesperidin 
interventions could be due to the presence of fructose: fructose can 
increase the expression of DHRS9, increasing fructose metabolism, 
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plasma TG levels and insulin resistance. In contrast, after EOJ 
consumption, the gene expression of DHRS9 decreased, which could 
be because hesperidin can counteract with the fructose content since the 
evidence suggests that higher doses of hesperidin in rats improve the 
insulin resistance and decrease blood glucose levels.(143,144) 
 
On the other hand, and contrary to expectations, hesperidin in OJ and 
EOJ also showed the capacity to downregulate anti-inflammatory 
related genes such as NFKB1A and TNFAIP3. The downregulated 
effect observed could also be explained by the fructose content of the 
fruit juices, although the product of the present RCT was natural juice 
or enriched juice. Some evidence suggests that a high consumption of 
fructose increases CVD risk because of its influence on inflammatory 
response.(196) However, other evidence is controversial because its 
pro-inflammatory effects are only observed after artificially sweetened 
beverage consumption but not after fruit juice consumption.(156) 
 
The present work is the first study to realize a transcriptomic approach 
of PBMCs in subjects with pre- and stage 1 hypertension after sustained 
and single dose consumption of hesperidin in OJ and EOJ. 
Transcriptomic analysis offers a unique opportunity to determine the 
effect of bioactive compounds such as hesperidin on metabolic and 
biological pathways. Additionally, transcriptomic analysis provides a 
way of knowing how the regulation of some pathways impacts the 
progression of chronic diseases.(197) Moreover, the transcriptomic 
approach allows for the identification of genes as biomarkers.  
Thus, the new information provided through our transcriptomic 
approach would allow us to better understand how hesperidin 
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consumption can influence cardiovascular health, providing an 
explanation of the observed health effects. However, although our 
results are promising, more studies are needed to corroborate this 
hypothesis to better understand the mechanism of action of hesperidin 
and its action on gene expression.  
 
In Project 4, we evaluated the effects of a single dose and sustained 
consumption of hesperidin for 12 weeks in OJ and EOJ in subjects with 
pre- or stage 1 hypertension on plasma, serum and urinary metabolomic 
profiles through targeted and nontargeted approach. After 12 weeks of 
hesperidin consumption in OJ and EOJ, compared to CD, the targeted 
metabolomics approach showed that the 6 compliance biomarkers were 
significantly increased in urine and plasma, but hesperetin 7-O-B-D-
glucuronide was the only metabolite that showed differences between 
OJ and EOJ, indicating that hesperetin 7-O-B-D-glucuronide could be 
a candidate marker to distinguish between different hesperidin doses 
consumed in the long-term. Additionally, we observed a negative 
correlation between the urine levels of hesperetin 7-O-B-D-glucuronide 
and SBP levels, suggesting that this metabolite can have hypotensive 
actions. To the best of our knowledge, this is the first study to show a 
negative correlation between the urine metabolite hesperetin 7-O-B-D-
glucuronide and the levels of SBP. 
 
On the other hand, nontargeted metabolomics approach showed that 
after hesperidin consumption in OJ and EOJ for 12 weeks and after 6 
hours of a single dose study, serum and urine metabolites that are 
inversely associated with BP levels,(173) such as proline betaine, were 
significantly increased. Moreover, decreased serum and urine levels of 
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the metabolites valine, leucine and isoleucine were reported after OJ 
and EOJ consumption, which were related to lower BP levels and 
improvement in insulin resistance.(125) Additionally, metabolites such 
as NAG and pseudouridine, related to inflammatory and oxidative 
stress status,(176) were decreased in serum and urine, after 12 weeks of 
OJ and EOJ consumption. Also, hesperidin consumption in OJ and EOJ, 
changes the choline metabolism changing related metabolites such as 
trimethylamine and dimethylglycine, which are increased, suggesting a 
lower microbial choline metabolism and thereby alterations in one-
carbon metabolism that could improve the SBP levels in these patients. 
Furthermore, uraemic toxins such as dimethylamine, 4-cresyl sulfate 
and creatinine were decreased in urine after OJ and EOJ consumption, 
which is beneficial for the cardiovascular system because their 
accumulation produces vascular inflammation and endothelial 
dysfunction.(183) 
 
On the other hand, and as reported in the literature, we observed a large 
interindividual variability in flavanone absorption and for that reason 
we divided the subjects into two groups in the single dose study: high 
and low total flavanone absorbers regardless of their consumption of OJ 
and EOJ. In this sense, we observed that the subjects who absorbed 
more flavanones showed higher plasma levels of ketone bodies such as 
acetoacetate and 3-hydroxybutyrate 6 h hours postprandially. It is 
known that increased ketone bodies produced by a ketogenic diet 
produce vasodilation and lower BP levels.(187) Therefore, this could 
be another mechanism through which hesperidin can improve BP levels 





In Project 5, we evaluated the effects of hesperidin supplementation at 
100 mg/kg body weight/day for 8 weeks on the proteomic profiles of 
heart and kidney tissue samples from healthy and metabolic syndrome 
rats. The human equivalent dose of 100 mg/body weigh/day hesperidin 
was 1350 mg per day for a 60 kg human,(198) a dose achievable with 
an orange juice enriched with hesperidin. 
 
After 8 weeks of hesperidin supplementation by diet, the metabolic 
syndrome rats had changes in their proteome in both heart and kidney 
tissues. In the heart and kidney tissue samples, 35 proteins and 53 
proteins were differentially expressed, respectively. To the best of our 
knowledge, there are no data about the capacity of hesperidin to change 
the proteome profile of tissue samples of metabolic syndrome rats. 
Therefore, this is the first study to observe it. 
According to our results, hesperidin supplementation showed positive 
effects on different parameters in metabolic syndrome rats, 
upregulating the expression of proteins related to the cardiovascular 
system (ATP1A1), BP and endothelial function (ATP5PF and IGFBP7, 
respectively), and atherosclerosis pathogenesis (TPT). Additionally, 
hesperidin supplementation exerts positive effects by downregulating 
the expression of proteins related to free radical scavenging 
(ALDH7A1), heart development (FLNA), glucose metabolism 
(CD2AP) and insulin sensitivity (EPHX2). However, hesperidin can 
also change the expression of some proteins with negative or 
controversial effects on cardiovascular health: hesperidin 
downregulated the expression of antioxidant proteins (SOD1 and 
TXN2), proteins related negatively to BP (SLC9A3R1) and proteins 
related negatively to lipid metabolism (APOA4).  
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In this sense, and contrary to expectations, we observed controversial 
results after the proteomics approach in rats as in the transcriptomics 
approach in humans. Therefore, more studies are needed in this area to 
explain and clarify the effects of hesperidin on these differentially 
expressed proteins.   
On the other hand, some studies have performed proteomics analysis in 
cells and rats treated with flavonoids such as quercetin and observed 
interesting and positive results. After quercetin treatment in K562 cells 
(a cellular model of human chronic myeloid leukaemia), several 
proteins related to RNA metabolism, the antioxidant defense system 
and lipid metabolism changed, influencing the early stages of the 
apoptosis response.(199) On the other hand, in rats with cerebral 
ischaemia, quercetin treatment can change the expression of proteins 
related to cellular differentiation, metabolism and oxidative stress, 
reducing ischaemic injury.(200) 
 
Thus, promising effects of hesperidin capacity to influence the 
proteome profile to exert beneficial effects on interestingly expressed 
proteins to promote cardiovascular health were reported and need to be 
verify in humans. 
 
OVERALL DISCUSSION 
We can observe that higher doses of hesperidin (670 mg/day in 500 
mL/day in EOJ) have more beneficial effects than usual doses (392 
mg/day in 500 mL/day in OJ). This is suggested because of the results 
from the CITRUS study regarding BP and PP, the transcriptomic 
approach performed in PBMCs which observed interestingly actions 
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decreasing proinflammatory genes, and the metabolomic approach 
realised in urine and plasma/serum samples which suggests changes on 
several metabolites related with lower levels of BP and beneficial 
effects on cardiovascular system. 
Therefore, hesperidin consumption in OJ and EOJ can decrease BP 
levels and PP in a dose-dependent manner in subjects with pre- and 
stage 1 hypertension, and the mechanism of action of the flavonoid 
hesperidin, which exerts its beneficial effects, can be explained through 
transcriptomics and metabolomics analyses.  
Hesperidin showed the ability to decrease the expression of pro-
inflammatory genes and higher doses can improve glucose metabolism 
by interfering with the expression of genes related to insulin resistance. 
Furthermore, hesperidin in OJ and EOJ has an impact on the serum 
metabolomic profile, decreasing endogenous metabolite levels related 
to BP and inflammation, and decreasing urinary excretion of uraemic 
toxins and metabolites related to oxidative stress. 
Moreover, an experimental study in rats with metabolic syndrome also 
showed the capacity of hesperidin to influence kidney and heart 
proteome profiles by proteomics analysis. In this sense, hesperidin can 
change the expression of proteins related to cardiovascular health, 
improving endothelial function and BP homeostasis. Additionally, 
hesperidin showed the capacity to change protein expression of heart 
and kidney tissues to exert antioxidant effects and improve of glucose 
metabolism in metabolic syndrome rats. 
Thus, in the present work we reported promising effects of hesperidin 
consumption to promote cardiovascular health (Figure 14). 























 First, although our results are promising and indicate beneficial 
effects of hesperidin consumption reducing SBP linked to changes in 
gene expression, metabolites in humans and proteins in syndrome 
metabolic rats, more studies are needed to confirm our results.  
 
Moreover, to assess the effects of hesperidin on other CVDRFs 
biomarkers such as lipid metabolism, endothelial function, glucose 
metabolism and anthropometric parameters, further research is needed.  
 
Additionally, reviewing the types of studies performed with hesperidin 
consumption, the participants included in the RCT must be the proper 
population to ensure the observed positive effects on specific 
cardiovascular biomarkers. For example, if the hesperidin effects on TC 
plasma levels are to be evaluated, adult subjects with 
hypercholesterolaemia must be selected; or if the hesperidin effects on 
body weight want are to be evaluated, overweight or obese subjects 
must be selected. 
 
On the other hand, there is a bidirectional relationship between phenolic 
compounds and the microbiota of the human gut since phenolic 


















Figure 15. Flavonoids metabolism in the colon and metabolite 
absorption. 1. Dietary flavonoids can exert local effects in 
gastrointestinal tract, 2. Can interact with microbiota changing its 
profile and produce mainly aromatic and phenolic acids that will be 
absorbed producing systemic effects or exerting local effects; 3. and be 
metabolized by intestinal epithelial cells. Later metabolites will be 
absorbed or excreted. Abbreviations: GI, gastrointestinal. Source: 
(Fraga CG, et al. 2019).(56)  
 
 
The microbiota is a complex ecosystem that depends on individual 
characteristics and their environmental conditions, and plays a very 
important role in health status by modulating the immune system and 
protecting against pathogenic microorganisms.(201) Therefore, the 
microbiota influences on the development of several diseases.  
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In this sense, in other human studies OJ consumption showed a 
prebiotic effect in the intestinal mucosa by decreasing pathogenic 
microorganisms and increasing positive effects on the intestine.(202) 
Moreover, hesperidin has demonstrated in vivo and in vitro the capacity 
to inhibit the growth of gram-positive bacteria, thereby inhibiting the 
progression of pathogenic bacteria, and the ability to promote the 
growth of beneficial bacteria, thus demonstrating immunomodulatory 
action on the gut.(203) 
Furthermore, regarding BP, a recent study that was carried using the 
same rats as in Project 5 of the present thesis evaluated the effects of 
hesperidin consumption on the microbiota in metabolic syndrome rats, 
showing that hesperidin supplementation alters microbiota by acting as 
a hypertension modulator and modifying protein expression related to 
pathways metabolism such as amino acids and energy 
metabolism.(204) 
 
For that reason, since gut microbiota have a crucial role in disease 
development, such as CVDs, and also phenolic compounds is 
metabolized by gut microbiota, stool samples should also be collected 
in future RCT to evaluate the hesperidin effects on microbiota and their 
implication for CVDs. Furthermore, a metagenomic approach could be 
useful to understand the complex relationship between CVDs, the gut 
microbiome and hesperidin intake since metagenomics can analyse the 
genomic content of all microorganisms present in an ecosystem to 
define their biodiversity in each experimental condition.  
 
On the other hand, to the best of our knowledge, no proteomics 
approach has been realized in humans to evaluate the effects of 
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hesperidin consumption on proteomic profiles. Therefore, blood 
samples can also be collected in RCT to determine changes in serum 
and plasma proteins and to relate them to cardiovascular health.  
Finally, further analysis from the CITRUS study results will be realized 
to integrate all the information generated and to better relate the changes 
at the molecular level to the clinical changes observed. In this sense, 
more correlations between clinical parameters such as BP, PP, or 
endothelial function with inflammation biomarkers, differentially 
expressed genes and endogenous metabolites can be realized.  
 
Second, a multi-omics approach will be proposed thanks to the omics 
approach undertaken in the present work through transcriptomics, 
metabolomics and proteomics analysis, it has been possible to know the 
impact of the flavanone hesperidin on the transcriptome, metabolome 
and proteome to understand how hesperidin exerts beneficial effects on 
the cardiovascular system and CVD biomarkers. As results, each omics 
science provides specific insight into one study factor; however, an 
integrative new analysis proposal is currently emerging in the world of 
science and bioinformatics, and it is called the “multi-omics” approach. 
 
Multi-omics is an integrative analysis of omics data from different 
omics levels with the objective of better understanding their 
interrelation and combined influence on molecular function, disease 
aetiology and disease development.(129) However, the integrative 
analysis of different omics data is not straightforward and has several 
logistic and computational changes.(205) Nevertheless, realizing a 
multi-omics approach is one more step that future studies can perform 
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to integrate multi-omics profiles into the investigation of the 
mechanisms associated with CVDs.  
 
 
Third, considering that hesperidin has the ability to act on multiple 
factors, such as BP, lipid and glucose metabolism, as well as on 
inflammation and oxidative stress, studies could be carried out to 
determine the effects of hesperidin consumption in other chronic 
diseases such as cancer.  
In this sense, there is literature that reported that hesperidin 
consumption has beneficial effects on oxidation and other biological 
pathways related to metastasis and better prognosis described in tumor 
cells.(206,207)  
 
Figure 16 shows the role of hesperidin in apoptosis and the cell cycle: 
hesperidin generates reactive oxygen species in cancer cells, activates 








Figure 16. Role of hesperidin on apoptosis and cell cycle. Source: 
(Aggarwal V et al. 2020).(207) 
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Finally, with the currently active worldwide Coronavirus Disease 2019 
(COVID-19) pandemic, studies have been carried out linking the 
consumption of hesperidin with positive effects on COVID-19. The 
ability of hesperidin to inhibit angiotensin-converting enzyme 2, 
transmembrane protease serine 2 and binding immunoglobulin protein 
receptors is one of the reasons for its possible beneficial effects since 
these receptors are the most noticeable receptors causing COVID-
19.(208) Furthermore, flavonoids can have antiviral action because of 
their modulation of the immune system. Hesperidin showed the ability 
to bind to key proteins of severe acute respiratory syndrome 
coronavirus (SARS-CoV-2) with effective antiviral action that 
inhibited virus-induced cellular and systemic pathology.(209)  
 
Therefore, there is evidence that supports the promising use of 
hesperidin in the prophylaxis and treatment of COVID-19: hesperidin 
can improve host cellular immunity against infection and anti-
inflammatory action helping to control cytokine storms, and hesperidin 
mixed with specific drugs (diosmin co-administered with heparin) can 
protect against venous thromboembolism, which prevents the 
progression of the disease.  
 
Figure 17 shows the possible effect of hesperidin on the prophylaxis 












Figure 17. Possible effect of hesperidin on the prophylaxis and 
treatment of COVID-19. Abbreviations: ACE-2, angiotensin-




In summary, it can be observed that there are future study routes in 
relation to hesperidin and its capacity to protect against chronic diseases 
that can be followed and continued. Further RCT with higher quality 
with the collection of stool samples for the metagenomics approach, the 
collection of plasma samples for the proteomics approach in humans, 
realizing a multi-omics analysis to integrate all the biological 
information and evaluate the effects of hesperidin consumption on other 
chronic diseases such as cancer, can be future goals in the world of 
nutrition and health for the prevention and treatment of diseases. 
Moreover, studies that relate hesperidin consumption and COVID-19 




























 According to the results obtained, the conclusions about the 
effects of hesperidin consumption on CVD risk biomarkers are as 
follows: 
-After the systematic review, hesperidin consumption was found to 
improve glucose levels and lipid profiles in animal models, but no 
definitive conclusion regarding the effects of hesperidin in humans can 
currently be drawn (Objective 1 and Project 1). 
-After the CITRUS study, the intake of hesperidin in OJ decreased SBP 
and PP after sustained consumption in a dose-dependent manner with 
the hesperidin content of the beverage administered. Chronic 
consumption of EOJ enhances the postprandial response of decreasing 
SBP and PP. Decreases in homocysteine, uric acid and inflammatory 
markers at the systemic level and in PTX3 and NAMPT at the 
transcriptomic level could account for the observed changes in BP and 
PP (Objective 2 and Project 2). 
-After the transcriptomic analysis from CITRUS study, the single dose 
consumption of higher doses of hesperidin could induce a better 
response than the consumption of the naturally occurring doses of 
hesperidin in OJ because of their improvement of insulin resistance. 
Moreover, the sustained consumption of hesperidin in EOJ decrease the 
expression of proinflammatory genes providing a possible mechanism 
of action on inflammation pathway and thereby could induces 
beneficial effects on the cardiovascular system. (Objective 3 and 
Project 3). 
-The plasma and urine metabolite hesperetin 7-O-B-D-glucuronide is 
the only metabolite that reported hesperidin dose response differences, 
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and in urine it is inversely correlated with SBP levels. In addition, 
hesperidin consumption in OJ and EOJ for 12 weeks changed the serum 
metabolomic profile, decreasing the levels of endogenous metabolites 
related to BP, inflammation, and oxidative stress, and decreasing the 
urinary excretion of uraemic toxins. Additionally, after a single dose of 
hesperidin, changes in the serum levels of metabolites related to 
reduced BP levels and anti-inflammatory effects were observed 
(Objective 4 and Project 4). 
-After proteomic analysis in metabolic syndrome rats, hesperidin 
supplementation changed the proteomic profiles of the heart and kidney 
tissues and had a beneficial impact on the cardiovascular system, free 




Finally, the overall conclusion is that hesperidin reduces human BP and 
PP in a dose-dependent manner. Thus, the hesperidin enrichment 
achieved with EOJ can be a useful co-adjuvant tool for BP and PP 
management in pre- and stage 1 hypertensive subjects. The mechanisms 
of action by which hesperidin exerts its beneficial effects can be 
explained through transcriptomics and metabolomics approaches in 
humans which demonstrated cardioprotective actions through decreases 
in pro-inflammatory genes (transcriptomic approach), decreases in 
serum endogenous metabolites related to BP and oxidative stress and 
decreases in the urinary excretion of uraemic toxins (metabolomic 
approach). Moreover, the proteomic approach realized in kidney and 
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heart tissues of metabolic syndrome rats, showed that hesperidin 
changes proteomic profiles exerting positive effects on two main organs 
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